KOL | Roger F Butterworth∗Department of Medicine, University of Montreal, 45143 Cabot Trail, Englishtown, NS B0C 1H0 Canada | Department of Medicine, University of Montreal, Montreal, Canada | ... |
Kol CV for Roger F Butterworth∗
| Year | |
|---|---|
| 2021 | Department of Medicine, University of Montreal, 45143 Cabot Trail, Englishtown, NS B0C 1H0 Canada |
| 2020 | Department of Medicine, University of Montreal, Montreal, Canada |
| 2019 | Department of Medicine, University of Montreal, 45143 Cabot Trail, B0C 1H0, Englishtown, NS, Canada University of Montreal (St-Luc Hospital), Montreal, QC |
| 2018 | CHUM St-Luc Hospital and Department of Medicine, University of Montreal, Canada. University of Montreal (St-Luc Hospital), Montreal, Québec, Canada |
| 2015 | Department of Medicine, University of Montreal, Montreal, Quebec, Canada |
| 2014 | Neuroscience Research Unit, Hopital St-Luc (CHUM) and Department of Medicine, University of Montreal, Montreal, QC H2W 3J4, Canada |
| 2013 | Neuroscience Research Unit, Hôpital St-Luc (CHUM), 1058 Rue St-Denis, H2X 3J4, Montreal, QC, Canada |
| 2012 | Neuroscience Research Unit, Saint-Luc Hospital (CHUM), University of Montreal, Montreal, Quebec, Canada |
| 2011 | Department of Medicine, University of Montreal, Neuroscience Research Unit, Montreal, Quebec, Canada |
| 2010 | Neuroscience Research Unit, Hôpital Saint-Luc (CHUM), University of Montreal, 1058 St. Denis Street, Montreal, Quebec, Canada |
| 2009 | Neuroscience Research Unit, Hôpital Saint‐Luc, CHUM, Montreal, QC, Canada |
| 2008 | Neuroscience Research Unit, Université de Montréal, Montreal, QC, Canada |
| 2007 | Neuroscience Research Unit, CHUM (Campus Saint-Luc), University of Montreal, 1058, Saint-Denis Street, H2X 3J4, Montreal, Quebec, Canada |
| 2006 | Neuroscience Research Unit, University of Montreal (CHUM), Hôpital Saint-Luc, 1058 St-Denis Street, Montreal, Que., Canada H2X 3J4 |
| 2005 | Neuroscience Research Unit, Hôpital Saint-Luc (CHUM), Montréal, Quebec, Canada |
| 2004 | Neuroscience Research Unit, Montreal, Quebec, Canada |
Roger F Butterworth∗: Påvirke statistikk
Kjør rapport
| Concept | World rank |
|---|---|
| proinflammatory mechanisms | #1 |
| manganese deposition | #1 |
| regionselective increases | #1 |
| haloperidol humans haloperiodol | #1 |
| caudate nucleus cau | #1 |
| novo synthesis gaba | #1 |
| alterations neurological alterations | #1 |
| dha administration mnsod | #1 |
| 32°c–35°c | #1 |
| encephalopathy thiamine | #1 |
| vulnerable medial thalamus | #1 |
| regions pyrithiamine | #1 |
| grc integrity | #1 |
| encephalopathy humans pallidus | #1 |
| tdpase encephalopathy humans | #1 |
| devascularized rat | #1 |
| vicious cycle sarcopenia | #1 |
| rats direct evidence | #1 |
| mhe clinical practice | #1 |
| genetic xlinked deficiency | #1 |
| absence wernickes encephalopathy | #1 |
| 25mm nh4cl p005 | #1 |
| normothermic alf rats | #1 |
| inhibitory ammonium ions | #1 |
| normal limits findings | #1 |
| modulators hepatic | #1 |
| alf aom | #1 |
| histamine receptor sites | #1 |
| nacl calcium | #1 |
| removal bloodborne ammonia | #1 |
| ammonia mrna | #1 |
| 3hcitalopram sites | #1 |
| csf lactate pse | #1 |
| increased brain | #1 |
| loss righting reflexes | #1 |
| progression prevention | #1 |
| distribution 3htryptamine | #1 |
| astrocytic accumulation | #1 |
| congenital otc | #1 |
| hypothermia delay | #1 |
| exposure proinflammatory | #1 |
| tmpase tdpase | #1 |
| integrity gabaa receptors | #1 |
| encephalopathy expression | #1 |
| appearance neurological symptoms | #1 |
| mechanisms wemickes encephalopathy | #1 |
| experimental alf increases | #1 |
| flunitrazepam modulation | #1 |
| nmda receptor alf | #1 |
| wistar receptors pca | #1 |
| thiaminedeficient encephalopathy | #1 |
| cerebral γ‐aminobutyric acid | #1 |
| clinicallydefined entities | #1 |
| surgical probenecid rats | #1 |
| pallidal signal hyperintensity | #1 |
| 44433a | #1 |
| portacaval pcs rats | #1 |
| cns complications alf | #1 |
| reduction brain ammonia | #1 |
| genes brain edema | #1 |
| findings reported increase | #1 |
| alf messenger | #1 |
| thdoc brain tissue | #1 |
| wellestablished actions | #1 |
| material equal | #1 |
| encephalopathy humans opioid | #1 |
| encephalopathy pse | #1 |
| brain congenital | #1 |
| ammonia mechanisms | #1 |
| akgdh | #1 |
| alf azoxymethane | #1 |
| ammonia glutamate uptake | #1 |
| anastomosis pca | #1 |
| increased glutamine synthesis | #1 |
| term fluorescence phenomenon | #1 |
| progression thiamine deficiency | #1 |
| 24 hours pca | #1 |
| isomorphic model predictions | #1 |
| azoxymethane toxicity | #1 |
| mild hypothermia delay | #1 |
| ammonialowering agents | #1 |
| early astrocytic response | #1 |
| glutamine synthetase activities | #1 |
| decreased tdp concentrations | #1 |
| surgical rna messenger | #1 |
| synthesis intercellular transport | #1 |
| l‐deprenyl treatment | #1 |
| veratramines action parachlorophenylalanine | #1 |
| betaactin housekeeping gene | #1 |
| astrocytic glycine transporter | #1 |
| albumin dialysis systems | #1 |
| mechanisms brain edema | #1 |
| autopsied brain tissue | #1 |
| spf mice activities | #1 |
| cirrhotic brain tissue | #1 |
| hepatic encephalopathy activities | #1 |
| 3hcitalopram sites rats | #1 |
| additional bloodborne ammonia | #1 |
| decreased pdhc | #1 |
| brain herniation alf | #1 |
| brain glutamine | #1 |
| cirrhotic patients densities | #1 |
| alf proinflammatory | #1 |
| pse complication | #1 |
| animal pyridinium | #1 |
| pca rats patients | #1 |
| coding key | #1 |
| rats hepatic devascularization | #1 |
| leigh disease forms | #1 |
| selective increases | #1 |
| deficiency selective | #1 |
| hypermmonemia | #1 |
| alcoholrelated brain dysfunction | #1 |
| interferongamma brains | #1 |
| hepatic devascularization | #1 |
| endogenous opioid brain | #1 |
| thiamine deficiency 23 | #1 |
| reactive gliosis contrast | #1 |
| increased densities | #1 |
| selectively decreased | #1 |
| azoxymethane mouse model | #1 |
| hippocampus cirrhotic patients | #1 |
| acute hyperammonemia activation | #1 |
| pca increased | #1 |
| cirrhosis extrapyramidal symptoms | #1 |
| pathogenesis wernicke | #1 |
| encephalopathy vivo | #1 |
| rtpcr experiments betaactin | #1 |
| investigator predictions | #1 |
| unchanged brain | #1 |
| propanolamines putamen | #1 |
| cerebral cortex hypokinesia | #1 |
| hepatic coma patients | #1 |
| nacl taurine | #1 |
| ptbr expression pathogenesis | #1 |
| evidence thiamine deprivation | #1 |
| ammonia increased expression | #1 |
| cerebral disorder | #1 |
| manifest altered expression | #1 |
| abnormal pyruvate oxidation | #1 |
| 15–1788 pharmacokinetics | #1 |
| nnos expression result | #1 |
| liver failure ucds | #1 |
| hyperammonemic disorders | #1 |
| nh4 neurons | #1 |
| reversal neurological symptoms | #1 |
| noradrenaline transporter sites | #1 |
| encephalopathy | #1 |
| alterations brain glutamate | #1 |
| alf evidence | #1 |
| disease outcome prevention | #1 |
| maob encephalopathy humans | #1 |
| serotonin precursor metabolite | #1 |
| lactate brain regions | #1 |
| activation ptbr | #1 |
| alf37 degrees | #1 |
| precoma coma stages | #1 |
| inherited ataxias characteristics | #1 |
| pathogenesis portalsystemic encephalopathy | #1 |
| alf glucose | #1 |
| tdpase activities loss | #1 |
| major role mechanisms | #1 |
| perivenous hepatocytes brain | #1 |
| therapeutic efficacy lcarnitine | #1 |
| loss tdpase activities | #1 |
| cerebellar concentration aspartate | #1 |
| that11cpk11195 | #1 |
| 202 55 nm | #1 |
| nac animal hepatic | #1 |
| αkgdh onset | #1 |
| pfco frontal cortex | #1 |
| daily injections thiamine | #1 |
| increased levels allopregnanolone | #1 |
| previous exposure benzodiazepines | #1 |
| cerebral cortex pca | #1 |
| ptbrs | #1 |
| induction astrocytic cox2 | #1 |
| rats fpc | #1 |
| ptbr nnos | #1 |
| congenital hyperammonemia lcarnitine | #1 |
| ammonia intoxication rats | #1 |
| cyclase content | #1 |
| 071−084 | #1 |
| focal lactic acidosis | #1 |
| aom animal hypothermia | #1 |
| portacavalshunted rats protective | #1 |
| capacity ammonia removal | #1 |
| therapeutic efficacy prevention | #1 |
| edema energy | #1 |
| development nutritional recommendations | #1 |
| ouabain pyrimethamine | #1 |
| alf hepatic | #1 |
| ammonia exposure brain | #1 |
| lola effective | #1 |
| lola efficacy | #1 |
| deficiency densities | #1 |
| portocaval shunting activities | #1 |
| brain consequent increases | #1 |
| heneuropathology | #1 |
| opca messenger receptors | #1 |
| prophylaxis reductions | #1 |
| alf rats | #1 |
| hypothesis hepatic encephalopathy | #1 |
| acquired hyperammonemic | #1 |
| predictive model investigator | #1 |
| isoquinoline benzodiazepine ligands | #1 |
| investigator neurological disorders | #1 |
| brain portacaval anastomosis | #1 |
| glt1 encephalopathy humans | #1 |
| older cirrhotic patients | #1 |
| glut1 expression alf | #1 |
| alterations expression result | #1 |
| loss gfap expression | #1 |
| mbr astrocytes | #1 |
| encephalopathy central | #1 |
| increased brain ammonia | #1 |
| subjects transport defect | #1 |
| disorders ammonia metabolism | #1 |
| alf brain edema | #1 |
| pca portacaval shunt | #1 |
| thiamine deficiency synthesis | #1 |
| etanercept aom | #1 |
| hyperammonemia accounts | #1 |
| pathogenesis cerebral complications | #1 |
| flumazenil cirrhotic patients | #1 |
| brain ammonia pca | #1 |
| glast spraguedawley statistics | #1 |
| hepatic microcirculation patients | #1 |
| portacavalshunting | #1 |
| central thiamine | #1 |
| gaba 11 | #1 |
| prevention ohe | #1 |
| clf alf | #1 |
| region‐selective alterations | #1 |
| frontal cortex fco | #1 |
| ammonium acetate challenge | #1 |
| human hepatic encephalopathy | #1 |
| autopsied brain samples | #1 |
| oxygenase1 hepatic | #1 |
| acute male muscle | #1 |
| rat sustained hyperammonemia | #1 |
| peripheral‐type benzodiazepine receptors | #1 |
| astrocytic accumulation glutamine | #1 |
| reflex selective decreases | #1 |
| encephalopathy il1beta | #1 |
| muscle ammonia removal | #1 |
| onset brain edema | #1 |
| neurological symptoms encephalopathy | #1 |
| muscarinic m1 sites | #1 |
| activities thalamus | #1 |
| ptbr complex | #1 |
| ohe prevention prophylaxis | #1 |
| disproportionately levels | #1 |
| glutamine resonance | #1 |
| cox2 cuznsod | #1 |
| bloodborne ammonia | #1 |
| mental state grade | #1 |
| brain liver failure | #1 |
| neurobiology hepatic encephalopathy | #1 |
| portacaval anastomosis tips | #1 |
| glutaminecycle | #1 |
| sites thiamine | #1 |
| lad platelets | #1 |
| ammonia increased production | #1 |
| chat loss | #1 |
| alanine cerebral cortex | #1 |
| rats acute | #1 |
| plasma clearance halflife | #1 |
| thiamine deficiency humans | #1 |
| rats surgical probenecid | #1 |
| isoquinolinebinding moiety | #1 |
| inhibitors acute hyperammonemia | #1 |
| 90 fmol protein | #1 |
| administration novo synthesis | #1 |
| medium kcl | #1 |
| model human disorder | #1 |
| xlinked inherited defect | #1 |
| update hepatic encephalopathy | #1 |
| diabetes ataxia humans | #1 |
| dopamine thiamine deficiency | #1 |
| alf35 | #1 |
| blood ammonia improvement | #1 |
| pathophysiology cirrhosis | #1 |
| focal lactic | #1 |
| ldeprenyl thiamine deficiency | #1 |
| activation brain ptbr | #1 |
| rats antisense elements | #1 |
| 6hydroxydopamine anterolateral hypothalamus | #1 |
| liver failure modulation | #1 |
| alf include | #1 |
| portalsystemic encephalopathy | #1 |
| mg2dependentatpase | #1 |
| onset neurological symptoms | #1 |
| dawley amino | #1 |
| caveolin1 pathway | #1 |
| tk activity onset | #1 |
| shunted rat | #1 |
| pca increased densities | #1 |
| genes astrocytic proteins | #1 |
| omega 3 receptor | #1 |
| severity akinesia | #1 |
| pse portalsystemic shunting | #1 |
| phenols fig 1structure | #1 |
| pse findings | #1 |
| hepatic coma bbb | #1 |
| acquired hyperammonemia | #1 |
| iii flumazenil | #1 |
| brain distribution rats | #1 |
| vivo cerebral microdialysis | #1 |
| portalsystemic encephalopathy pse | #1 |
| enzyme perivenous hepatocytes | #1 |
| pharmaceutical benzodiazepine | #1 |
| immunohistochemistry spraguedawley statistics | #1 |
| hereditary familial hyperbilirubinemia | #1 |
| ammonia liver failure | #1 |
| alcoholic peripheral neuropathy | #1 |
| failure thiamine | #1 |
| initial reports pathogenesis | #1 |
| expression ptbrs | #1 |
| ” benzodiazepine receptors | #1 |
| hypokinesia et495 | #1 |
| mutant spf | #1 |
| induction epileptic patients | #1 |
| blood manganese etiology | #1 |
| stress alf | #1 |
| thiamine‐deficient rats | #1 |
| alf effects | #1 |
| cns pca | #1 |
| “peripheraltype | #1 |
| glast protein day | #1 |
| brain edema encephalopathy | #1 |
| surgical rna | #1 |
| ” benzodiazepine | #1 |
| edema complications | #1 |
| taurine electrolyte balance | #1 |
| electroencephalogram tracings | #1 |
| antiparkinson drugs hypokinesia | #1 |
| acute neurons mechanisms | #1 |
| gut ammonia | #1 |
| polyclonal antibody glt1 | #1 |
| ptbr increased expression | #1 |
| hepatic encephalopathy relationship | #1 |
| action ro15 | #1 |
| acids aaas | #1 |
| predilection neuropathologic damage | #1 |
| dehydrogenase complex transketolase | #1 |
| encephalopathy brain edema | #1 |
| ohe cirrhosis | #1 |
| reduction mild hypothermia | #1 |
| atp acetyl coa | #1 |
| increased csf lactate | #1 |
| encephalopathy male | #1 |
| cerebellar concentration | #1 |
| free neurological | #1 |
| decreased detoxification | #1 |
| dissected brain tissue | #1 |
| nonvulnerable frontal cortex | #1 |
| portacavalshunted pcs rats | #1 |
| cirrhosis brain dysfunction | #1 |
| muscle portacaval shunting | #1 |
| thiamine deficiency appearance | #1 |
| pse increased densities | #1 |
| pca rats | #1 |
| ammonia major roles | #1 |
| brains spf mice | #1 |
| neuroinflammation alf | #1 |
| glucose loading decreases | #1 |
| compounds pyrithiamine | #1 |
| neuroinflammatory response alf | #1 |
| alf neuroinflammation | #1 |
| edema glutamine | #1 |
| receptors thiamine | #1 |
| expression hyperglycemic | #1 |
| dehydrogenase complex friedreichs | #1 |
| hepatic encephalopathy integrity | #1 |
| brain altered expression | #1 |
| diencephalic cerebellar | #1 |
| cerebrospinal fluid ammonia | #1 |
| pca rats pca | #1 |
| 15–1788 | #1 |
| dawley thiamine | #1 |
| cerebral aminoacids | #1 |
| exp assessment | #1 |
| glur3 subunits opca | #1 |
| sparsefur spf mouse | #1 |
| shunted dogs | #1 |
| peripheral steroidal sources | #1 |
| receptor ptbr | #1 |
| sgc activation lymphocytes | #1 |
| failure alanine | #1 |
| nakatpase activity thalamus | #1 |
| monoamines hplc | #1 |
| failure brain | #1 |
| nimesulide thiamine deficiency | #1 |
| muscarinic thiamine | #1 |
| liver failure neuroinflammation | #1 |
| 15–1788 kinetics | #1 |
| nh4 forms neurons | #1 |
| portacaval | #1 |
| hyperammonemia aaas | #1 |
| encephalopathy cerebral edema | #1 |
| 3hpk11195 human brain | #1 |
| ptbr mrna | #1 |
| loss transporter sites | #1 |
| friedreich gilbert | #1 |
| ω3 receptor | #1 |
| cerebral energy deficit | #1 |
| progression encephalopathy | #1 |
| pallidal binding sites | #1 |
| experimental pse | #1 |
| hepatic encephalopathy authors | #1 |
| rats coma | #1 |
| 3hmuscimol binding studies | #1 |
| alf mild hypothermia | #1 |
| encephalopathy animals | #1 |
| ampa sites | #1 |
| improvements hepatic microcirculation | #1 |
| thalamus thiaminedeficient rats | #1 |
| deficiency wernicke | #1 |
| expression astrocytic | #1 |
| novo lactate synthesis | #1 |
| pfco | #1 |
| hepatocerebral disorders | #1 |
| thalamus symptomatic | #1 |
| region‐selective | #1 |
| distribution l3hnoarg | #1 |
| treatment mild encephalopathy | #1 |
| disorder isomorphic model | #1 |
| encephalopathy activities | #1 |
| shunting hyperammonemia | #1 |
| bioaccumulation neuropathology | #1 |
| brain human experimental | #1 |
| 3hpk11195 | #1 |
| alterations receptor sites | #1 |
| maoa activities cerebellum | #1 |
| ammoniaprecipitated coma | #1 |
| indwelling cisterna | #1 |
| animals thiamine deficiency | #1 |
| ucds liver failure | #1 |
| thiamine deficiency neurons | #1 |
| weeks portacaval | #1 |
| response alf | #1 |
| hepatic devascularized rats | #1 |
| ptbrs portacaval anastomosis | #1 |
| pglycoprotein willebrand factor | #1 |
| alterations pse | #1 |
| thiaminedeficient mothers | #1 |
| brain regions pyrithiamine | #1 |
| psychometric testing risk | #1 |
| parkinsonism cirrhosis | #1 |
| etanercept il6 levels | #1 |
| brain ammonia measurement | #1 |
| metabolites term fluorescence | #1 |
| alf37 | #1 |
| etanercept decreased plasma | #1 |
| thiamine deficiency brains | #1 |
| maob cerebellum | #1 |
| superoxide dismutase rat | #1 |
| fasting intravenous injection | #1 |
| glutamine synthetase capacity | #1 |
| otc deficiency activities | #1 |
| jadad cochrane ohe | #1 |
| thalamus vulnerable region | #1 |
| neuropathologic damage | #1 |
| kgdh activities | #1 |
| direct hepatoprotective effects | #1 |
| subclass sites | #1 |
| lcarnitine energy metabolites | #1 |
| congenital otc deficiencies | #1 |
| glial filament network | #1 |
| therapy refractive tle | #1 |
| glutamateper | #1 |
| pathogenesis wernicke encephalopathy | #1 |
| 3htryptamine receptors | #1 |
| pss degree | #1 |
| pathogenesis brain | #1 |
| pfco cirrhotic patients | #1 |
| patient olivopontocerebellar atrophy | #1 |
| ammonia proinflammatory | #1 |
| loss 3hnisoxetine sites | #1 |
| continues rely | #1 |
| pca operation | #1 |
| nacl mm nacl | #1 |
| alzheimertype astrocytosis | #1 |
| affinity ptbr | #1 |
| pca cns | #1 |
| exclusion brain diseases | #1 |
| cau cirrhotic patients | #1 |
| thalamus cirrhotic patients | #1 |
| fig dansyl | #1 |
| portacaval shunting activities | #1 |
| liver pathology increases | #1 |
| thiaminedeficient animals | #1 |
| thiamine deficiency | #1 |
| gabaaassociated receptors | #1 |
| thalamus wernicke encephalopathy | #1 |
| glutamate originating | #1 |
| selective ptbr ligand | #1 |
| pca encephalopathy humans | #1 |
| neurological disorders selection | #1 |
| lola prevention | #1 |
| ammonia toxins | #1 |
| effective approach prevention | #1 |
| neuronal crosstalk | #1 |
| brain osmolytes | #1 |
| pse surgical probenecid | #1 |
| medial thalamus day | #1 |
| astrocytic glycine | #1 |
| ammonia increased | #1 |
| liver spf mice | #1 |
| lumbar gray matter | #1 |
| tdpase activities | #1 |
| hepatic encephalopathy | #1 |
| neuroinflammationinflammation | #1 |
| raphe serotonin serotonin | #1 |
| action acute hyperammonemia | #1 |
| pathogenesis clinic | #1 |
| central thiamine antagonist | #1 |
| spectrum neuropsychiatric abnormalities | #1 |
| alterations brain dopamine | #1 |
| 3hpk11195 ligands | #1 |
| deficiency binding | #1 |
| pfco brain tissue | #1 |
| gabaa neurosteroids | #1 |
| cultured cells mrna | #1 |
| aqp4 proinflammatory mediators | #1 |
| neuromodulatory site | #1 |
| manganese phosphate mmt | #1 |
| alterations 3h8ohdpat | #1 |
| symptomatic pyrithiamine | #1 |
| perivascular endothelial cells | #1 |
| tdpase tdpase activities | #1 |
| expression ptbr | #1 |
| pathogenesis pse | #1 |
| autopsy brain choline | #1 |
| nonsclerotic tle patients | #1 |
| nacetylcysteine cerebral complications | #1 |
| pathogenesis hepatic encephalopathy | #1 |
| reduction bbb breakdown | #1 |
| encephalopathy alanine | #1 |
| neurosteroid modulatory | #1 |
| neurological symptoms normalisation | #1 |
| pregnenolone brain tissue | #1 |
| treatment lola | #1 |
| alterations increased expression | #1 |
| protective findings | #1 |
| occludin medial thalamus | #1 |
| alcohol‐thiamine interactions | #1 |
| microglia evidence | #1 |
| disorder portalsystemic encephalopathy | #1 |
| symptoms wernicke | #1 |
| rats probenecid treatment | #1 |
| kidney portacaval anastomosis | #1 |
| metabolic scavengers | #1 |
| brain prominent neurotoxin | #1 |
| taurine hepatic encephalopathy | #1 |
| alf mice deletion | #1 |
| dismutase hyperglycemic | #1 |
| hyperammonemic spf mice | #1 |
| precipitation severe stages | #1 |
| ethanol nutritional deficit | #1 |
| alf rats expression | #1 |
| increased binding sites | #1 |
| ouabain doses | #1 |
| modulatory sites | #1 |
| pons gaba content | #1 |
| increased expression ptbribp | #1 |
| 001 cerebral | #1 |
| neuronastrocytic trafficking | #1 |
| severity brain edema | #1 |
| selective loss | #1 |
| local brain production | #1 |
| encephalopathy cirrhosis | #1 |
| increased activities tdpase | #1 |
| pbz receptor densities | #1 |
| therapy ornithine transcarbamylase | #1 |
| rat wernickes encephalopathy | #1 |
| opioid encephalopathy humans | #1 |
| congenital acquired hyperammonemia | #1 |
| failure hepatic | #1 |
| encephalopathy cau | #1 |
| alf animals expression | #1 |
| lcarnitine doses | #1 |
| concentrations olfactory bulb | #1 |
| pathogenesis wernickekorsakoff syndrome | #1 |
| failure amino | #1 |
| ouabain pyrimethamine rats | #1 |
| seasonal ataxia | #1 |
| establishment adult activities | #1 |
| liver failure muscle | #1 |
| brain portacaval | #1 |
| normalisation enzyme activities | #1 |
| pathophysiology hepatic | #1 |
| edema acute | #1 |
| lactate medial thalamus | #1 |
| pca brainstem | #1 |
| severe liver atrophy | #1 |
| spraguedawley statistics immunohistochemistry | #1 |
| coma edema stages | #1 |
| humans wernickes encephalopathy | #1 |
| ngnitrol3harginine | #1 |
| cox2 tle | #1 |
| 3htryptamine receptor | #1 |
| liver diseases range | #1 |
| male pyrithiamine | #1 |
| encephalopathy alf | #1 |
| rate thiamine turnover | #1 |
| hyperammonemic spf | #1 |
| increases glutamine | #1 |
| histamine caudate putamen | #1 |
| molecular standpoint | #1 |
| encephalopathy adult | #1 |
| pyrithiaminetreated rats | #1 |
| concomitantly increased | #1 |
| surgical portacaval anastomosis | #1 |
| transketolase enzyme activities | #1 |
| cns relation | #1 |
| sodium benzoate atp | #1 |
| 8 cirrhotic patients | #1 |
| brain dysfunction pse | #1 |
| thiamine neurochemistry | #1 |
| propanolamines putamen rats | #1 |
| betaep brain | #1 |
| 100 microm manganese | #1 |
| measurement aqp4 levels | #1 |
| sparsefur spf mice | #1 |
| benzoate spf | #1 |
| 70 tk | #1 |
| activities neuronal | #1 |
| malnutrition hepatic failure | #1 |
| selective damage pdhc | #1 |
| stages igg immunohistochemistry | #1 |
| igg extravasation reduction | #1 |
| brain ammonia removal | #1 |
| pbgd mrna expression | #1 |
| azoxymethane brain | #1 |
| excess bloodborne ammonia | #1 |
| astrocytes ammonia levels | #1 |
| encephalopathy alcoholic | #1 |
| dose dependent swelling | #1 |
| rats ouabain pyrimethamine | #1 |
| activities alpha kgdh | #1 |
| csf ammonia control | #1 |
| gabaa ammonia animals | #1 |
| brain ammonia concentrations | #1 |
| hypoglycaemia cerebral cortex | #1 |
| pons thiamine treatment | #1 |
| 2 mm ammonia | #1 |
| exposure azoxymethane | #1 |
| brain levels dheas | #1 |
| csf portacaval anastomosis | #1 |
| alcoholic manganese | #1 |
| chronic hyperammonemic syndromes | #1 |
| fastigial interpositus | #1 |
| rats insulin hypoglycaemia | #1 |
| caudate putamen 57 | #1 |
| fluid taurine | #1 |
| alpha1 isoform ec50 | #1 |
| mhe life | #1 |
| deterioration neurological status | #1 |
| hyperammonemic pathologies | #1 |
| result manganese deposition | #1 |
| deficiency transketolase | #1 |
| humans gabaa steroids | #1 |
| thiaminedependent enzymes establishment | #1 |
| glt1 transporter proteins | #1 |
| rats pca | #1 |
| alf amino | #1 |
| wernickes encephalopathy aids | #1 |
| ammonia central nervous | #1 |
| protein coma stages | #1 |
| routine neurological evaluation | #1 |
| h1 receptor density | #1 |
| 5mm nh4cl p0001 | #1 |
| csf concentrations ammonia | #1 |
| in3hpk11195 binding sites | #1 |
| glucose loading precipitates | #1 |
| wks spraguedawley receptors | #1 |
| death wernicke | #1 |
| pca rat | #1 |
| neuroprotection onset | #1 |
| pca loss | #1 |
| agents metabolic potential | #1 |
| ptbr mrna thalamus | #1 |
| neuroinhibitory steroid | #1 |
| encephalopathy alf rats | #1 |
| thiamine‐dependent enzymes | #1 |
| 10 microm flumazenil | #1 |
| oxotremorine particle size | #1 |
| lcarnitinetreated | #1 |
| reduction circulating neurotoxins | #1 |
| neuronal thalamus | #1 |
| downregulation glutamate transporter | #1 |
| primary astrocytopathy | #1 |
| brain ptbr | #1 |
| ptbr alterations | #1 |
| pca beta endorphin | #1 |
| fur spf | #1 |
| thiamine deficiency activities | #1 |
| modulation nitric oxide | #1 |
| cirrhosis ammonia hepatic | #1 |
| tissues spf mice | #1 |
| alf alterations | #1 |
| pathogenesis reversible symptoms | #1 |
| brain edema complications | #1 |
| r071–084 | #1 |
| lola reductions | #1 |
| protective portacavalshunted rats | #1 |
| cerebellum sustained hyperammonemia | #1 |
| coma stages | #1 |
| pca penicillamine | #1 |
| ldopa trace amines | #1 |
| peripheral inflammation etanercept | #1 |
| thiamine deficiency decreases | #1 |
| coa levels brain | #1 |
| brain pregnant rats | #1 |
| ammonia acute | #1 |
| ammonia normal conditions | #1 |
| additional thiamine | #1 |
| blood ammonia md | #1 |
| etanercept hepatic | #1 |
| olivopontocerebellar atrophy expression | #1 |
| oatreated rats alf | #1 |
| deficiency tritium | #1 |
| rats alf | #1 |
| plasma alf rats | #1 |
| encephalopathy sham | #1 |
| liver failure upregulation | #1 |
| findings therapeutic efficacy | #1 |
| lola mental state | #1 |
| hepatic encephalopathy activation | #1 |
| pse altered expression | #1 |
| cerebellar amino acids | #1 |
| surgical rats rats | #1 |
| nh4cl glutamates hippocampus | #1 |
| thiamine deficiency alcoholics | #1 |
| preference pca | #1 |
| hepatic glt1 | #1 |
| liver normal cd1 | #1 |
| 15–1788 pharmacokinetics cirrhosis | #1 |
| precise nature | #1 |
| degree pss | #1 |
| selective alterations | #1 |
| caudate putamen concentrations | #1 |
| nuclei fastigial interpositus | #1 |
| selective reversible decreases | #1 |
| circulating ammonia | #1 |
| 3hpk11195 binding sites | #1 |
| finding loss | #1 |
| encephalopathy selective loss | #1 |
| selectively increased | #1 |
| lipoamide dehydrogenase lad | #1 |
| astrocytic integrity | #1 |
| ammonia brain | #1 |
| pyrithiamine pyruvate | #1 |
| nonvulnerable fpc | #1 |
| brain pse | #1 |
| thiaminedeficient ataxic gait | #1 |
| l3hnoarg binding | #1 |
| reduced astrocytic uptake | #1 |
| nac neurological complications | #1 |
| cerebral hepatic levels | #1 |
| astrocyte morphology alterations | #1 |
| copper pallidum | #1 |
| proinflammatory cytokines strategies | #1 |
| relation energy metabolism | #1 |
| antagonist pyrithiamine | #1 |
| ligand3hpk11195 | #1 |
| cell damage mechanisms | #1 |
| acute hyperammonemic syndromes | #1 |
| serum lad friedreich | #1 |
| hypoglycaemic convulsions | #1 |
| spf mutant | #1 |
| encephalopathy new | #1 |
| mild hypothermia onset | #1 |
| loss nmda | #1 |
| glyt1 mrna | #1 |
| chronic thiamine deprivation | #1 |
| fumazenil | #1 |
| spine neurochemical | #1 |
| ammonium acetate administration | #1 |
| ω3 receptor 3hpk11195 | #1 |
| pyrithiamine | #1 |
| encephalopathy binding | #1 |
| cerebellum 22 | #1 |
| vulnerable medial | #1 |
| protective pathogenesis | #1 |
| ligand3h | #1 |
| result toxins | #1 |
| alf hypothermia | #1 |
| stages encephalopathy | #1 |
| encephalopathy brain | #1 |
| serotonin transporter deficit | #1 |
| benzodiazepine site contrast | #1 |
| hepatic encephalopathy neurobiology | #1 |
| chronic hyperammonemia syndromes | #1 |
| hepatic microcirculation addition | #1 |
| densities 3hpk11195 sites | #1 |
| neuroinflammation liver failure | #1 |
| densities ptbr sites | #1 |
| relationship blood manganese | #1 |
| activities maob | #1 |
| cuznsod cox2 | #1 |
| ptbr expression | #1 |
| iotal6 | #1 |
| tdwt mice | #1 |
| increased synthesis cell | #1 |
| brain thiamine metabolism | #1 |
| cirrhosis nature | #1 |
| glutamate exposure ammonia | #1 |
| liver dysfunction findings | #1 |
| progressive volume increase | #1 |
| borne ammonia | #1 |
| widespread alterations | #1 |
| mm nacl nacl | #1 |
| ptbr | #1 |
| human brain ammonia | #1 |
| aom nac | #1 |
| aom mice nac | #1 |
| lola nash | #1 |
| effective urea cycle | #1 |
| hereferences | #1 |
| l‐3harginine | #1 |
| rtpcr experiments messenger | #1 |
| cell swelling major | #1 |
| platelet taurine uptake | #1 |
| pss dopamine hepatic | #1 |
| novo synthesis aspartate | #1 |
| astrocytic proteins | #1 |
| regionselective reductions | #1 |
| acute male microglia | #1 |
| liver pca | #1 |
| 5mm nh4cl | #1 |
| congenital otc deficiency | #1 |
| mbr decreased expression | #1 |
| congenital hyperammonemia nakatpase | #1 |
| relation deterioration | #1 |
| friedreichs ataxia dehydrogenase | #1 |
| alf rats precoma | #1 |
| dying hepatic | #1 |
| brain major | #1 |
| thiamine interactions | #1 |
| pregnanolone brain chemistry | #1 |
| glutamine astrocyte | #1 |
| presence brain extracts | #1 |
| igg extravasation expression | #1 |
| postshunt myelopathy | #1 |
| minocyclinetreated alf rats | #1 |
| normal conditions gut | #1 |
| 3hkainate sites | #1 |
| pyrithiamine treatment | #1 |
| portacaval shunting hyperammonemia | #1 |
| prevention ammoniaprecipitated coma | #1 |
| mitochondrial enzyme αkgdh | #1 |
| circulating neurotoxins | #1 |
| rendered ataxic | #1 |
| ptbr brain | #1 |
| thiamine monophosphatetmp | #1 |
| key astrocytic | #1 |
| pse probenecid | #1 |
| taurine medium | #1 |
| osmotic actions | #1 |
| hyperglycemic focal | #1 |
| anastomosis ammonia | #1 |
| ptbr sites | #1 |
| alf restricted transfer | #1 |
| tnfα delayed progression | #1 |
| alf37 alf37 degrees | #1 |
| csf lactate accumulation | #1 |
| brain hepatic | #1 |
| fco cau | #1 |
| rats varying degrees | #1 |
| hepatic encephalopathies | #1 |
| microglia neuroinflammatory response | #1 |
| ptbr ligand | #1 |
| effects ammonia | #1 |
| 2 7fold increases | #1 |
| l3hnoarg | #1 |
| failure ammonia | #1 |
| daily injections ldeprenyl | #1 |
| dipeptides hepatic | #1 |
| specific l3hnoarg binding | #1 |
| alf nmda receptor | #1 |
| age time interval | #1 |
| brain gaba uptake | #1 |
| astrocyte undergoes | #1 |
| matkowskyj | #1 |
| animal liver failure | #1 |
| lipopolysaccharide precipitates | #1 |
| expression glyt1 transporter | #1 |
| severe encephalopathy coma | #1 |
| pcs rats protective | #1 |
| reversible symptoms | #1 |
| liver failure increases | #1 |
| specific energy metabolism | #1 |
| 3865 258 nm | #1 |
| alf therapeutic | #1 |
| hypokinesia stereotaxic microinjection | #1 |
| methylspiperone pet | #1 |
| magna catheter | #1 |
| alzheimer type astrocytosis | #1 |
| liver failure alterations | #1 |
| metabolism ammonia | #1 |
| friedreichs ataxia thiaminedeficient | #1 |
| csf benzodiazepine | #1 |
| cox2 ca1 subfield | #1 |
| lornithinelaspartate prevention | #1 |
| previous portacaval anastomoses | #1 |
| thiamine daily administration | #1 |
| hyperammonemic syndromes | #1 |
| offspring animal pyruvate | #1 |
| lornithine laspartate ammonia | #1 |
| alf increases | #1 |
| edema encephalopathy | #1 |
| acute male pregnenolone | #1 |
| cerebral levels glutamine | #1 |
| proinflammatory mechanisms pathogenesis | #1 |
| type astrocytosis | #1 |
| hippocampal sclerosis induction | #1 |
| 062 009 liter | #1 |
| neurosteroids hepatic encephalopathy | #1 |
| brain edema rats | #1 |
| hepatic abnormality characteristics | #1 |
| pdhc activities | #1 |
| capacity cerebral cortex | #1 |
| ammonialowering strategies | #1 |
| surgical probenecid | #1 |
| concentrations serotonin precursor | #1 |
| increased activities maoa | #1 |
| 57 caudate putamen | #1 |
| neurological syndrome nature | #1 |
| csf concentrations bzrls | #1 |
| encephalopathy nitrogen | #1 |
| brains pcs rats | #1 |
| inhibitory nh4cl | #1 |
| cell increased synthesis | #1 |
| fco cirrhotic patients | #1 |
| hypothermia prevents | #1 |
| edema formation mnsod | #1 |
| ligand 3hpk11195 | #1 |
| onset hypoglycaemic convulsions | #1 |
| electroencephalogram tracings patients | #1 |
| mrnas ampa receptor | #1 |
| wernickes encephalopathy humans | #1 |
| etanercept biological plausibility | #1 |
| increased activity katpase | #1 |
| pathogenesis brain edema | #1 |
| loss 3hcitalopram sites | #1 |
| stress encephalopathy | #1 |
| precise role glutamine | #1 |
| amines hepatic | #1 |
| encephalopathy prevention | #1 |
| pharmaceutical benzodiazepines | #1 |
| brain astrocytes alterations | #1 |
| etanercepttreated alf mice | #1 |
| ammonia removal brain | #1 |
| alcoholic peripheral | #1 |
| freechoice drinking paradigm | #1 |
| manganese extrapyramidal symptoms | #1 |
| brain glutamate synthesis | #1 |
| liver spleen ratios | #1 |
| aom mice | #1 |
| thalamus pyrithiamine treatment | #1 |
| 1 lola | #1 |
| brains alf rats | #1 |
| normal conditions kidney | #1 |
| experimental model metabolic | #1 |
| αkgdh | #1 |
| ammoniainduced reduction | #1 |
| alf animal hypothermia | #1 |
| mice encephalopathy | #1 |
| pbg pbgd | #1 |
| congenitally hyperammonemic | #1 |
| radioenzymatic assays activities | #1 |
| glut1 alf | #1 |
| sustained hyperammonemia pca | #1 |
| thiamine deficiency result | #1 |
| elucidation neurotransmitter | #1 |
| regional variation bckdh | #1 |
| ammonia central | #1 |
| hypothermia brain | #1 |
| nac normalization | #1 |
| increased gabaergic | #1 |
| azoxymethane mouse | #1 |
| portacaval shunted | #1 |
| binding sites cerebellum | #1 |
| mild hypothermia alf | #1 |
| markedly impaired | #1 |
| autopsy cirrhotic | #1 |
| ammonia pca | #1 |
| thiaminedeficient rats | #1 |
| abstract5fluoromethylornithine | #1 |
| effective approach onset | #1 |
| primary energy failure | #1 |
| catecholaminelike trace amines | #1 |
| pse lornithinelaspartate | #1 |
| veratramines action | #1 |
| bilirubin ataxics | #1 |
| hyperammonaemia brain function | #1 |
| congenital ornithine | #1 |
| azoxymethane bloodbrain barrier | #1 |
| pathogenetic defect | #1 |
| bzrls cirrhotic patients | #1 |
| key astroglial proteins | #1 |
| evidence otc deficiency | #1 |
| prevents brain | #1 |
| pca astrocytic | #1 |
| “ peripheral | #1 |
| pfco fco | #1 |
| thiamine deficiency encephalopathy | #1 |
| thiaminedeficient medium 7 | #1 |
| loss thiamine | #1 |
| ammoniainduced decrease | #1 |
| died hepatic | #1 |
| transketolase tk activities | #1 |
| 3hnisoxetine sites | #1 |
| comatose rats | #1 |
| regional lactate levels | #1 |
| etanercept treatment reduction | #1 |
| direct evidence rats | #1 |
| receptor cirrhotic patients | #1 |
| neuropsychiatric disorder evidence | #1 |
| cirrhotic patients cau | #1 |
| encephalopathy increased | #1 |
| l‐3hnitroarginine | #1 |
| frontal cortex exp | #1 |
| animal model encephalopathy | #1 |
| disorder thiamine deficiency | #1 |
| pharmacological manipulation ptbr | #1 |
| experimental portacaval shunt | #1 |
| glast medial thalamus | #1 |
| pca activities | #1 |
| cirrhosis psychometric testing | #1 |
| ptbr ligand 3hpk11195 | #1 |
| pdhc step | #1 |
| thiamine‐deficient | #1 |
| hepatic encephalopathy cirrhosis | #1 |
| shunted rats presence | #1 |
| pathogenesis hepatic | #1 |
| enos gene deletion | #1 |
| 213caspartate | #1 |
| restricted transfer cell | #1 |
| encephalopathy zidovudine | #1 |
| cloned rat ptbr | #1 |
| 15–1788 plasma levels | #1 |
| glutamine synthetase protein | #1 |
| nh4ac rats | #1 |
| nh4oac administration | #1 |
| ptbr densities | #1 |
| atrophy brain glutamate | #1 |
| lornithine laspartate lola | #1 |
| alcoholthiamine interactions | #1 |
| bbb permeability alf | #1 |
| 7 thiaminedeficient medium | #1 |
| aspartate pons | #1 |
| manganese distribution brain | #1 |
| animal hepatectomy hepatitis | #1 |
| prevention brain edema | #1 |
| thalamus symptomatic rats | #1 |
| daily pyrithiamine treatment | #1 |
| pugh score iii | #1 |
| s‐3h5‐fluorowillardiine | #1 |
| decreased detoxification ammonia | #1 |
| ligand3hpirenzepine | #1 |
| reduction cognitive dysfunction | #1 |
| key astrocytic proteins | #1 |
| ethanol preference ratio | #1 |
| pss rats | #1 |
| sgc cerebral cortex | #1 |
| acute chronic hyperammonemia | #1 |
| 3h8ohdpat frontal cortex | #1 |
| 3hpk11195 rats | #1 |
| binding sites 3hpk11195 | #1 |
| brain cirrhotic patients | #1 |
| region selective alterations | #1 |
| pca ethanol | #1 |
| findings ammonia | #1 |
| deficiency encephalopathy | #1 |
| reversal antiparkinson drugs | #1 |
| taurines role | #1 |
| regionselective alterations | #1 |
| neurotransmitter alterations prevention | #1 |
| spf mouse | #1 |
| bzrls | #1 |
| coma pathophysiologic basis | #1 |
| neuroinflammation cns complications | #1 |
| neurosteroids pregnenolone allopregnanolone | #1 |
| aom treatment alf | #1 |
| thiaminedeficient encephalopathy implications | #1 |
| microglial activation protective | #1 |
| ammonia cns function | #1 |
| nac aom | #1 |
| lola treatment | #1 |
| lornithinelaspartate therapeutic efficacy | #1 |
| neurological complications alf | #1 |
| atp free coenzyme | #1 |
| receptors pca | #1 |
| monoaminergic synaptic function | #1 |
| cox2 cuznsod mrna | #1 |
| pca portacaval anastomosis | #1 |
| thiaminedeficient medium | #1 |
| wernickekorsakoff syndrome disturbances | #1 |
| encephalopathy hypothermia | #1 |
| combined metabolic stresses | #1 |
| edema cytokines | #1 |
| encephalopathy neuropsychiatric | #1 |
| cirrhotic patients benzodiazepines | #1 |
| severe pse | #1 |
| increase brain extracts | #1 |
| increased brain content | #1 |
| hypoglycaemia onset | #1 |
| brains increased concentrations | #1 |
| tissue cirrhotic | #1 |
| degree shunting hyperammonemia | #1 |
| ligase hepatic | #1 |
| restricted transfer glutamine | #1 |
| autopsied frontal cortex | #1 |
| experimental thiamine | #1 |
| liver pca rats | #1 |
| blood ammonia concentrations | #1 |
| nh4cl glutamate release | #1 |
| portacaval‐shunted rat | #1 |
| encephalopathy histamine humans | #1 |
| rats thiamine deficiency | #1 |
| brain glutamine severity | #1 |
| precoma | #1 |
| doses lcarnitine | #1 |
| varying degrees pss | #1 |
| pse neurotransmitter agents | #1 |
| ro15 10 microm | #1 |
| pse csf lactate | #1 |
| 3acetyl pyridine rats | #1 |
| astrocyticneuronal cross | #1 |
| transverese friedreich ataxia | #1 |
| atp free coa | #1 |
| ohe mhe patients | #1 |
| findings manganese | #1 |
| symptomatic stages encephalopathy | #1 |
| components brain glutamate | #1 |
| measured homogenates | #1 |
| familial hyperbilirubinemia | #1 |
| thalamus thiamine deficiency | #1 |
| brain levels tmp | #1 |
| maternal thiamine | #1 |
| akinesia rats | #1 |
| manganese pathogenesis | #1 |
| spf mice | #1 |
| assessment locomotor activities | #1 |
| ptbribp frontal cortex | #1 |
| decarboxylase hepatic | #1 |
| increased gabaergic tone | #1 |
| pca portacaval | #1 |
| ammoniainduced inhibition | #1 |
| osmotic disturbance | #1 |
| overt encephalopathy alterations | #1 |
| neuroinflammatory mechanisms pathogenesis | #1 |
| pca rats phosphate | #1 |
| dawley ammonia | #1 |
| decreased expression glt1 | #1 |
| alf relation | #1 |
| control alf37 | #1 |
| thiamine deficiency expression | #1 |
| maternal thiamine deficiency | #1 |
| increased blood manganese | #1 |
| pathogenesis hyperammonemic syndromes | #1 |
| acute symptomatic animals | #1 |
| nakatpase activities striatum | #1 |
| activities thiamine | #1 |
| p005 5mm nh4cl | #1 |
| immunohistochemistry cox2 immunoreactivity | #1 |
| reflex pdhc activities | #1 |
| microsomes medium | #1 |
| relation sustained hyperammonemia | #1 |
| cirrhosis vicious cycle | #1 |
| poor nutrition vitamin | #1 |
| cns wernickekorsakoff | #1 |
| flunitrazepam hepatic | #1 |
| stroke forms | #1 |
| shunting hyperammonemia rats | #1 |
| maximal binding absence | #1 |
| wernicke′s encephalopathy | #1 |
| mmt manganese phosphate | #1 |
| neurotransmitter function | #1 |
| deficiency prior | #1 |
| normal cd1 | #1 |
| thiamine deficiency bckdh | #1 |
| prior detoxification liver | #1 |
| prevention brain | #1 |
| portacaval anastomosis brain | #1 |
| ptbr mrna levels | #1 |
| region selective | #1 |
| thiamine phosphatases | #1 |
| rats metallic | #1 |
| 25mm nh4cl | #1 |
| thalamus thiamine | #1 |
| ptbrs binding | #1 |
| kgdh decreased | #1 |
| ptbribp | #1 |
| content pallidum | #1 |
| experimental wernicke | #1 |
| thiamine deficiency implications | #1 |
| mild hypothermia prevention | #1 |
| cau lobe hepatic | #1 |
| alf precise role | #1 |
| caudate putamen sum | #1 |
| efficacy lola | #1 |
| taurine microsomes | #1 |
| altered thiamine neurochemistry | #1 |
| hyperammonemic sparse | #1 |
| 3hpk11195 binding | #1 |
| pathogenesis neuronal loss | #1 |
| dansyl chloride microassay | #1 |
| pyrithiamine rats | #1 |
| homogenates cirrhotic patients | #1 |
| testis densities | #1 |
| pglycoprotein mild hypothermia | #1 |
| pbz binding site | #1 |
| oatreated rats | #1 |
| induced stereotyped behavior | #1 |
| inflammation thiamine deficiency | #1 |
| locomotor activities difference | #1 |
| manganese etiology | #1 |
| mild hypothermia reduction | #1 |
| sites ptbr | #1 |
| increased brain concentrations | #1 |
| serum lad patients | #1 |
| 3hpk binding | #1 |
| experimental thiamine deficiency | #1 |
| hypothermia ammonia | #1 |
| 3hpk cultured astrocytes | #1 |
| thiaminedeficient brain | #1 |
| pfco cau | #1 |
| role endogenous benzodiazepines | #1 |
| ammonia metabolism disorders | #1 |
| densities 3hpk11195 | #1 |
| brain ammonia reduction | #1 |
| coma stages encephalopathy | #1 |
| bbb animal hepatic | #1 |
| 11 thiamine deficiency | #1 |
| inhibition bloodbrain transfer | #1 |
| αkgdh activities | #1 |
| ldopa octopamine | #1 |
| 3h 11195 | #1 |
| pbgd rat model | #1 |
| cox2 il1beta mrna | #1 |
| alf studies | #1 |
| brain edema increases | #1 |
| astrocytic cox2 | #1 |
| experimental portal | #1 |
| reduced thiamine intake | #1 |
| rats portacaval | #1 |
| free coa atp | #1 |
| findings neuroinflammatory response | #1 |
| spontaneous release glutamate | #1 |
| brain pca rats | #1 |
| pyrithiamine quinuclidinyl | #1 |
| viral hepatitis alf | #1 |
| portacaval anastomosis | #1 |
| enzyme activities loss | #1 |
| seesection | #1 |
| psychometric testing falls | #1 |
| cytokines mild | #1 |
| sgc activation brain | #1 |
| tissue distribution neuropathology | #1 |
| accumulate brain | #1 |
| increased extracellular brain | #1 |
| complications alf | #1 |
| dehydrogenase αkgdh | #1 |
| ammoniainduced alterations | #2 |
| reduced brain dheas | #2 |
| thiamine deprivation loss | #2 |
| pallidum cirrhotic patients | #2 |
| spf mutant mice | #2 |
| ammonia gabaergic neurotransmission | #2 |
| gaba ammonia | #2 |
| brain samples alcoholics | #2 |
| male portacaval shunt | #2 |
| mrna expression gfap | #2 |
| alanine frontal cortex | #2 |
| fold allopregnanolone | #2 |
| precoma stages p001 | #2 |
| kinetics taurine | #2 |
| glt1 increased | #2 |
| reduction dopamine turnover | #2 |
| wks decreased activities | #2 |
| millimolar concentrations brain | #2 |
| glutamate glur2 | #2 |
| 4week portacaval | #2 |
| reflex stage | #2 |
| increased activities | #2 |
| progression ohe | #2 |
| loss eaat2 expression | #2 |
| ammonia octanoic acid | #2 |
| edema hepatic | #2 |
| lornithinelaspartate | #2 |
| phosphate sulfate mixture | #2 |
| encephalopathy onset | #2 |
| pathogenesis friedreichs ataxia | #2 |
| 3beta5alphathp | #2 |
| 2 brain samples | #2 |
| death thiamine | #2 |
| membranes tomography | #2 |
| encephalopathy portacaval | #2 |
| brain glutamine synthesis | #2 |
| hydrolases aged | #2 |
| 3acetyl pyridine | #2 |
| mental state trials | #2 |
| sustained hyperammonemia | #2 |
| brain portacaval shunting | #2 |
| form ataxia | #2 |
| neurons nmr | #2 |
| reduced brain levels | #2 |
| brain edema concentrations | #2 |
| glutamine hepatic | #2 |
| cerebellum cirrhotic patients | #2 |
| glutamine intracranial | #2 |
| loss eaat2 protein | #2 |
| cuznsod mrna cuznsod | #2 |
| selective increase | #2 |
| restricted transfer | #2 |
| lower levels arginine | #2 |
| thp metabolites fatigue | #2 |
| shunted pcs | #2 |
| densities bmax | #2 |
| pathogenesis portal | #2 |
| hepatic cerebral | #2 |
| vulnerable brain structures | #2 |
| thiaminedeficient mice | #2 |
| carboxamide binding | #2 |
| thiamine deprivation | #2 |
| encephalopathy glutamine concentrations | #2 |
| ammoniainduced neurotoxicity | #2 |
| l‐ornithine‐l‐aspartate | #2 |
| 3hpk11195 brain regions | #2 |
| pyrithiamine induced | #2 |
| intracranial hypertension alf | #2 |
| ammonia animal hepatic | #2 |
| brain taurine concentrations | #2 |
| swelling cortical astrocytes | #2 |
| osmotic effects glutamine | #2 |
| encephalopathy aids | #2 |
| isomorphic model | #2 |
| encephalopathy histamine | #2 |
| development ethanol preference | #2 |
| failure alf | #2 |
| nmda receptor pca | #2 |
| disorder loss | #2 |
| methyhistamine | #2 |
| early precoma stages | #2 |
| precoma coma | #2 |
| encephalopathy wernicke | #2 |
| hyperammonaemia hepatic encephalopathy | #2 |
| hepatic encephalopathy controls | #2 |
| pathophysiologic mechanisms | #2 |
| increase coma stages | #2 |
| hyperammonemic brain | #2 |
| concentrations dheas | #2 |
| thiamine deficiency patients | #2 |
| nash addition | #2 |
| hyperammonemia synaptosomes | #2 |
| 970±079 | #2 |
| rat brain relation | #2 |
| fold thdoc | #2 |
| central neuroinflammatory | #2 |
| mice alf | #2 |
| ataxia animals | #2 |
| decreased gfap immunoreactivity | #2 |
| gammagba nalphaacetylarginine nalphaaa | #2 |
| 67 coma stages | #2 |
| activities maoa | #2 |
| kidney ammonia | #2 |
| bath concentration ammonia | #2 |
| cortical astrocytes ammonia | #2 |
| animals hepatic | #2 |
| experimental alf | #2 |
| induced liver failure | #2 |
| modulation brain | #2 |
| cisterna magna catheter | #2 |
| shunted | #2 |
| cirrhotic patients modulation | #2 |
| alf drug | #2 |
| plasma proinflammatory cytokines | #2 |
| thirtytwo cirrhotic patients | #2 |
| pca rats allopregnanolone | #2 |
| brain shunted rats | #2 |
| neuropsychiatric complication | #2 |
| controls 3alpha5alphathp | #2 |
| increased manganese | #2 |
| thiamine bloodbrain barrier | #2 |
| aged muscimol | #2 |
| 2 flumazenil | #2 |
| implicated pathogenesis | #2 |
| taurine platelets | #2 |
| diseases manganese | #2 |
| isomorphic models | #2 |
| cerebral complications alf | #2 |
| inbred strains glutamine | #2 |
| 3alpha5alphathp 3alpha5betathp | #2 |
| computed wernicke encephalopathy | #2 |
| concentrations gammaguanidinobutyric acid | #2 |
| symptomatic rats | #2 |
| disorder mystery | #2 |
| sites increased | #2 |
| cisterna magna catheters | #2 |
| body fatigue rats | #2 |
| gammagba | #2 |
| modulation sgc | #2 |
| activities choline acetyltransferase | #2 |
| defect membrane transport | #2 |
| edematous cerebral cortex | #2 |
| thiamine‐dependent | #2 |
| cirrhotic patients pathology | #2 |
| gabaa encephalopathy humans | #2 |
| alcoholics absence | #2 |
| 3alpha5betathp patients | #2 |
| sustained deficiency arginine | #2 |
| gfap immunoreactivity degree | #2 |
| portacaval anastomosis pca | #2 |
| haloperiodol | #2 |
| hepatic encephalopathy complication | #2 |
| cerebral edema loss | #2 |
| glutamate syndrome | #2 |
| ammonia metabolism astrocytes | #2 |
| allopregnanolone fold | #2 |
| brain lactate increase | #2 |
| mice congenital | #2 |
| increased brain turnover | #2 |
| bergmann glial pathology | #2 |
| 3000 microg m3 | #2 |
| liver thiamine | #2 |
| ammonia central role | #2 |
| brain levels neurosteroids | #2 |
| hyperammonemia increased | #2 |
| dheas reduced | #2 |
| increase coma | #2 |
| treatment asparagine | #2 |
| mouse astrocytes effects | #2 |
| enzyme deficits | #2 |
| encephalopathy major | #2 |
| wks enzyme activities | #2 |
| brain lactate synthesis | #2 |
| concentrations ammonium chloride | #2 |
| precoma stages increase | #2 |
| wernickes encephalopathy | #2 |
| liver failure studies | #2 |
| pca brain regions | #2 |
| decreased reuptake | #2 |
| thiaminedependent enzymes | #2 |
| thiamine dependent | #2 |
| wernickes encephalopathy patients | #2 |
| brains 36 patients | #2 |
| protein levels glast | #2 |
| neuropathic pain etanercept | #2 |
| alf control | #2 |
| cerebellum output | #2 |
| extracellular brain | #2 |
| increased levels pregnenolone | #2 |
| neuroinhibitory steroids | #2 |
| impaired gaba function | #2 |
| bckdh bckdh activity | #2 |
| ornithine aminotransferase administration | #2 |
| plasma levels 3alpha5alphathp | #2 |
| rats portacaval anastomosis | #2 |
| sgc brain | #2 |
| alf mrna expression | #2 |
| ataxic animals | #2 |
| 150 dose increase | #2 |
| encephalopathy acute | #2 |
| computerized autotrack | #2 |
| cns consequences | #2 |
| autopsy delay intervals | #2 |
| neurons glutamine synthesis | #2 |
| increasing dheas currents | #2 |
| liver failure gfap | #2 |
| hepatic encephalopathy gabaa | #2 |
| cholinergic neuronal loss | #2 |
| thiamine‐dependent enzyme | #2 |
| deficiency include | #2 |
| astrocytic benzodiazepine | #2 |
| portacaval shunting | #2 |
| 26 153 | #2 |
| neurosteroid pregnenolone fold | #2 |
| dheas hepatic | #2 |
| activities muscle | #2 |
| reduced concentrations dheas | #2 |
| pallidal manganese | #2 |
| pyrithiamine rats rats | #2 |
| chronic thiamine | #2 |
| hypokinesia produced | #2 |
| edema alf | #2 |
| tdp dependent enzymes | #2 |
| alpha kgdh | #2 |
| gabaa receptor indomethacin | #2 |
| mri neurological evaluation | #2 |
| neuronal loss alterations | #2 |
| lactate coma stages | #2 |
| vesicular dysfunction | #2 |
| model wernicke | #2 |
| ohe encephalopathy humans | #2 |
| failure altered | #2 |
| novo synthesis lactate | #2 |
| improvement mental state | #2 |
| symptoms thiamine | #2 |
| liver cirrhosis activation | #2 |
| tyrosine tyr levels | #2 |
| thiamine phosphorylation | #2 |
| liver spf | #2 |
| rats cortex male | #2 |
| pyrithiamine treated | #2 |
| animal hepatic encephalopathy | #2 |
| dheas body fatigue | #2 |
| responsible neurological | #2 |
| hepatic encephalopathy ohe | #2 |
| ouabain upregulation | #2 |
| iggimmunoreactivity | #2 |
| ligand 3hpk | #2 |
| deficient encephalopathy | #2 |
| rats thiamine | #2 |
| degree gfap immunoreactivity | #2 |
| serum lad | #2 |
| alpha1 sites | #2 |
| treatment cns complications | #2 |
| 5ht turnover brain | #2 |
| densities binding | #2 |
| brain organic myoinositol | #2 |
| brain dehydroepiandrosterone dhea | #2 |
| densities binding sites | #2 |
| aqp4 cerebral cortex | #2 |
| immunohistochemistry liver failure | #2 |
| csf ammonia | #2 |
| nitric oxide brain | #2 |
| pdh activity platelets | #2 |
| moderate grade iii | #2 |
| thiamine deficiency wks | #2 |
| congenital hyperammonemias | #2 |
| coma stages p001 | #2 |
| thiaminedeficiency | #2 |
| indomethacin locomotor deficit | #2 |
| thiamine turnover | #2 |
| binding 3hpk11195 | #2 |
| ammonia detoxification glutamine | #2 |
| dheas bdl rats | #2 |
| mice acetaminophen toxicity | #2 |
| increased novo synthesis | #2 |
| electrified grid | #2 |
| systemic encephalopathy | #2 |
| human brain contrast | #2 |
| thdoc fold | #2 |
| synthesis aspartate | #3 |
| brain portocaval anastomosis | #3 |
| cerebral cortex pons | #3 |
| lobe hepatic | #3 |
| 5fmorn treatment | #3 |
| liver–brain axis | #3 |
| repetitive removal | #3 |
| brain edema alf | #3 |
| hepatic neurological | #3 |
| βendorphin apomorphine basal | #3 |
| hyperammonemia acute | #3 |
| coma equal | #3 |
| astrocyte glutamine | #3 |
| predictions disorder | #3 |
| statistical significance regions | #3 |
| late symptomatic stages | #3 |
| skeletal portacaval shunt | #3 |
| binding sites heart | #3 |
| ganglia structures | #3 |
| ammoniatreated cells | #3 |
| protein hepatic | #3 |
| 13 consecutive weeks | #3 |
| ammonia brain edema | #3 |
| kornetsky | #3 |
| rats αmt | #3 |
| severity reviews see1–4 | #3 |
| neuroglial proteins | #3 |
| globus pallidus putamen | #3 |
| glutamates hippocampus rats | #3 |
| administration ammonium | #3 |
| protective glutamine | #3 |
| endogenous agonists role | #3 |
| increase brain lactate | #3 |
| edema intracranial | #3 |
| coma stage | #3 |
| reflex serotonin βendorphin | #3 |
| cirrhosis agents | #3 |
| rats pathogenesis | #3 |
| electrically stimulated release | #3 |
| potent neuroactive properties | #3 |
| testis preparations | #3 |
| pca odn immunolabeling | #3 |
| homologous models | #3 |
| glutamine brain edema | #3 |
| peripheral‐type | #3 |
| doubt25 ammonia | #3 |
| corneal reflex apomorphine | #3 |
| abstract hepatic encephalopathy | #3 |
| onset neurological signs | #3 |
| αketoglutarate dehydrogenase | #3 |
| hepatobiliary route | #3 |
| selective down‐regulation | #3 |
| precoma stages | #3 |
| major neurotransmitter systems | #3 |
| deficiency acidosis | #3 |
| cholinergic m1 | #3 |
| pdhc acetyl coa | #3 |
| ammonia glutamate | #3 |
| ammonia hepatic | #3 |
| lcarnitine atp | #3 |
| type ” | #3 |
| encephalopathy hepatic | #3 |
| signs mild personality | #3 |
| rats glutamates hippocampus | #3 |
| intraneuronal release | #3 |
| medium 5 mm | #3 |
| altered glial | #3 |
| 3hdaspartate uptake | #3 |
| glial cells ammonia | #3 |
| platelets 10 patients | #3 |
| mk‐801‐sensitive nitration | #3 |
| hypothermia brain edema | #3 |
| deficiency thiamine | #3 |
| αmt midbrain | #3 |
| 38 alcoholic patients | #3 |
| operated controls | #3 |
| rats pyrithiamine | #3 |
| autotrack | #3 |
| nmda subclass | #3 |
| models thiamine | #3 |
| muscle glutamine synthetase | #3 |
| prevents cerebral | #3 |
| thiamine phosphate | #3 |
| decreased aspartate | #3 |
| cerebellum activities | #3 |
| blood transketolase | #3 |
| addition astrocyte morphology | #3 |
| acids cerebrospinal | #3 |
| ishen guidelines | #3 |
| central cholinergic deficit | #3 |
| pbgd study | #3 |
| animals coma | #3 |
| brain densities | #3 |
| cholestasis‐associated fatigue | #3 |
| astrocytic cell swelling | #3 |
| decreased concentrations striatum | #3 |
| acrylamide pyrithiamine | #3 |
| thiamine deficient | #3 |
| neurobiological characterization | #3 |
| ammonia‐induced brain edema | #3 |
| vitro binding technique | #3 |
| akinesia βendorphin | #3 |
| genial expression | #3 |
| transporter snat5 | #3 |
| homogenates frontal cortex | #3 |
| selective brain lesions | #3 |
| il6 levels brain | #3 |
| deletion delays | #3 |
| hepatic devascularized rat | #3 |
| thiamine deficiency wernicke | #3 |
| humans neurotransmitter | #3 |
| abstract mild hypothermia | #3 |
| treatment portalsystemic encephalopathy | #3 |
| portacavalshunted rats | #3 |
| tetrahydrodesoxycorticosterone | #3 |
| acute ammonia exposure | #3 |
| doubt25 | #3 |
| activities reduced | #3 |
| drug situ nickend | #3 |
| 5fmorn | #3 |
| pallidal signals | #3 |
| encephalopathy aged | #3 |
| midbrain turnover study | #3 |
| ammonia energy metabolism | #3 |
| 320350 degrees | #3 |
| portocaval anastomosis pca | #3 |
| adequate substrates | #3 |
| decreased densities | #3 |
| αmt βendorphin | #3 |
| pallidus hepatic | #3 |
| activities brains | #3 |
| effects ro15 | #3 |
| total brain glutamine | #3 |
| carnitine ammonia | #3 |
| akinesia corneal reflex | #3 |
| βendorphin akinesia | #3 |
| cogent explanation | #3 |
| regions cns | #3 |
| decreased concentrations αmt | #3 |
| pathogenesis central | #3 |
| portacaval anastomosis rats | #3 |
| ammoniainduced impairment | #3 |
| increased ptbr | #3 |
| cerebellar amino | #3 |
| concentrations αmt | #3 |
| strains thiamine | #3 |
| turnover study rats | #3 |
| rats pse | #3 |
| transketolase activities | #3 |
| pcs rat brain | #3 |
| animals profiles | #3 |
| mhe lola | #3 |
| cirrhosis iii | #3 |
| pdh friedreich | #3 |
| brain improvement | #3 |
| increases il1beta | #3 |
| cellspecific pathways | #3 |
| increased uptake capacity | #3 |
| gfap mrna gfap | #3 |
| congenital hyperammonemia | #3 |
| odn immunolabeling | #3 |
| male portacaval | #3 |
| tissue ornithine concentrations | #3 |
| amphetamine amphetamine animals | #3 |
| βendorphin decreased concentrations | #3 |
| encephalopathy inflammation | #3 |
| glutamate transporter cells | #3 |
| singlesite model | #3 |
| alf animals | #3 |
| controls emax | #3 |
| effects ldeprenyl | #3 |
| ammonia swelling | #3 |
| hepatic encephalopathy humans | #3 |
| neurotransmission failure | #3 |
| mrna ammonia | #3 |
| basal ganglia βendorphin | #3 |
| alcoholics wks | #3 |
| bckdh activity rats | #3 |
| acids relation | #3 |
| brain concentrations rats | #3 |
| thiochrome derivatives | #4 |
| edema gene | #4 |
| otcdeficient mice | #4 |
| sham mmars | #4 |
| histaminergic histamine | #4 |
| aged pyruvate | #4 |
| plasma clearance groups | #4 |
| normal coupling | #4 |
| thiamine diphosphatase | #4 |
| alcohol thiamine deficiency | #4 |
| acute liver failure | #4 |
| calcium microsomes | #4 |
| 6 hrs alf | #4 |
| astrocytic genes | #4 |
| cases alcohol abuse | #4 |
| onset severe encephalopathy | #4 |
| arterial ammonia alf | #4 |
| benzodiazepines increase | #4 |
| alf | #4 |
| effects mild hypothermia | #4 |
| albumin dialysis alf | #4 |
| guanylate cyclase patients | #4 |
| maoa isoform | #4 |
| brain thiamine | #4 |
| tdpase | #4 |
| wernickekorsakoff syndrome | #4 |
| time mmars | #4 |
| anastomosis rat | #4 |
| thiamine‐deficient rat brain | #4 |
| ouabainlike compounds | #4 |
| extrapyramidal symptoms patients | #4 |
| increased concentrations prostaglandins | #4 |
| 13 moles | #4 |
| early microglial response | #4 |
| alf brain | #4 |
| gaba friedreich | #4 |
| locomotor deficit | #4 |
| neurotransmitter dysfunction | #4 |
| activities prefrontal cortex | #4 |
| ammonia levels blood | #4 |
| icp arterial ammonia | #4 |
| lornithine laspartate | #4 |
| cerebral amino acids | #4 |
| tspo sites | #4 |
| arterial ammonia mmars | #4 |
| total shunting | #4 |
| brain neuroinflammation | #4 |
| glt1 transcript | #4 |
| activities brain | #4 |
| decreased activities | #4 |
| vitro techniques ketoglutarate | #4 |
| liver central | #4 |
| thiamine deficiency rats | #4 |
| ornithine aspartate | #4 |
| patients wernicke | #4 |
| inos mnsod | #4 |
| amino acids areas | #4 |
| degree alzheimer type | #4 |
| encephalopathy coma | #4 |
| acute ammonia treatment | #4 |
| ions synaptic | #4 |
| newly synthesized glutamine | #4 |
| brain glutamic | #4 |
| subclinical seizure activity | #4 |
| surgical rna rats | #4 |
| regional amino | #4 |
| severe neuronal dysfunction | #4 |
| administration central | #4 |
| postmortem delay interval | #4 |
| brain dopamine receptor | #4 |
| opioid pca | #4 |
| mmars time | #4 |
| cbf inflammatory mediators | #4 |
| liver brain | #4 |
| expression alf | #4 |
| hepatocytes ascorbate | #4 |
| brain hepatic encephalopathy | #4 |
| protein expression brain | #4 |
| taurine friedreichs ataxia | #4 |
| ischemic liver failure | #4 |
| tdinduced cell death | #4 |
| loss glt1 | #4 |
| ouabain ec50 | #4 |
| 5 mm nh4cl | #4 |
| amino acids regions | #4 |
| alcoholism thiamine | #4 |
| thiamine thiamine pyrophosphate | #4 |
| shunted rats | #4 |
| peripheral‐type benzodiazepine | #4 |
| mmars increased icp | #4 |
| mmars brain water | #4 |
| rats portacaval shunting | #4 |
| brain 5ht release | #4 |
| thiamine deficient animals | #4 |
| carnitine energy | #4 |
| cerebral cortex kidney | #4 |
| brain energy failure | #4 |
| synaptic membrane preparations | #4 |
| rats asparagine | #4 |
| brain pregnenolone content | #4 |
| pse increased | #4 |
| thp metabolites | #4 |
| p001 hypothermia | #4 |
| locomotor evaluation | #4 |
| treatment hepatic encephalopathy | #4 |
| astrocytic metabolic | #4 |
| izuru matsumoto | #4 |
| xlinked deficiency | #4 |
| deoxyglucose endothelium | #4 |
| shamoperated controls | #4 |
| activities glutamine synthetase | #4 |
| affinities densities | #4 |
| increased brain glutamine | #4 |
| alf expression | #4 |
| condition development | #4 |
| increased icp alf | #4 |
| animals liver failure | #4 |
| elevated ammonia levels | #4 |
| rat brain pca | #4 |
| mhe mildest form | #4 |
| thiamine antagonist | #4 |
| inflammation mediators icp | #4 |
| brain edema increase | #4 |
| inbred strains ammonia | #4 |
| transketolase wernicke | #4 |
| postsynaptic action | #4 |
| rats βendorphin | #4 |
| topic rifaximin | #5 |
| spf mice controls | #5 |
| acetyl pyridine | #5 |
| increases ammonia | #5 |
| congenital urea | #5 |
| pregnenolone content | #5 |
| treatment malnutrition | #5 |
| rats portacaval shunts | #5 |
| manganese astrocytes | #5 |
| tk activities | #5 |
| glutamine hypothesis | #5 |
| amino acid regions | #5 |
| glutamate symporters | #5 |
| branchedchain analysis | #5 |
| neurological status | #5 |
| prevention prophylaxis | #5 |
| convulsions onset | #5 |
| methioninesulfoximine | #5 |
| result altered | #5 |
| encephalopathy cerebral | #5 |
| onset coma | #5 |
| pet scan study | #5 |
| currents concentrations | #5 |
| mild personality | #5 |
| hepatic encephalopathy gaba | #5 |
| maoa function | #5 |
| transporter sites | #5 |
| patients hepatic | #5 |
| intracranial hypertension rats | #5 |
| liver assist devices | #5 |
| monoamines metabolites | #5 |
| saturation binding isotherms | #5 |
| sustained deficiency | #5 |
| kgdh | #5 |
| glur2 glur3 subunits | #5 |
| allopregnanolone gabaa | #5 |
| hyperammonemia liver | #5 |
| extracellular quin | #5 |
| vulnerable regions | #5 |
| allopregnanolone thdoc | #5 |
| acute magnetic | #5 |
| ammonia muscle | #5 |
| reduction glutamate | #5 |
| tpp cofactor | #5 |
| alcoholic receptors | #5 |
| studied brain | #5 |
| 45 cirrhotic patients | #5 |
| brain ammonia | #5 |
| cns ammonia | #5 |
| thiaminedeficient diet | #5 |
| brain glutamate concentrations | #5 |
| maoa activities | #5 |
| alf ammonia | #5 |
| surgical receptors | #5 |
| exposure cultured astrocytes | #5 |
| activities cerebellum | #5 |
| ammonia lowering | #5 |
| laspartate lola | #5 |
| activities choline | #5 |
| neurotransmitter pool | #5 |
| kstimulated ca2dependent release | #5 |
| thiamine status | #5 |
| amino acids pathogenesis | #5 |
| adequate experimental models | #5 |
| latenight snack | #5 |
| complication acute | #5 |
| mmars | #5 |
| alterations glutamatergic | #5 |
| sites peripheral | #5 |
| astrocytic | #5 |
| homologous model | #5 |
| hand densities | #5 |
| kinetics pharmacology | #5 |
| wernicke | #5 |
| ammonia metabolism | #5 |
| age matched subjects | #5 |
| aspartate lola | #5 |
| responsible brain | #5 |
| brain histamine receptors | #5 |
| publication animals rats | #5 |
| anterolateral hypothalamus | #5 |
| content modulation | #5 |
| reserpinelike | #5 |
| hexyl1h | #5 |
| cytokines ammonia | #5 |
| pse encephalopathy humans | #5 |
| cerebral hepatic | #5 |
| ammonia removal | #5 |
| tissue autopsy | #5 |
| gait animals | #5 |
| genetics astrocytes blotting | #5 |
| chronic exposure manganese | #5 |
| brain acute | #5 |
| activities gad | #5 |
| vulnerable brain | #5 |
| spectroscopy tomography emissioncomputed | #5 |
| rats fatigue | #5 |
| acute rats rats | #5 |
| medial thalamus | #5 |
| liver disease rats | #5 |
| activities liver | #6 |
| glt1 brain | #6 |
| tmpase | #6 |
| thiamine esters | #6 |
| hypothermia alf | #6 |
| alf nac | #6 |
| 3nmol | #6 |
| mars alf | #6 |
| increased glut1 expression | #6 |
| deterioration neurological | #6 |
| platelets 11 patients | #6 |
| enzymes pyruvate | #6 |
| liver failure | #6 |
| unaltered distribution | #6 |
| output cerebellum | #6 |
| relationship neurological symptoms | #6 |
| alphaketoglutarate dehydrogenase | #6 |
| models alf | #6 |
| hyperammonemic | #6 |
| brain benzodiazepine | #6 |
| ascorbate protects | #6 |
| ammonia glutamine | #6 |
| fur mice | #6 |
| glt1 glast protein | #6 |
| 14c taurine | #6 |
| implications pathogenesis | #6 |
| benzodiazepine intake | #6 |
| fmorn | #6 |
| hepatic encephalopathy effects | #6 |
| endstage liver failure | #6 |
| perispinal etanercept | #6 |
| expression astrocytic genes | #6 |
| capacity removal | #6 |
| frontal cortex rats | #6 |
| righting reflexes | #6 |
| dehydrogenase pdhc | #6 |
| blood‐brain barrier integrity | #6 |
| dha administration | #6 |
| 3htryptamine binding | #6 |
| acetyl lcarnitine | #6 |
| term fluorescence | #6 |
| disease ammonia | #6 |
| gabaergic tone | #6 |
| controls arginine | #6 |
| receptors hepatic | #6 |
| basal ganglia structures | #6 |
| lola improvement | #6 |
| cerebral cortex activities | #6 |
| glast transporter | #6 |
| thiamine phosphate esters | #6 |
| inflammatory mediators groups | #6 |
| nencki | #6 |
| mice nacetylcysteine | #6 |
| brain cirrhotic | #6 |
| enzymes brains | #6 |
| concomitant 24fold increase | #6 |
| increased expression aqp4 | #6 |
| dogs hepatic encephalopathy | #6 |
| induced thiamine | #6 |
| cerebellum caudate nucleus | #6 |
| central proinflammatory | #6 |
| encephalopathy humans | #6 |
| nac alf | #6 |
| pca sham | #6 |
| 3htryptamine binding sites | #6 |
| humans hyperammonemia | #6 |
| cerebral amino | #6 |
| plasma frontal cortex | #6 |
| astrocyte cell volume | #6 |
| direct neurotoxic | #6 |
| arginine brain | #6 |
| animal hepatic | #7 |
| transporter deficit | #7 |
| thiamine absorption | #7 |
| neurological symptoms | #7 |
| rats ammonium acetate | #7 |
| mediators liver | #7 |
| notion activation | #7 |
| metallic phosphate | #7 |
| vpmt | #7 |
| surgical rats | #7 |
| perineuronal astrocytes | #7 |
| chronic deprivation | #7 |
| central neuroinflammation | #7 |
| icp alf | #7 |
| brain glutamate | #7 |
| inhibitor src | #7 |
| 70 mm kcl | #7 |
| pregnant rats offspring | #7 |
| nutritional management patients | #7 |
| astrocytic transporters | #7 |
| gdh activities | #7 |
| acute minocycline | #7 |
| glutamine increased | #7 |
| l3harginine uptake | #7 |
| igg immunohistochemistry | #7 |
| alf arterial ammonia | #7 |
| encephalopathy findings | #7 |
| neuronal cell loss | #7 |
| fulminant liver failure | #7 |
| neuropsychiatric abnormalities patients | #7 |
| neuroinhibitory | #7 |
| failure acute | #7 |
| edema plasma | #7 |
| fatigue severity patients | #7 |
| alcoholic brain damage | #7 |
| chemistry disease | #7 |
| uremic coma | #7 |
| tppdependent enzymes | #7 |
| edema extracellular | #7 |
| alf sham | #7 |
| wernicke‐korsakoff syndrome | #7 |
| concentrations allopregnanolone | #7 |
| liver hepatic encephalopathy | #7 |
| size portacaval | #7 |
| hiaa increased | #7 |
| flumazenil 10 microm | #7 |
| hepatic encephalopathy studies | #7 |
| skeletal muscle adapts | #7 |
| glutamine synthesis ammonia | #7 |
| ischemia hyperglycemic | #7 |
| flumazenil patients | #7 |
| kcl medium | #7 |
| tdp ttp | #7 |
| columbia rating scale | #7 |
| transketolase animals | #7 |
| thiamine dependent enzymes | #7 |
| severe thiamine deficiency | #7 |
| ammonia kidney | #7 |
| swelling astrocytes | #7 |
| central benzodiazepine receptors | #7 |
| cerebral alterations alf | #7 |
| typical friedreichs ataxia | #7 |
| pca pss | #7 |
| glutamate acute | #7 |
| cyclase hepatic | #7 |
| increased cerebellum | #7 |
| loss transporter | #7 |
| frontal cortex controls | #7 |
| 3htryptamine | #7 |
| content frontal cortex | #8 |
| antisense elements genetics | #8 |
| chronic brain dysfunction | #8 |
| neuropathologic consequences | #8 |
| normal metabolic balance | #8 |
| synthesis thiamine | #8 |
| nmda sites | #8 |
| tellez | #8 |
| clive harper | #8 |
| loss congenital | #8 |
| tests ataxia | #8 |
| result decreased | #8 |
| strains ornithine | #8 |
| cerebellum activation | #8 |
| intracranial pressure increase | #8 |
| portalsystemic shunting | #8 |
| activities glutamine | #8 |
| arterial ammonia concentrations | #8 |
| izuru | #8 |
| elfar adalsteinsson | #8 |
| taurine ca2 | #8 |
| hyperglycemic cerebral ischemia | #8 |
| lactate synthesis | #8 |
| falls cirrhosis | #8 |
| ammonium ions | #8 |
| prefrontal nmda | #8 |
| regional alterations | #8 |
| thalamus cerebellum | #8 |
| assessment bioaccumulation | #8 |
| direct toxic actions | #8 |
| induced akinesia | #8 |
| gaba reverse | #8 |
| expression glyt1 | #8 |
| central noradrenergic function | #8 |
| brain increased expression | #8 |
| autopsied human | #8 |
| dependent enzymes | #8 |
| study binding sites | #8 |
| disease gad | #8 |
| cells ammonia | #8 |
| affinity glutamate uptake | #8 |
| complications liver disease | #8 |
| portocaval anastomosis | #8 |
| neuroprotective steroids | #8 |
| alcohol brain damage | #8 |
| voluntary ethanol consumption | #8 |
| peter dodd | #8 |
| brain ammonia levels | #8 |
| ammonia metabolites | #8 |
| receptors mitochondrial | #8 |
| ammonia hyperammonemia | #8 |
| sourkes | #8 |
| active pyruvate dehydrogenase | #8 |
| alf administration | #8 |
| neurobehavioral damage | #8 |
| spraguedawley temporal lobe | #8 |
| cirrhotic patients | #8 |
| concentrations thdoc | #8 |
| 3alpha5betathp | #8 |
| synthesis lactate | #8 |
| proinflammatory mediators expression | #8 |
| alcohol thiamine | #8 |
| probenecid 5 | #8 |
| measurement cell volume | #8 |
| ultraviolet uv spectrum | #8 |
| alterations modulation | #8 |
| hyperglycemic cerebral | #8 |
| rindi | #8 |
| brain herniation | #9 |
| sham alf | #9 |
| hepatocerebral | #9 |
| acute nitric oxide | #9 |
| acid hepatic | #9 |
| brain postsynaptic | #9 |
| arterial ammonia concentration | #9 |
| rat brain density | #9 |
| male cirrhotic patients | #9 |
| 5fluoromethylornithine | #9 |
| hepatic encephalopathy ammonia | #9 |
| central gabaa receptor | #9 |
| vulnerable brain regions | #9 |
| portal hypertension result | #9 |
| adolf pfefferbaum | #9 |
| order address | #9 |
| 11 cirrhotic patients | #9 |
| portacaval rat | #9 |
| cerebellum medulla oblongata | #9 |
| binding sites brain | #9 |
| hepatic coma | #9 |
| glutamate glt1 | #9 |
| edith sullivan | #9 |
| hyperammonemia liver cirrhosis | #9 |
| kinetics distribution | #9 |
| pcs rats | #9 |
| animals acute | #9 |
| observed frontal | #9 |
| binding sites nmda | #9 |
| acute hyperammonemia | #9 |
| glucose hypothermia | #9 |
| ammonia neurotoxicity | #9 |
| pallidal signal | #9 |
| manganese dust | #9 |
| prevention complications | #9 |
| joanne lewohl | #9 |
| acute rats | #9 |
| taurine binding | #9 |
| taurine calcium | #9 |
| edema rats | #9 |
| gabaa tissue distribution | #9 |
| sites frontal | #9 |
| nonneuronal elements | #9 |
| autopsied brain | #9 |
| perispinal administration | #9 |
| cerebral ammonia toxicity | #9 |
| thiamine monophosphatase | #9 |
| transcarbamylase otc | #9 |
| ammonia key role | #9 |
| 37 decrease | #9 |
| protein glut1 | #9 |
| gaba reference | #9 |
| rats phosphate | #9 |
| glutamate receptor ligands | #9 |
| disease thiamine | #9 |
| mild hypothermia | #9 |
| activities skeletal muscle | #9 |
| mechanisms responsible | #9 |
| neurotoxic substance | #9 |
| ammonia induced | #9 |
| glial tca cycle | #9 |
| ammonia binding | #9 |
| glyt1 transporter | #9 |
| neuroinhibition | #9 |
| fur mouse | #10 |
| subsequent gc analysis | #10 |
| deficiency congenital | #10 |
| bdl surgery | #10 |
| brain edema | #10 |
| activation pathogenesis | #10 |
| neuroactive amino acids | #10 |
| rats daily injections | #10 |
| thiamine transketolase | #10 |
| loss reflex | #10 |
| selective brain regions | #10 |
| rats nimesulide | #10 |
| mechanisms free radicals | #10 |
| 10 mm concentration | #10 |
| nh4 forms | #10 |
| disorders include | #10 |
| identification alterations | #10 |
| thiamine replenishment | #10 |
| mechanisms tnfalpha | #10 |
| massive brain edema | #10 |
| mnsod cuznsod | #10 |
| progression hepatic encephalopathy | #10 |
| rats stereotyped behavior | #10 |
| flumazenil hepatic | #10 |
| neuropsychiatric disorder | #10 |
| nh4ac | #10 |
| cerebral consequences | #10 |
| labeling glutamine | #10 |
| thalamic structures | #10 |
| encephalopathy grade | #10 |
| cerebellum pons | #10 |
| urea cycle enzymopathies | #10 |
| encephalopathy cirrhotic | #10 |
| glutathione levels expression | #10 |
| 3hketanserin binding sites | #10 |
| ammonia study | #10 |
| 200 appearance | #10 |
| 3omethylglucose animals animals | #10 |
| hrqol mhe | #10 |
| mechanisms include | #10 |
| 3hpk | #10 |
| affinities binding sites | #10 |
| model alf | #10 |
| brain pca | #10 |
| decreased glutamate | #10 |
| anastomosis hepatic | #10 |
| dissected material | #10 |
| glutamine synthesis astrocytes | #10 |
| rat leads | #10 |
| expression superoxide | #10 |
| neurological symptomatology | #10 |
| stress thiamine | #10 |
| complication chronic | #10 |
| cord taurine | #10 |
| swelling ammonia | #10 |
| gabaergic tonic currents | #11 |
| biosynthetic purposes | #11 |
| ammonia animals rats | #11 |
| experimental design limitations | #11 |
| benzodiazepinelike compounds | #11 |
| patients gabaa | #11 |
| brain alf | #11 |
| glutamate gammaaminobutyric acid | #11 |
| ammonia amino acids | #11 |
| pca brain | #11 |
| ammonia pathogenesis | #11 |
| isoforms mrna | #11 |
| dehydrogenase alpha | #11 |
| benzodiazepines neurosteroids | #11 |
| alterations brain | #11 |
| time icp | #11 |
| pca p005 | #11 |
| brain liver | #11 |
| brain h1 | #11 |
| dawley thalamus | #11 |
| impaired oxidation | #11 |
| fluoromethylornithine | #11 |
| halflife age | #11 |
| oxidative nitrosative stress | #11 |
| signal hyperintensity | #11 |
| cerebral vulnerability | #11 |
| 1h‐13c | #11 |
| ammonia astrocytes | #11 |
| portal systemic | #11 |
| reduced activities | #11 |
| hypothermia liver | #11 |
| cirrhotic patients relationship | #11 |
| impaired locomotor activity | #11 |
| rats nh4cl | #11 |
| increased expression brain | #11 |
| studies convincing evidence | #11 |
| deficiency brain | #11 |
| hyperammonemias | #11 |
| placebo benzodiazepines | #11 |
| brain increased | #11 |
| amino acids rats | #11 |
| benzodiazepine bdz receptors | #11 |
| capacity ammonia | #11 |
| pdh alpha | #11 |
| manganese blood | #11 |
| selective radioligands | #12 |
| blood manganese concentrations | #12 |
| brains rats | #12 |
| binding sites ligands | #12 |
| ammonia amino | #12 |
| deficiency amino | #12 |
| prevention hepatic encephalopathy | #12 |
| total glutamine | #12 |
| rats glut1 | #12 |
| clinical hepatic encephalopathy | #12 |
| mild hypothermia patients | #12 |
| binding medium | #12 |
| ammonia | #12 |
| neuroactive amino | #12 |
| shunt surgical | #12 |
| selective inactivator | #12 |
| diphosphate form | #12 |
| thiamine deficient diet | #12 |
| humans hepatic | #12 |
| acetyltransferase disease | #12 |
| contribute pathogenesis | #12 |
| brain slices synaptosomes | #12 |
| aqp4 brain edema | #12 |
| mm nh4cl | #12 |
| p005 pca | #12 |
| selective loss expression | #12 |
| anaplerotic activity | #12 |
| brain chronic | #12 |
| ammonia salts | #12 |
| perispinal | #12 |
| loss righting | #12 |
| thiamin triphosphate | #12 |
| igg extravasation | #12 |
| humans ketoglutarate | #12 |
| improvement neurological symptoms | #12 |
| cerebellar tissue | #12 |
| hyperammonemia liver failure | #12 |
| thalamus cerebral cortex | #12 |
| subclinical encephalopathy | #12 |
| ammonia animals | #12 |
| increased ammonia | #12 |
| microglial activation brain | #12 |
| patients frontal cortex | #12 |
| pairfed control mice | #12 |
| hyperammonemic conditions | #13 |
| evidence central | #13 |
| ammonia manganese | #13 |
| amino acids lactate | #13 |
| hyperammonemia ammonia | #13 |
| patients flumazenil | #13 |
| increased brain lactate | #13 |
| neuroprotection pretreatment | #13 |
| loss chat | #13 |
| levels octopamine | #13 |
| neurosteroids pregnenolone | #13 |
| thiamine intake | #13 |
| pallidal dopamine | #13 |
| hepatic encephalopathy patients | #13 |
| ishen | #13 |
| liver toxins | #13 |
| development severe encephalopathy | #13 |
| tissuespecific alterations | #13 |
| ammonia cytokines | #13 |
| increased copper content | #13 |
| endogenous neuropeptide ligands | #13 |
| cerebral edema icp | #13 |
| growing body evidence | #13 |
| hand activities | #13 |
| presence hippocampal sclerosis | #13 |
| cytokines hepatic | #13 |
| peripheral nerve conduction | #13 |
| complex ketone | #13 |
| loss gfap | #13 |
| ampa receptor glur2 | #13 |
| survival liver injury | #13 |
| increased csf concentrations | #13 |
| butyrylglycine | #13 |
| body fatigue | #13 |
| hyperglycemic ischemia | #13 |
| postsynaptic gaba | #13 |
| neurosteroids gabaa | #13 |
| regions rat brain | #13 |
| blood csf concentrations | #13 |
| acute ammonia | #13 |
| transcarbamylase deficiency | #13 |
| treatment liver failure | #13 |
| frontal cortex administration | #13 |
| role selective vulnerability | #13 |
| gfap protein | #13 |
| greatest vulnerability | #13 |
| brain water accumulation | #13 |
| expression ammonia | #13 |
| veratramine | #13 |
| sites brain | #13 |
| systemic shunting | #14 |
| sparse fur | #14 |
| portacaval rats | #14 |
| glutamine concentrations | #14 |
| ataxia neurological signs | #14 |
| gfap aqp4 | #14 |
| αmt | #14 |
| mammillary body atrophy | #14 |
| brain energy metabolites | #14 |
| aged biogenic | #14 |
| hypothermia reduction | #14 |
| clinical neurological signs | #14 |
| antibiotic minocycline | #14 |
| striatum concentrations | #14 |
| manganese distribution | #14 |
| cerebellum cerebellar cortex | #14 |
| models hepatic | #14 |
| pathogenesis | #14 |
| 8024 | #14 |
| gabaa reference values | #15 |
| 3hpk 11195 | #15 |
| white matter cbf | #15 |
| vulnerable region | #15 |
| astrocytic volume | #15 |
| moderate drinkers | #15 |
| treatment measurement | #15 |
| cerebral complications | #15 |
| thiamin metabolism | #15 |
| glur3 subunits | #15 |
| acute liver | #15 |
| manganese phosphate | #15 |
| purkinje cell terminals | #15 |
| fulminant liver | #15 |
| ataxics | #15 |
| cirrhosis systematic review | #15 |
| apaptreated mice | #15 |
| failure encephalopathy | #15 |
| hyperintensity patients | #15 |
| portocaval shunts | #15 |
| microglial activation neuroinflammation | #15 |
| activity pdhc | #15 |
| alcoholic brain | #15 |
| role thiamine | #15 |
| 3hquisqualate | #15 |
| hypothermia 35 | #16 |
| isoform gene | #16 |
| brain proinflammatory | #16 |
| animal modelling | #16 |
| encephalopathy loss | #16 |
| pcs sham | #16 |
| addition degree | #16 |
| glutamine increase | #16 |
| agonal status | #16 |
| new prospects | #16 |
| benzodiazepine ligands | #16 |
| encephalopathy liver | #16 |
| proteins implicated | #16 |
| encephalopathy chronic | #16 |
| cirrhosis ammonia | #16 |
| brain modulation | #16 |
| socalled type | #16 |
| hypothesises | #16 |
| endothelial glucose | #16 |
| taurine brain | #16 |
| new mechanistic basis | #16 |
| wks | #16 |
| pathophysiologic cascade | #16 |
| distribution tritium | #16 |
| benzodiazepine gaba | #16 |
| hepatic metabolic pathways | #16 |
| gabaa receptor complex | #16 |
| nonvulnerable | #16 |
| synthetase activities | #17 |
| loss liver | #17 |
| vulnerable structures | #17 |
| pathogenesis complications | #17 |
| 4fold increases | #17 |
| glutamate enzyme | #17 |
| surgical construction | #17 |
| complications malnutrition | #17 |
| acids ammonia | #17 |
| neuroinflammatory mechanisms | #17 |
| encephalopathy rats | #17 |
| acid thiamine | #17 |
| cerebellum enzyme | #17 |
| dependent enzyme | #17 |
| early glial | #17 |
| platelets dopamine | #17 |
| reprint | #17 |
| isoquinoline carboxamide | #17 |
| absence ammonia | #17 |
| patient malnutrition | #17 |
| day heavy drinking | #17 |
| benzoate therapy | #17 |
| endogenous benzodiazepines | #17 |
| glutamine phenylalanine | #17 |
| ammonia induces | #17 |
| excess ammonia | #17 |
| early microglial | #17 |
| cox2 expression immunohistochemistry | #17 |
| onset convulsions | #17 |
| liver disease mice | #17 |
| antibiotic rifaximin | #17 |
| pregnenolone allopregnanolone | #17 |
| cortical astrocyte | #17 |
| activation sgc | #17 |
| upregulation aqp4 | #17 |
| brain regions rat | #18 |
| active pyruvate | #18 |
| wernicke korsakoff | #18 |
| beta endorphin betaep | #18 |
| 11195 binding | #18 |
| encephalopathy patients | #18 |
| patients therapeutic options | #18 |
| neurological psychiatric | #18 |
| portocaval shunting | #18 |
| administration aom | #18 |
| condition evidence | #18 |
| prevention progression | #18 |
| result molecules | #18 |
| activities alpha | #18 |
| astrocytes blotting | #18 |
| wernicke korsakoff syndrome | #18 |
| generalized reduction | #18 |
| type benzodiazepine | #18 |
| neuropathologic evaluation | #18 |
| binding sites hippocampus | #18 |
| compared pair | #18 |
| coa levels | #18 |
| alcoholic cirrhotic patients | #18 |
| selective neuronal | #18 |
| 13c isotopomer analysis | #18 |
| astrocytic glutamine synthetase | #18 |
| neuropathological damage | #18 |
| reversible coma | #18 |
| concentrations kcl | #18 |
| doserelated reduction | #18 |
| autopsied | #18 |
| bbb igg | #18 |
| ornithine transcarbamylase | #19 |
| blood manganese | #19 |
| exposure cultured | #19 |
| treatment mhe | #19 |
| agents hepatic | #19 |
| severe encephalopathy | #19 |
| brain peripheral | #19 |
| astrocytic neuronal | #19 |
| cirrhotic patients controls | #19 |
| disease frontal | #19 |
| complications acute | #19 |
| endogenous benzodiazepine | #19 |
| expression result | #19 |
| pathophysiology hepatic encephalopathy | #19 |
| serum ammonia levels | #19 |
| lola patients | #19 |
| energy metabolism brain | #19 |
| csf concentrations 5hiaa | #19 |
| distribution binding | #19 |
| 125iiodopindolol | #19 |
| increase brain water | #19 |
| response neurodegeneration | #19 |
| errors mice | #19 |
| free coa | #19 |
| equal age | #19 |
| synthetase protein | #19 |
| brain lactate | #19 |
| outcome prevention | #19 |
| cholinergic cell loss | #19 |
| rats stages | #19 |
| glutamates glutamine | #19 |
| acids glutamate | #19 |
| control groups animals | #19 |
| benzodiazepine medication | #20 |
| bbb alterations | #20 |
| brain autopsy samples | #20 |
| effects neurosteroids | #20 |
| coma brain | #20 |
| regions rat | #20 |
| lola | #20 |
| glutamate increased | #20 |
| adequate dietary protein | #20 |
| pallidal hyperintensity | #20 |
| glutamate nmda receptors | #20 |
| biochemical lesion | #20 |
| brain organic osmolytes | #20 |
| l3harginine | #20 |
| alf mars | #20 |
| aids patients patients | #20 |
| acute ammonia toxicity | #20 |
| volume plasmapheresis | #20 |
| diencephalic | #20 |
| rats patients | #20 |
| expression oxidative stress | #20 |
| syndrome wks | #20 |
| animals tests | #20 |
| animal frontal | #20 |
| mild hypothermia survival | #21 |
| selective loss neurons | #21 |
| nakatpase activities | #21 |
| sgc nitric oxide | #21 |
| direct neurotoxic effects | #21 |
| symptomatic stages | #21 |
| failure skeletal | #21 |
| metabolic trafficking | #21 |
| protective hypothermia | #21 |
| 3alpha5alphathp | #21 |
| mhe encephalopathy humans | #21 |
| tetrahydrodeoxycorticosterone | #21 |
| endorphin induced | #21 |
| cisterna magna csf | #21 |
| 5 p0001 | #21 |
| 8094 | #21 |
| hyperammonemia rats | #21 |
| blood–brain barrier permeability | #21 |
| glast protein | #21 |
| alanine increased | #21 |
| vivo cerebral | #21 |
| transport ammonia | #21 |
| deficiency synthesis | #21 |
| plasma ammonia concentrations | #21 |
| sites cerebral | #22 |
| deficiency alterations | #22 |
| brain alanine | #22 |
| 3alpha5beta | #22 |
| zieve | #22 |
| brain experimental | #22 |
| alf infection | #22 |
| partial inverse agonists | #22 |
| antiparkinson drugs | #22 |
| effects glutamate | #22 |
| acute hepatic encephalopathy | #22 |
| cerebral cortex brainstem | #22 |
| gaba regions | #22 |
| sham operation rats | #22 |
| 3hafdx | #22 |
| gabaa receptors humans | #22 |
| inbred strains cns | #22 |
| sites measured | #22 |
| normal circumstances | #22 |
| stereotyped behavior rats | #22 |
| hepatic carnitine | #22 |
| characterized model | #22 |
| distribution amino acids | #22 |
| exposed manganese | #22 |
| concentrations glycine | #22 |
| temporal cortex cerebellum | #22 |
| astrocytic protein | #23 |
| impaired absorption | #23 |
| cortex male rats | #23 |
| brain cell function | #23 |
| gabaa steroids | #23 |
| bckdh activity | #23 |
| cerebral gaba | #23 |
| ammonia lactate | #23 |
| glutamine neurons | #23 |
| amino acids model | #23 |
| diphosphate dependent | #23 |
| treatment sarcopenia | #23 |
| proinflammatory cytokines mice | #23 |
| portal systemic encephalopathy | #23 |
| marrero | #23 |
| increased sites | #23 |
| dewhurst | #23 |
| glutamine accumulation | #23 |
| mm ammonia | #23 |
| brain neurosteroid | #23 |
| neuropathological evaluation | #23 |
| ammonia liver | #23 |
| aspartate alanine | #23 |
| thiamine homeostasis | #23 |
| glutamine taurine | #23 |
| oxidative stress nac | #23 |
| deficiency animals | #23 |
| hippocampus thalamus | #23 |
| encephalopathy ammonia | #24 |
| external warming | #24 |
| controls cirrhotic | #24 |
| sites ligands | #24 |
| pathophysiological levels | #24 |
| serotonin 5ht metabolism | #24 |
| brain coenzyme | #24 |
| p005 activities | #24 |
| activites | #24 |
| ” ligands | #24 |
| neuropathologic studies | #24 |
| katpase src | #25 |
| ammonia reduction | #25 |
| sites glutamate | #25 |
| extracellular glutamine | #25 |
| deficiency regulation | #25 |
| damage dysfunction | #25 |
| chronic hepatic | #25 |
| mousseau | #25 |
| uptake 14c | #25 |
| inhalation exposure rats | #25 |
| severe muscle damage | #25 |
| 11195 | #25 |
| glutamine synthesis | #25 |
| transketolase tk | #25 |
| glutamine liver | #25 |
| copper zinc concentrations | #25 |
| human experimental | #25 |
| cytotoxic brain edema | #25 |
| synthase activities | #25 |
| cns complication | #25 |
| nmdareceptor | #25 |
| malnutrition chronic | #25 |
| synthesis amino acids | #26 |
| oxidative stress processes | #26 |
| treatment hepatic | #26 |
| ketoglutarate dehydrogenase | #26 |
| adult patterns | #26 |
| arterial ammonia levels | #26 |
| flumazenil placebo | #26 |
| failure increased | #26 |
| anastomosis rats | #26 |
| 17 39 | #26 |
| aqp4 levels | #26 |
| alanine concentrations | #26 |
| 60p | #26 |
| pathophysiological significance | #26 |
| fluid amino | #26 |
| isoquinolines ligands | #26 |
| pathogenesis cerebral | #26 |
| concentrations ammonia | #26 |
| cerebellum brain | #27 |
| rifaximin mhe | #27 |
| liver fasting | #27 |
| treatment cirrhosis | #27 |
| regional densities | #27 |
| alf induced | #27 |
| noradrenaline transport | #27 |
| increased concentrations | #27 |
| binding 3hmuscimol | #27 |
| onset encephalopathy | #27 |
| brain serotonin metabolism | #27 |
| manganese ammonia | #27 |
| beta sites | #27 |
| support potential | #27 |
| binding site densities | #27 |
| deficient brain | #27 |
| glucose loading | #27 |
| asparagine glutamine | #27 |
| ornithine transcarbamylase otc | #27 |
| fgin1 | #27 |
| accumulation glutamine | #27 |
| oxidative stress evidence | #27 |
| activities decreased | #28 |
| chronic liver failure | #28 |
| allosteric modulatory | #28 |
| astrocytic metabolism | #28 |
| experimental acute | #28 |
| metabolism relation | #28 |
| glutamate transporter activity | #28 |
| devascularized | #28 |
| type hepatic | #28 |
| eaat3 expression | #28 |
| astrocytes loss | #28 |
| selective neuronal loss | #28 |
| wernicke encephalopathy | #28 |
| ataxic gait | #28 |
| baldessarini | #28 |
| effects thiamine | #28 |
| dust rats | #29 |
| effective adjunct therapy | #29 |
| cerebral energy failure | #29 |
| optimal supply | #29 |
| increased glutamine | #29 |
| diverse etiology | #29 |
| induction mild hypothermia | #29 |
| glutamine content | #29 |
| subchronic inhalation exposure | #29 |
| travelled distance | #29 |
| oxide brain | #29 |
| rats probenecid | #29 |
| 3hro5 | #29 |
| shamoperated control animals | #29 |
| frontal temporal cortex | #29 |
| cerebral cortex thalamus | #29 |
| superoxide scavenger | #29 |
| putamen frontal cortex | #29 |
| serotonin turnover | #29 |
| striatum contrast | #29 |
| isopregnanolone | #29 |
| dopamine metabolism striatum | #29 |
| re‐evaluation | #29 |
| pairfed controls | #29 |
| flumazenil flunitrazepam | #29 |
| cytoplasmic nuclear signal | #29 |
| glutamate cgmp | #30 |
| gaba receptor complex | #30 |
| west criteria | #30 |
| stroke neurological | #30 |
| flumazenil gaba | #30 |
| glutamate content | #30 |
| presymptomatic animals | #30 |
| quantitative receptor | #30 |
| aspartate glutamine | #30 |
| frontal cortex samples | #30 |
| glycine glutamine | #30 |
| 3dsrt | #30 |
| blood ammonia concentration | #30 |
| chronic hyperammonemia | #30 |
| increased nmda | #30 |
| nonabsorbable disaccharides | #30 |
| progression liver injury | #30 |
| neurotransmitter amino acids | #30 |
| neuronal cell counts | #30 |
| mediated excitotoxicity | #30 |
| encephalopathy portal | #30 |
| hyperglycemic stroke | #30 |
| studies experimental | #30 |
| inflammatory cascades | #30 |
| chat activities | #30 |
| production microglial | #31 |
| cuznsod protein | #31 |
| antisense elements | #31 |
| shunted animals | #31 |
| leading increased | #31 |
| stupor | #31 |
| brain decreased | #31 |
| peripheral type | #31 |
| brain monoamine oxidase | #31 |
| dogs hepatic | #31 |
| clinical prospects | #31 |
| glutamate nmda | #31 |
| study ammonia | #31 |
| cerebral glutamate | #31 |
| neuroinflammation pathogenesis | #31 |
| expression tight junction | #31 |
| pannecrosis | #31 |
| astrocytes ammonia | #32 |
| 2 alteration | #32 |
| hepatoprotective properties | #32 |
| telemethylhistamine | #32 |
| acute hyperglycemic | #32 |
| hepatic symptoms | #32 |
| increased nitric | #32 |
| binding sites presence | #32 |
| detoxification unit | #32 |
| indian national association | #32 |
| gabaa receptor ligands | #32 |
| binding gaba | #32 |
| temporal cortex patients | #32 |
| friedreichs ataxia | #32 |
| cerebral ammonia | #32 |
| minimal mhe | #32 |
| intracellular osmolarity | #32 |
| akinesia | #32 |
| deficiencies vitamins | #32 |
| effects mild | #32 |
| fixed intervals | #32 |
| uptake ammonia | #32 |
| clinical laboratory findings | #33 |
| ohe patients | #33 |
| gaba aspartate | #33 |
| nash treatment | #33 |
| cns complications | #33 |
| snat5 | #33 |
| et495 | #33 |
| reversible alterations | #33 |
| binding microsomes | #33 |
| cns concentrations | #33 |
| rats ammonia | #33 |
| selective decreases | #33 |
| proinflammatory cytokines brain | #33 |
| monoamines brain | #33 |
| regions brains | #33 |
| species rats | #33 |
| neuronal cell survival | #33 |
| brain gaba levels | #33 |
| failing liver | #33 |
| glycine aspartate | #33 |
| otc deficiency | #33 |
| hand addition | #33 |
| severe neurological dysfunction | #34 |
| nac reduction | #34 |
| nonepileptic controls | #34 |
| stupor coma | #34 |
| ammonium tartrate | #34 |
| inadequate dietary intake | #34 |
| gad activities | #34 |
| severe neurological symptoms | #34 |
| 11 agematched controls | #34 |
| acetylcholinesterase activities | #34 |
| relation brain | #34 |
| encephalopathy hippocampus | #34 |
| hepatic artery ligation | #34 |
| metabolite 5 | #34 |
| nh4oac | #34 |
| cytotoxic brain | #34 |
| groups cirrhotic patients | #34 |
| dawley reverse | #35 |
| astrocytic glutamate | #35 |
| fatigue rats | #35 |
| neuropsychiatric abnormalities | #35 |
| fluid ammonia | #35 |
| chapter 29 | #35 |
| free hepatic | #35 |
| overt encephalopathy | #35 |
| effects manganese | #35 |
| octadecaneuropeptide | #35 |
| activation proinflammatory | #35 |
| ammonia concentrations | #35 |
| total thiamine | #35 |
| type gaba | #35 |
| manganese tricarbonyl | #35 |
| neurotransmitter amino | #35 |
| space glutamic | #35 |
| severe compromise | #35 |
| chronic hepatic encephalopathy | #35 |
| synthesis glutamate | #36 |
| muscarinic sites | #36 |
| arterial ammonia | #36 |
| cerebral cortical astrocytes | #36 |
| thioacetamide treatment | #36 |
| uptake glutamate | #36 |
| acid brain | #36 |
| electricalfield stimulation | #36 |
| brain regions studies | #36 |
| cycle glucose | #36 |
| astrocyte glutamate | #36 |
| astrocytic glutamine | #36 |
| numerous etiologies | #36 |
| detoxification product | #36 |
| aom treatment | #36 |
| alf mice | #37 |
| 3beta5alpha | #37 |
| protein glutamate | #37 |
| mice ammonia | #37 |
| increased voluntary | #37 |
| perivenous hepatocytes | #37 |
| mild hypothermia therapy | #37 |
| excitotoxic mechanism | #37 |
| blood manganese levels | #37 |
| increased blood glucose | #37 |
| acute receptors | #37 |
| csf cisterna magna | #37 |
| astrocytic marker | #38 |
| failure male | #38 |
| ammonium acetate | #38 |
| glutamatergic function | #38 |
| corneal reflex | #38 |
| increase glutamine | #38 |
| brain amino acids | #38 |
| glutamate ammonia | #38 |
| brain rats | #38 |
| gfap immunohistochemistry | #38 |
| hypothermia attenuates | #38 |
| posterior columns | #39 |
| concomitant decreases | #39 |
| pdhc | #39 |
| thiamine administration | #39 |
| glutamine formation | #39 |
| loss gene expression | #39 |
| clive | #39 |
| hyperammonaemic | #39 |
| severe liver dysfunction | #39 |
| findings increased | #39 |
| benzodiazepine antagonist | #39 |
| chronic alcoholism | #39 |
| brain regional distribution | #39 |
| pca surgery | #39 |
| nitroarginine rats rats | #40 |
| dheas | #40 |
| regionally selective | #40 |
| nmdamediated excitotoxicity | #40 |
| etiology severity | #40 |
| argininic acid | #40 |
| increased density | #40 |
| ammonia homeostasis | #40 |
| arginine uptake | #40 |
| glutamine glycine | #40 |
| neurological alterations | #40 |
| concentrations catecholamines | #40 |
| seizures mental retardation | #40 |
| acetylcoa levels | #40 |
| concentration areas | #40 |
| quin levels | #40 |
| liver inasl | #40 |
| regiondependent manner | #40 |
| brain taurine | #41 |
| complications chronic | #41 |
| regulation caveolin1 | #41 |
| detoxification ammonia | #41 |
| vulnerable area | #41 |
| thiamine metabolism | #41 |
| acid neurotransmitter | #41 |
| brain extracts | #41 |
| regions concentrations | #41 |
| increased glutamate release | #41 |
| cellcell signalling | #41 |
| sgc activation | #41 |
| brain benzodiazepine receptors | #41 |
| lateral vestibular nucleus | #41 |
| deficiency disease | #41 |
| activation nmda receptor | #41 |
| illness terminology topic | #42 |
| cerebral glutamine | #42 |
| thdoc | #42 |
| pk11195 binding | #42 |
| trace amines | #42 |
| benzodiazepine sites | #42 |
| cerebral alterations | #42 |
| complex pdhc | #42 |
| glutamine insulin | #43 |
| liver assist | #43 |
| metabolism acute | #43 |
| gabaa tritium | #43 |
| acute ammonia intoxication | #43 |
| nonalcoholic patients | #43 |
| transcarbamylase | #43 |
| carbamoyltransferase deficiency | #43 |
| increased neuronal | #43 |
| ohe mhe | #44 |
| behavioral excitation | #44 |
| reduction brain | #44 |
| aged portacaval | #44 |
| sarcopenia cirrhosis | #44 |
| cerebral levels | #44 |
| ammonia increases | #44 |
| mechanisms disorder | #44 |
| acid glutamine | #44 |
| western brain dna | #44 |
| toxic liver | #44 |
| increased serotonin | #44 |
| severe hyperammonemia | #44 |
| treament | #44 |
| ataxia humans | #44 |
| ventral white matter | #45 |
| mice etanercept | #45 |
| glutamate transporter | #45 |
| small meals | #45 |
| mild encephalopathy | #45 |
| cortex dose | #45 |
| aspartate gaba | #45 |
| isoquinolines kinetics | #45 |
| model congenital | #45 |
| cholinergic neuronal | #45 |
| welldefined areas | #45 |
| thiamin deficiency | #45 |
| normoglycemic rats | #46 |
| fatigue controls | #46 |
| treatment downregulation | #46 |
| brain gamma | #46 |
| exposed ammonia | #46 |
| 11cnmethylspiperone | #46 |
| cortex glutamate | #46 |
| brain oxidative metabolism | #46 |
| human rat brain | #47 |
| rtpcr experiments | #47 |
| microsomes isolated | #47 |
| neurosteroid | #47 |
| metabolism astrocytes | #47 |
| pathophysiologically | #47 |
| alcoholic cirrhotics | #47 |
| brain amino | #47 |
| benzodiazepine receptors | #47 |
| glutamate removal | #47 |
| glutamate aspartate | #47 |
| distinctive pattern | #47 |
| anaplerotic flux | #47 |
| maob | #48 |
| 113cglucose | #48 |
| thalamus pons | #48 |
| concomitant increases | #48 |
| mitochondrial benzodiazepine | #48 |
| 3hmuscimol | #48 |
| hyperammonemia | #48 |
| tnf brain | #48 |
| amino acid synthesis | #48 |
| central nervous function | #48 |
| neurotoxic agents | #48 |
| sites nmda | #48 |
| cerebral dysfunction | #48 |
| cerebellum medulla | #48 |
| age injection | #48 |
| allopregnanolone concentrations | #48 |
| brain tryptophan | #49 |
| cerebellum patients | #49 |
| glycerol phenylbutyrate | #49 |
| neurotoxic actions | #49 |
| nmda binding | #49 |
| central benzodiazepine | #49 |
| rcts low risk | #49 |
| pallidal | #49 |
| voluntary ethanol | #49 |
| ammonia detoxification | #49 |
| increased extracellular | #50 |
| effects body temperature | #50 |
| tyrosine ammonia | #50 |
| rational explanation | #50 |
| hepatic congestion | #50 |
| levels brain | #50 |
| manganese middle | #50 |
| expression glt1 | #50 |
| hepatic encephalopathy study | #50 |
| alcoholic dementia | #50 |
| extracellular glycine | #50 |
| brain banks | #50 |
| false neurotransmitters | #51 |
| early microglial activation | #51 |
| righting | #51 |
| electromyographic evaluation | #51 |
| lcarnitine treatment | #51 |
| glutamate receptors nmda | #51 |
| management hepatic | #51 |
| inflamed brain | #51 |
| acids measured | #51 |
| mice carnitine | #52 |
| alcoholic cirrhotic | #52 |
| friedreichs ataxia patients | #52 |
| vivo microdialysis | #52 |
| severe stages | #52 |
| 12 rats | #52 |
| complex rats | #52 |
| nitroarginine rats | #52 |
| pse | #52 |
| early losses | #52 |
| synthesis glutamine | #52 |
| altered permeability | #52 |
| brain concentrations | #52 |
| cognitive motor dysfunction | #52 |
| neurobehavioral disturbances | #52 |
| neurosteroid synthesis | #53 |
| 3hmuscimol binding | #53 |
| pathophysiologic | #53 |
| treatment alf | #53 |
| central histaminergic | #53 |
| neurosteroid pregnenolone | #53 |
| 3hkainate | #53 |
| rats portacaval shunt | #53 |
| mechanisms proposed | #54 |
| substitutive therapy | #54 |
| cerebral inflammation | #54 |
| activation guanylate cyclase | #54 |
| neuropsychiatric syndrome | #54 |
| kidney testis | #54 |
| portacaval shunts | #54 |
| mildest form | #54 |
| gene expression liver | #54 |
| subsequent alteration | #54 |
| portacaval shunt pcs | #54 |
| ischemic liver | #54 |
| stroke penumbra | #54 |
| liver atrophy | #54 |
| human disorder | #55 |
| hyperglycemic | #55 |
| concomitant reductions | #55 |
| encephalopathy hyperammonemia | #55 |
| activation glutamate receptors | #55 |
| neurotransmitter agents | #55 |
| heterogenity | #55 |
| messenger spraguedawley receptors | #55 |
| glutathione plasma | #55 |
| occludin levels | #55 |
| deficiency decreased | #56 |
| oxidative nitrosative | #56 |
| levels allopregnanolone | #56 |
| regions rats | #56 |
| ca2dependent release | #56 |
| severe cognitive dysfunction | #56 |
| delays onset | #56 |
| awaits | #56 |
| type mitochondrial | #57 |
| brain glutamate levels | #57 |
| current therapeutic options | #57 |
| resonance signal | #57 |
| tetrahydroprogesterone | #57 |
| coma patients | #57 |
| increased intracellular ca2 | #57 |
| failure muscle | #57 |
| h1 receptors | #57 |
| rats ouabain | #57 |
| ammonia exposure | #57 |
| mechanisms implicated | #57 |
| levels amino acids | #58 |
| probenecid treatment | #58 |
| astrocytes glutamate | #58 |
| nervous complications | #58 |
| pdhc activity | #58 |
| levels ammonia | #58 |
| portacaval shunt | #58 |
| swelling brain | #58 |
| activation glutamate | #58 |
| lowering strategies | #58 |
| dansyl derivatives | #58 |
| severity encephalopathy | #58 |
| brain histamine | #58 |
| manganese copper | #58 |
| uptake arginine | #59 |
| neuropharmacological studies | #59 |
| bilirubin metabolism | #59 |
| patients thiamine | #59 |
| mechanism protective | #59 |
| saline treated controls | #59 |
| hyperammonaemia | #59 |
| 13c enrichments | #59 |
| gfap gfap mrna | #59 |
| acetaminophen toxicity | #59 |
| energy metabolites | #60 |
| alcoholic patients | #60 |
| cirrhosis middle | #60 |
| spontaneous synaptic activity | #60 |
| required cofactor | #60 |
| lazabemide | #60 |
| alcoholics patients | #60 |
| purposing | #60 |
| brain production | #60 |
| ammonia toxicity | #60 |
| cirrhotic patients patients | #60 |
| ammonia intoxication | #60 |
| 015 mmol | #61 |
| excitotoxic brain injury | #61 |
| threefold increase | #61 |
| stem cerebral | #61 |
| maob maoa | #61 |
| acid distribution | #61 |
| sham operated | #61 |
| opioid penicillamine | #61 |
| comparable magnitude | #61 |
| bz receptors | #61 |
| affinity gaba | #61 |
| concentrations glutamate | #61 |
| il1beta mrna expression | #61 |
| subjects free | #61 |
| ataxia friedreich | #61 |
| hypertension brain | #62 |
| brain1 | #62 |
| βendorphin | #62 |
| ultimate test | #62 |
| elevated uptake | #62 |
| suggested role | #62 |
| receptors pathogenesis | #62 |
| forebrain cholinergic neurons | #62 |
| taurine synthesis | #62 |
| increased expression mrna | #62 |
| gaba glutamic acid | #63 |
| focal increases | #63 |
| metabolism glutamine | #63 |
| manganese treatment | #63 |
| role glutamate | #63 |
| heavy drinking day | #63 |
| subclinical hepatic | #63 |
| manganese intoxication | #63 |
| spectroscopy tomography | #63 |
| thiamine | #63 |
| regions contrast | #63 |
| portocaval | #63 |
| rtpcr gene expression | #63 |
| failure evidence | #63 |
| brain | #64 |
| thalamus gamma | #64 |
| sodium phenylacetate | #64 |
| transketolase activity | #64 |
| neurosteroid allopregnanolone | #64 |
| disease activities | #64 |
| fatigue pbc | #64 |
| neurotoxic substances | #64 |
| parietal lobe rats | #64 |
| attenuates oxidative | #64 |
| deficiency induced | #65 |
| 2454 | #65 |
| female flumazenil | #65 |
| brain cell death | #65 |
| glutamine ammonia | #65 |
| manganese deposits | #65 |
| kcl nacl | #65 |
| hypokinesia | #65 |
| symptoms addition | #65 |
| brain chemistry | #65 |
| frontal parietal cortex | #65 |
| sodium benzoate | #65 |
| methylhistamine | #65 |
| butyrylcholinesterases | #65 |
| ataxia patients | #66 |
| isethionic | #66 |
| uptake cultured | #66 |
| 13cnmr | #66 |
| gaba animals | #66 |
| putative endogenous ligands | #66 |
| increases brain | #66 |
| mice sodium | #66 |
| brain water | #66 |
| brain 24 | #67 |
| tyrosine content | #67 |
| αmethylptyrosine | #67 |
| humans korsakoff | #67 |
| cerebral energy metabolism | #67 |
| erythrocyte transketolase | #67 |
| lactate increase | #67 |
| ascorbate synthesis | #67 |
| brain patients | #67 |
| glutamate transporter glast | #68 |
| benzodiazepine receptor ligands | #68 |
| selective reductions | #68 |
| indian national | #68 |
| decreased concentrations | #68 |
| reduction ammonia | #68 |
| serotonin transport | #68 |
| unleaded gasoline | #69 |
| hepatoprotection | #69 |
| processing product | #69 |
| osmotic effects | #69 |
| substance rats | #69 |
| rats sham operation | #69 |
| decreased removal | #69 |
| active removal | #69 |
| drug repositioning humans | #69 |
| attenuation effects | #69 |
| bergmann glial | #70 |
| glutamic acid hippocampus | #70 |
| m1 sites | #70 |
| electronic manual searches | #70 |
| cortex caudate | #70 |
| reduces brain | #70 |
| medium concentrations | #71 |
| glutamates glutamic | #71 |
| shunting | #71 |
| animals benzodiazepines | #71 |
| carbamoyltransferase | #71 |
| alloxan diabetes | #71 |
| failure animals | #71 |
| cortex increased | #72 |
| glutamine brain | #72 |
| agematched control subjects | #72 |
| brain allopregnanolone | #72 |
| gabaa tomography | #72 |
| hyperammonemia male | #72 |
| concentration norepinephrine | #72 |
| common inborn error | #72 |
| organic aciduria | #72 |
| pse patients | #73 |
| thiamine treatment | #73 |
| glutamine glutamate | #73 |
| astrocyte swelling | #73 |
| onset neurological | #73 |
| alterations mitochondrial function | #73 |
| homologous structures | #73 |
| hippocampal ca1 subfield | #73 |
| sites observed | #73 |
| cerebroprotective effects | #73 |
| ro15 | #73 |
| glutamic | #74 |
| astrocytes brain | #74 |
| cortex chromatography | #74 |
| gaba steroids | #74 |
| decrease brain | #74 |
| brain content | #74 |
| bath concentration | #74 |
| mechanisms involving | #74 |
| thiamine transport | #75 |
| nature distribution | #75 |
| acids hepatic | #75 |
| normal limits | #75 |
| expression glial | #75 |
| severe neurological impairment | #75 |
| fully elucidated | #75 |
| superfused slices | #75 |
| cerebral cortex patients | #75 |
| cirrhosis brain | #76 |
| transporter eaat3 | #76 |
| gaba glutamine | #76 |
| glutamate binding | #76 |
| receptors studied | #76 |
| larginine uptake | #76 |
| receptors gaba | #76 |
| direct toxic effects | #76 |
| muscle acute | #77 |
| metabolite acetaldehyde | #77 |
| alcoholic patients cirrhosis | #77 |
| glycine concentrations | #77 |
| millimolar range | #77 |
| glutamate concentration | #77 |
| brain skeletal muscle | #77 |
| function hepatic | #78 |
| lnitroarginine methyl ester | #78 |
| benzodiazepines binding | #78 |
| muscle glutamine | #78 |
| interatomic bonds | #78 |
| brain glucose metabolism | #78 |
| nnos protein | #78 |
| oxide liver | #78 |
| excited ground states | #79 |
| hepatic energy | #79 |
| previous reports | #79 |
| deep coma | #79 |
| methylcyclopentadienyl | #79 |
| cns function | #79 |
| taming | #79 |
| neuronally | #79 |
| l‐carnitine | #79 |
| semiquantitative rtpcr | #79 |
| thiamine triphosphate | #79 |
| metabolism brain | #79 |
| failure nitric | #80 |
| gaba benzodiazepine | #80 |
| medullapons | #80 |
| emerging therapeutic target | #80 |
| neurosteroid biosynthesis | #80 |
| maximal binding | #80 |
| encephalopathy treatment | #80 |
| expression glutamate | #80 |
| quantitative autoradiographic | #80 |
| pathogenesis animals | #80 |
| cresyl violet staining | #80 |
| study sections | #81 |
| controls increased | #81 |
| glutamine astrocytes | #81 |
| 85 mmol | #81 |
| astrocyte morphology | #81 |
| muscle ammonia | #81 |
| molecular neurobiology | #81 |
| glutamate nitric | #82 |
| receptor regions | #82 |
| chaired | #82 |
| brain extracellular | #82 |
| shortchain acylcoa dehydrogenase | #82 |
| agents receptors | #82 |
| lcarnitine administration | #82 |
| glutamate brain | #83 |
| proposed explain | #83 |
| 3hro15 | #83 |
| treatment thiamine | #83 |
| ethanol preference | #83 |
| tca cycle flux | #83 |
| 3hflumazenil | #84 |
| devascularization | #84 |
| pathophysiologic basis | #84 |
| water channel protein | #84 |
| cerebral cortex striatum | #84 |
| patients decreases | #84 |
| aom induced | #84 |
| elevated ammonia | #84 |
| measured brain | #84 |
| pbgd | #84 |
| 3hgammaaminobutyric acid | #85 |
| role glutamine | #85 |
| increase brain | #85 |
| concomitant decrease | #85 |
| ammonia patients | #85 |
| 5ht turnover | #85 |
| arga | #85 |
| decreased ca2 | #85 |
| maoa maob | #85 |
| urea cycle enzymes | #85 |
| central muscarinic | #86 |
| glutamate amino | #86 |
| release synaptic | #86 |
| spraguedawley statistics | #87 |
| wilsonian | #87 |
| rats sacrificed | #87 |
| benzodiazepines brain | #88 |
| complication cirrhosis | #88 |
| 52 mmol | #88 |
| tissue brain | #88 |
| csf lactate | #88 |
| selective vulnerability | #88 |
| brain binding | #88 |
| concomitantly | #88 |
| role human diseases | #89 |
| exposure ammonia | #89 |
| undoubtedly | #89 |
| sham operations | #89 |
| caudate nuclei | #89 |
| edema cerebral | #89 |
| olivopontocerebellar atrophy opca | #89 |
| brain regions rats | #89 |
| alpha ketoglutarate | #89 |
| prior onset | #89 |
| encephalopathy ohe | #90 |
| glutamatemediated excitotoxicity | #90 |
| rats species | #90 |
| lactate increased | #90 |
| receptor ligand | #90 |
| patients alf | #90 |
| bcaa concentrations | #91 |
| gaba modulators | #91 |
| reduced brain | #91 |
| monoamine neurotransmitters | #91 |
| leucine concentrations | #92 |
| enzymopathies | #92 |
| bckdh | #92 |
| altered protein expression | #92 |
| neuroinflammatory response | #92 |
| amino acids brain | #92 |
| widespread damage | #93 |
| congenital deficiencies | #93 |
| acid liver | #93 |
| induced alf | #93 |
| mri intensity | #94 |
| thiamin diphosphate | #94 |
| neuronal loss | #94 |
| manganese poisoning | #94 |
| brain kidney | #94 |
| brain compared | #94 |
| increases extracellular | #94 |
| acetate administration | #95 |
| patients liver failure | #95 |
| induced stereotyped | #95 |
| glutamine synthetase expression | #95 |
| benzodiazepines treatment | #95 |
| inhibitory neurotransmission | #95 |
| ammonia accumulation | #95 |
| astrocytic function | #96 |
| discrete areas | #96 |
| 16 mmol | #96 |
| skeletal muscle brain | #96 |
| βlipotropin | #96 |
| ornithine phenylacetate | #96 |
| molecules brain | #97 |
| covert hepatic encephalopathy | #97 |
| ammonia release | #97 |
| astrocytes neurons | #97 |
| brain cytokine | #97 |
| brain vivo | #97 |
| hepatocerebral degeneration | #98 |
| glutamate glutamine | #98 |
| glycine transporters | #98 |
| dorsal tegmental nucleus | #98 |
| thiamine diphosphate | #98 |
| acrylamides animals | #98 |
| carbamoyltransferase ornithine | #98 |
| receptors increased | #98 |
| dehydroascorbic acid | #98 |
| walking gait | #99 |
| examination role | #99 |
| 3045 | #99 |
| stress ammonia | #99 |
| symptomatic stage | #100 |
| aspartate levels | #100 |
| fatigue impact scale | #100 |
| commonly encountered | #100 |
| animal hypothermia | #101 |
| inhibitory amino acids | #101 |
| temporal cortex | #101 |
| pressure liver | #101 |
| proinflammatory | #101 |
| increases levels | #101 |
| levels dheas | #102 |
| treatment complications | #102 |
| synergistic mechanisms | #102 |
| brain barrier breakdown | #102 |
| tk activity | #102 |
| microdialysis rats | #102 |
| cerebral cortex cerebellum | #102 |
| lcarnitine | #102 |
| neurological symptoms patients | #102 |
| collisional deactivation | #103 |
| brain levels | #103 |
| removal ammonia | #103 |
| brain extracellular space | #103 |
| benzodiazepine receptor | #103 |
| controls cirrhotic patients | #103 |
| cerebral oxidative metabolism | #104 |
| label incorporation | #104 |
| 90 loss | #104 |
| methylspiperone | #104 |
| thiamine monophosphate | #104 |
| experimental animal models | #104 |
| regional distribution | #104 |
| transporter glt1 | #105 |
| neurological consequences | #105 |
| m3 exposure | #105 |
| olivopontocerebellar atrophy | #105 |
| experimental models | #105 |
| fatigue severity | #105 |
| loss cholinergic | #105 |
| receptors brain | #105 |
| toxic liver injury | #106 |
| complication liver | #106 |
| concentrations serotonin | #107 |
| receptors rats | #107 |
| 3h8ohdpat | #107 |
| monoamines | #108 |
| gaba content | #108 |
| current theories | #108 |
| characteristic alterations | #108 |
| sham operated controls | #108 |
| dopaminergic dysfunction | #108 |
| t1weighted magnetic resonance | #109 |
| symptomatic animals | #109 |
| glutamate plasma | #109 |
| disease hepatic | #109 |
| ldeprenyl | #109 |
| azoxymethane aom | #110 |
| rats hepatic | #110 |
| 3hnisoxetine | #110 |
| extrapyramidal symptoms | #110 |
| glutamates humans | #110 |
| deficiency humans | #110 |
| glt1 glast | #111 |
| reye syndrome | #111 |
| enzymes brain | #111 |
| 3alpha5alpha | #112 |
| evidence role | #112 |
| activities | #113 |
| lymphocytes rats | #113 |
| brain preparations | #113 |
| hypertension liver | #113 |
| midbrain striatum | #113 |
| ligated rats | #113 |
| glutamate synaptic | #113 |
| metabolic block | #113 |
| expression testis | #113 |
| nutritional management | #114 |
| 57 reduction | #114 |
| radioenzymatic assay | #114 |
| fco | #114 |
| rat astrocytes | #114 |
| experimental animals | #115 |
| nmda receptor expression | #115 |
| brain dogs | #115 |
| decreased synthesis | #116 |
| gabaa gabaergic | #116 |
| 3hmepyramine | #116 |
| mammillary body | #116 |
| pallidum putamen | #116 |
| tips procedure | #117 |
| controls plasma levels | #117 |
| opioid brain | #117 |
| cholinergic deficit | #117 |
| growing body | #117 |
| cortex alzheimer | #117 |
| friedreich ataxia patients | #117 |
| brain dopamine | #118 |
| mechanism ammonia | #118 |
| arginine deficiency | #118 |
| allopregnanolone | #118 |
| albumin dialysis | #118 |
| amine levels | #118 |
| myelin synthesis | #118 |
| cirrhotic | #118 |
| hydroxylating | #119 |
| patients fatty liver | #119 |
| pathologic manifestations | #119 |
| opioid beta | #119 |
| apapinduced | #119 |
| cerebral energy | #119 |
| site densities | #119 |
| nervous dysfunction | #119 |
| glutamates | #120 |
| frontal cortex | #120 |
| genes coding | #120 |
| ouabain induced | #120 |
| balb cbyj mice | #120 |
| pugh score | #121 |
| monoamine oxidaseb | #121 |
| mechanisms pathogenesis | #121 |
| copper manganese | #121 |
| 3hketanserin | #121 |
| bergmann glia | #122 |
| brain enzyme | #122 |
| rat brain synaptosomes | #122 |
| nuclear signal | #122 |
| complex activities | #122 |
| unleaded | #122 |
| brain evidence | #122 |
| normal human brains | #123 |
| selective damage | #123 |
| beneficial patients | #123 |
| implicated | #123 |
| modulatory site | #124 |
| newborn astrocytes cells | #124 |
| gene expression brain | #124 |
| asterixis | #124 |
| neurological signs | #125 |
| icp cbf | #125 |
| striatum cerebellum | #125 |
| ammonia control | #125 |
| role ammonia | #126 |
| ornithine aminotransferase | #126 |
| brain male | #126 |
| ol20 | #126 |
| synthase nitroarginine | #126 |
| glt1 | #126 |
| ala2mephe4met0ol | #126 |
| 11cpk11195 | #126 |
| high‐affinity | #127 |
| taurine uptake | #128 |
| proteins nitric | #128 |
| neuronal cell | #128 |
| cytokines brain | #128 |
| glutamate concentrations | #129 |
| patients friedreichs ataxia | #129 |
| cox2 immunoreactivity | #129 |
| chronic alcoholic patients | #129 |
| neurochemical mechanisms | #129 |
| unanesthetized dogs | #130 |
| agonist action | #130 |
| blood ethanol levels | #130 |
| spontaneous activities | #130 |
| cox2 levels | #130 |
| observed brain | #131 |
| ammonia levels | #131 |
| primary deficit | #131 |
| llactate dehydrogenase | #131 |
| carnitine administration | #132 |
| taurine release | #132 |
| animals azoxymethane | #132 |
| blood ammonia | #132 |
| continuous supply | #132 |
| hepatic abnormalities | #132 |
| factor pathogenesis | #133 |
| lipoamide dehydrogenase | #133 |
| friedreich | #133 |
| site human | #133 |
| ischemia rat | #133 |
| α ketoglutarate | #133 |
| nacetyl cysteine | #133 |
| manganese neurotoxicity | #133 |
| brain glial | #134 |
| lactate accumulation | #134 |
| models acute | #135 |
| concentrations gaba | #135 |
| exposure manganese | #135 |
| kidney skeletal muscle | #135 |
| endogenous amino acids | #135 |
| impact treatments | #136 |
| function addition | #137 |
| acid ammonia | #137 |
| psychometric testing | #137 |
| 3hcitalopram | #137 |
| manganese toxicity | #137 |
| increased intracranial pressure | #137 |
| release glutamate | #137 |
| pregnenolone rats | #137 |
| spinocerebellar degeneration | #138 |
| neuropsychiatric complications | #138 |
| inherited ataxias | #138 |
| cycle enzyme | #139 |
| glutamine alanine | #139 |
| disorder animals | #139 |
| tracer doses | #139 |
| cerebral herniation | #139 |
| lornithine | #139 |
| nanomolar affinity | #139 |
| −70°c | #139 |
| chatpositive neurons | #139 |
| patients friedreich | #140 |
| nutritional recommendations | #140 |
| concentrations nacl | #141 |
| aminobutyric acid | #141 |
| cortex male | #141 |
| dehydrogenase pdh | #141 |
| nonbenzodiazepine | #141 |
| alcoholic nonalcoholic | #142 |
| huntingtons chorea | #142 |
| cerebellar ataxias | #142 |
| gaba synaptic | #142 |
| development hepatic | #142 |
| humans isoquinolines | #142 |
| cbyj | #142 |
| diminished activity | #143 |
| lactate alanine | #143 |
| hypothermia induced | #143 |
| alternative site | #143 |
| serotonin precursor | #143 |
| brain glucose uptake | #143 |
| monoamine oxidasea | #143 |
| brain gaba | #144 |
| insulin hypoglycaemia | #144 |
| glutamateglutamine | #144 |
| delayed myelination | #144 |
| taurine content | #144 |
| selective brain | #144 |
| allosteric agonists | #144 |
| dopamine metabolism | #144 |
| ornithine carbamoyltransferase | #144 |
| cerebral microdialysis | #145 |
| inferior olivary nucleus | #145 |
| brain tissue | #145 |
| hyperglycemic rats | #145 |
| brain hypothermia | #146 |
| brain peripheral tissues | #146 |
| receptormediated responses | #146 |
| glucose load | #146 |
| relation degree | #146 |
| rapid filtration | #147 |
| increase presence | #147 |
| lateral vestibular | #147 |
| comparable degree | #147 |
| animals brain | #148 |
| lactate brain | #148 |
| energy failure | #148 |
| acetyllcarnitine | #149 |
| neurosteroids | #149 |
| ohe | #149 |
| coa acetyl | #149 |
| western cells rats | #149 |
| cirrhosis hepatic | #149 |
| diazepam binding inhibitor | #149 |
| glutamate neurons | #149 |
| failure studies | #150 |
| consumption ethanol | #150 |
| metabolic impairments | #150 |
| probenecid rats | #150 |
| animals astrocytes | #151 |
| patient tissue | #151 |
| protein tyrosine nitration | #151 |
| fatigue scores | #151 |
| progesterone metabolites | #151 |
| female friedreich | #151 |
| zo2 | #151 |
| selective neuronal death | #152 |
| beta actin | #152 |
| patients hepatic encephalopathy | #152 |
| inhibition binding | #153 |
| increased synthesis | #153 |
| testis brain | #153 |
| concentrations amino | #153 |
| impaired brain | #154 |
| tight junction proteins | #154 |
| alcoholism brain | #154 |
| transporter protein | #154 |
| 15 1788 | #155 |
| increased cerebral | #155 |
| ammonia ligase | #156 |
| brain cerebrospinal | #156 |
| experimental male rats | #156 |
| neuroactive | #157 |
| 1788 | #157 |
| radioenzymatic | #157 |
| protein acute | #157 |
| affinity uptake | #157 |
| dimethadione | #158 |
| korsakoff syndrome | #158 |
| ethanol day | #158 |
| glt1 expression | #159 |
| water brain | #159 |
| increased 5 | #159 |
| gfap expression | #159 |
| nitrosative | #159 |
| prominent increase | #159 |
| groups responses | #160 |
| brain dysfunction | #160 |
| astrocytosis | #160 |
| 3methoxytyramine | #160 |
| glutamate ampa | #160 |
| gfap mrna | #161 |
| neuropathologically | #161 |
| expression hepatic | #161 |
| reaction ammonia | #161 |
| diphosphatase | #161 |
| homogenates | #162 |
| perivenous | #162 |
| mercaptans | #162 |
| synaptosomal uptake | #162 |
| increased stimulation | #162 |
| affinity transport | #163 |
| vicious cycle | #163 |
| rats nitric | #163 |
| neurological evaluation | #163 |
| manganese concentrations | #164 |
| increased degradation | #164 |
| mice acetaminophen | #164 |
| glutamine production | #164 |
| transketolase | #164 |
| victor | #165 |
| human alcoholics | #165 |
| glast | #166 |
| extracellular concentrations | #166 |
| brain energy metabolism | #166 |
| bergmann glial cells | #166 |
| regions levels | #166 |
| aids aidsrelated complex | #167 |
| male manganese | #167 |
| increased cerebrospinal | #167 |
| severe signs | #167 |
| increased csf | #167 |
| dansyl chloride | #167 |
| neurotransmitter | #167 |
| benzodiazepine | #167 |
| neurotoxic compounds | #168 |
| deficiency liver | #168 |
| surgical models | #168 |
| precise role | #169 |
| malateaspartate shuttle | #169 |
| monophosphatase | #170 |
| strains spectrometry | #170 |
| acetaminophen acetylcysteine | #171 |
| complications liver | #171 |
| increase pge2 | #171 |
| elevated activities | #171 |
| medial geniculate nucleus | #171 |
| expression alpha1 | #172 |
| apap administration | #172 |
| early increases | #172 |
| ketoglutarate | #172 |
| transport brain | #172 |
| terms relationship | #172 |
| rats protective | #173 |
| protein gfap | #174 |
| complex pyruvate | #174 |
| synergistic actions | #175 |
| brain energy | #175 |
| stereotyped behavior | #175 |
| taurine concentrations | #175 |
| dehydroascorbic | #175 |
| chain amino | #175 |
| binding calcium | #175 |
| gfap immunoreactivity | #176 |
| guanidino compounds | #177 |
| neurological dysfunction | #178 |
| eaat4 | #178 |
| neurological complications | #178 |
| patients plasma levels | #179 |
| fine motor function | #179 |
| rats csf | #180 |
| brain monoamine | #180 |
| serotonin 5hydroxytryptamine | #180 |
| symptoms including | #180 |
| 3hflunitrazepam | #181 |
| brain concentration | #181 |
| experimental hepatic | #181 |
| autoradiography binding | #181 |
| dehydroepiandrosterone sulphate | #182 |
| biochemical consequences | #182 |
| accumulation brain | #182 |
| dheas dhea | #182 |
| competitive brain | #183 |
| neuropsychiatric | #183 |
| patients mhe | #183 |
| nnos mrna | #184 |
| animals antimetabolites | #184 |
| nutritional consequences | #184 |
| neurological disorder | #185 |
| branchedchain amino acids | #185 |
| fluorescence analysis | #185 |
| amphetamine apomorphine | #185 |
| glast glt1 | #185 |
| mm kcl | #186 |
| stress pathogenesis | #187 |
| sequellae | #187 |
| spraguedawley serotonin | #187 |
| expression occludin | #187 |
| controls regions | #187 |
| compared sham | #188 |
| dehydrogenase complex | #188 |
| pcr ratio | #188 |
| cb154 | #188 |
| otc | #188 |
| dawley serotonin | #188 |
| alcar | #188 |
| highaffinity uptake | #189 |
| vasogenic brain edema | #189 |
| rat cerebellum | #189 |
| agonist properties | #190 |
| aminobutyric | #190 |
| dopamine turnover | #191 |
| aged ammonia | #192 |
| specific ligand | #192 |
| pregnanolone | #192 |
| studies alterations | #193 |
| pavlov | #194 |
| righting reflex | #194 |
| patient material | #194 |
| gilles tourettes syndrome | #194 |
| patients immunohistochemistry | #195 |
| limited therapeutic | #195 |
| of3h | #195 |
| gamma aminobutyric | #195 |
| intracellular receptors | #196 |
| mice acute | #197 |
| expression tight | #197 |
| tissue patients | #197 |
| concomitant loss | #198 |
| astrocyte function | #198 |
| guanidino | #198 |
| manganese compounds | #198 |
| unaltered | #198 |
| mrna protein expression | #198 |
| thalamus hippocampus | #199 |
| substitutive | #200 |
| 35 degrees | #200 |
| etiology patients | #200 |
| experimental chronic | #200 |
| noradrenaline transporter | #200 |
| glutamatergic synaptic | #200 |
| mitochondria neurons | #200 |
| brainstem structures | #201 |
| highest density | #201 |
| synthetase expression | #201 |
| csf concentrations | #201 |
| severity liver disease | #202 |
| translation clinic | #202 |
| equal | #202 |
| activation brain | #202 |
| cerebral glucose utilization | #202 |
| activities increased | #203 |
| vitro receptor | #203 |
| therapeutic interventions | #203 |
| benzodiazepine binding | #204 |
| chronic alcohol abuse | #204 |
| cns dysfunction | #205 |
| ketone oxidoreductases | #205 |
| poor nutrition | #206 |
| cuznsod | #206 |
| manganism | #206 |
| grc | #206 |
| trials low risk | #206 |
| ldh1 | #207 |
| ldh5 | #207 |
| central noradrenergic | #207 |
| neuropathological studies | #209 |
| astrocytic response | #209 |
| immunohistochemistry messenger receptors | #209 |
| laboratory rat | #209 |
| ethanol increased | #210 |
| uptake pattern | #210 |
| bergmann | #210 |
| concomitant increase | #210 |
| overt hepatic | #210 |
| millimolar concentrations | #211 |
| patients liver dysfunction | #212 |
| cns gaba | #212 |
| laspartate | #212 |
| histopathological studies | #212 |
| brain structures | #212 |
| isoquinolines male | #212 |
| cerebellum striatum | #213 |
| patients died | #214 |
| gabaa receptor agonist | #214 |
| plasma ammonia | #214 |
| address issue | #214 |
| 3h8 | #215 |
| role pathogenesis | #215 |
| animals liver | #216 |
| glutamine cycle | #216 |
| key factor | #216 |
| failure mice | #216 |
| nitrite nitrate levels | #216 |
| noradrenergic function | #217 |
| bbb breakdown | #217 |
| glutamine synthetase activity | #217 |
| cultured rat astrocytes | #218 |
| taurine animals | #219 |
| thiamine vitamin | #219 |
| 3hro | #219 |
| inbred strains spectrometry | #220 |
| new therapeutic opportunities | #221 |
| excitatory neurotransmitters | #221 |
| agonal | #221 |
| glutamate exposure | #221 |
| level severity | #222 |
| 3 post | #222 |
| terry | #223 |
| deficient animals | #224 |
| death mechanisms | #224 |
| cyclase sgc | #225 |
| vulnerable period | #226 |
| 2 quality | #226 |
| gaba receptor | #227 |
| exposure inhalation | #228 |
| gaba cns | #228 |
| hepatic microcirculation | #228 |
| il1beta mrna | #228 |
| cortical synaptosomes | #229 |
| acute chronic exposure | #229 |
| animals effects | #229 |
| excitatory transmitter | #229 |
| cholestatic rats | #230 |
| mk801 treatment | #230 |
| muscarinic cholinergic | #230 |
| shunt | #230 |
| opca | #230 |
| glutamate excitotoxicity | #231 |
| hippocrates | #231 |
| receptor ligands | #231 |
| previous report | #231 |
| extracellular glutamate | #232 |
| rats weeks | #233 |
| increasing evidence | #234 |
| increased intracranial | #234 |
| spraguedawley reference values | #234 |
| glutamate transport | #234 |
| brain deposition | #235 |
| cau | #235 |
| phosphate esters | #235 |
| pair fed | #236 |
| liver injury mice | #236 |
| resonance study | #236 |
| serotonin tryptophan | #237 |
| 3hglutamate | #237 |
| pdh complex | #238 |
| lc3 lipidation | #238 |
| glial proliferation | #238 |
| animals rats | #239 |
| encephalopathy mhe | #239 |
| end‐stage liver disease | #240 |
| multiple systematic reviews | #240 |
| reduced glutathione levels | #240 |
| concentrations elevated | #240 |
| levels glutamate | #240 |
| binding brain | #240 |
| minimal hepatic | #241 |
| caudate putamen | #241 |
| presynaptic neuron | #241 |
| psychoactive medications | #241 |
| nacl kcl | #241 |
| 13cacetate | #242 |
| cycle disorders | #242 |
| brain samples | #242 |
| neurobehavioral | #243 |
| treatment central | #243 |
| sgc | #243 |
| glur2 | #243 |
| cerebral cortex hippocampus | #244 |
| normal processes | #244 |
| neuronal localization | #244 |
| neuronal membrane | #244 |
| alf patients | #244 |
| manganese concentration | #244 |
| hypothalamus hypothalamus | #245 |
| aged monoamine | #245 |
| tritium animals | #246 |
| bloodbrain barrier breakdown | #246 |
| acids animals | #246 |
| glutamine concentration | #246 |
| neurologic assessment | #246 |
| unchanged | #246 |
| synaptosomal preparations | #247 |
| soluble guanylate | #247 |
| plasma brain | #247 |
| nonpregnant rats | #247 |
| histaminergic | #248 |
| minimal hepatic encephalopathy | #248 |
| neuroactive steroids | #248 |
| 5 hydroxyindoleacetic | #248 |
| hippocampal sclerosis | #248 |
| deficient rats | #249 |
| allosteric coupling | #249 |
| betaep | #249 |
| increased expression | #250 |
| glutamate transporter glt1 | #250 |
| synaptic transmission | #250 |
| glutamate gaba | #251 |
| reactive nitrogen intermediates | #251 |
| findings activation | #251 |
| gaba uptake | #252 |
| fatigue chronic | #252 |
| reduced cerebral | #253 |
| animals aspartic | #253 |
| symptoms brain | #253 |
| focal loss | #254 |
| rats taurine | #255 |
| watersoluble vitamins | #256 |
| brain caudate | #256 |
| rat cerebellar | #256 |
| brain disorder | #257 |
| norepinephrine turnover | #257 |
| 4513 | #257 |
| alterations expression | #257 |
| therapeutic measures | #257 |
| soluble guanylate cyclase | #257 |
| mhe | #258 |
| animals ataxia | #258 |
| pallidum | #258 |
| rats time factors | #259 |
| receptor autoradiography | #259 |
| – brain | #259 |
| choline acetyltransferase | #259 |
| ed1 | #259 |
| transporters amino | #259 |
| glutamine synthetase | #260 |
| agents rats | #260 |
| phenylalanine levels | #260 |
| precipitating factors | #260 |
| liver liver failure | #261 |
| gene expression alterations | #261 |
| liver skeletal muscle | #262 |
| treatment neurological disorders | #262 |
| endogenous ligands | #262 |
| binding ligands | #262 |
| acetyl carnitine | #263 |
| neurological impairment | #263 |
| liver testis | #264 |
| muscle rigidity | #264 |
| alcoholic male | #264 |
| gamma tumor | #264 |
| concentrations brain | #264 |
| spf | #264 |
| cisterna | #265 |
| rats compared | #265 |
| gabaergic neurotransmission | #265 |
| calleja | #265 |
| cerebellar pathology | #266 |
| reactive gliosis | #267 |
| dopamine noradrenaline | #267 |
| male c57bl6 mice | #267 |
| dopamine spiperone | #267 |
| protein gene expression | #268 |
| isoquinolines | #268 |
| cell volume regulation | #268 |
| electrically stimulated | #268 |
| contributory | #269 |
| expression nitric | #270 |
| female hepatic | #271 |
| sleep abnormalities | #271 |
| hepatic | #271 |
| displaceable | #272 |
| hydroxyindoleacetic acid | #272 |
| microdialysates | #272 |
| octanoic acid | #272 |
| brain human | #272 |
| pharmacological manipulation | #272 |
| brains | #274 |
| neurotransmitter systems | #274 |
| greenwood | #276 |
| normal conditions | #277 |
| quin | #277 |
| expression brain | #277 |
| neuronal cell death | #278 |
| glutamate uptake | #279 |
| tryptamine | #280 |
| gamma liver | #280 |
| national association | #280 |
| neurotoxic action | #280 |
| 14c2 | #281 |
| microassay | #281 |
| metal toxicity | #281 |
| striatum cerebral cortex | #281 |
| gaba levels | #282 |
| intracranial hypertension | #282 |
| guanylate cyclase | #282 |
| glur3 | #283 |
| maoa | #283 |
| cortical astrocytes | #284 |
| severe neurological | #284 |
| 3mt | #284 |
| behavioural impairment | #284 |
| concentrations dopamine | #285 |
| ucds | #285 |
| barrier breakdown | #285 |
| nitrated proteins | #285 |
| ht release | #285 |
| acute hepatic failure | #287 |
| glomerular filtrate | #287 |
| deficiency disorders | #288 |
| excitatory amino acids | #289 |
| acid astrocytes | #289 |
| adult values | #290 |
| reduction oxidative stress | #290 |
| apap hepatotoxicity | #290 |
| azoxymethane | #291 |
| patients fatigue | #292 |
| ligands male | #292 |
| mice cerebral | #292 |
| human liver disease | #292 |
| brain cerebellum | #292 |
| autoradiographic studies | #293 |
| concentrations zinc | #293 |
| glutamine | #293 |
| effects hypothermia | #293 |
| brain regional | #293 |
| failure rats | #293 |
| reduced capacity | #293 |
| altered expression | #294 |
| blood – | #294 |
| induced swelling | #294 |
| odn | #294 |
| substantial increases | #295 |
| synthase expression | #296 |
| betaactin | #297 |
| rats increased | #297 |
| rats western cells | #300 |
| overt hepatic encephalopathy | #300 |
| actin mrna | #304 |
| brain choline | #304 |
| groups sham | #304 |
| dawley receptors opioid | #304 |
| rifamycins rifaximin | #305 |
| cytotoxic mechanism | #306 |
| lnoarg | #306 |
| damaged liver | #306 |
| severe alterations | #306 |
| gamma aminobutyric acid | #306 |
| powerful antioxidant | #307 |
| 3hsch | #307 |
| selection model | #307 |
| glutamate | #307 |
| cerebral function | #308 |
| dihydrolipoamide | #308 |
| bioaccumulation | #308 |
| tight junction protein | #310 |
| molecular biological techniques | #310 |
| serotonin metabolism | #311 |
| brain genes | #312 |
| agonists gaba | #312 |
| gaba taurine | #312 |
| 4864 | #312 |
| treatment rats | #313 |
| rats messenger | #313 |
| male osmolar | #314 |
| secondary biliary cirrhosis | #315 |
| brain serotonin | #316 |
| receptors glutamate | #316 |
| chloride animals | #316 |
| nitrogen metabolism | #318 |
| adjacent sections | #318 |
| mice mutant | #318 |
| humans manganese | #319 |
| mitochondrial proliferation | #319 |
| quantitative autoradiography | #319 |
| basal ganglia patients | #319 |
| cultured hippocampal neurons | #320 |
| cell death mechanisms | #320 |
| rats brain | #320 |
| tailpipe | #321 |
| dehydrogenase activity | #321 |
| eaat3 | #322 |
| 235triphenyltetrazolium chloride | #322 |
| isethionate | #323 |
| aqp4 expression | #324 |
| thalamus | #325 |
| acid 5 | #325 |
| decreased brain | #327 |
| nervous function | #327 |
| complications outcome | #327 |
| neurochemical studies | #327 |
| olivopontocerebellar | #328 |
| 5 hiaa | #328 |
| pathol | #329 |
| uptake increased | #329 |
| flumazenil | #330 |
| cerebellar astrocytes | #330 |
| β endorphin | #331 |
| sites human | #331 |
| proinflammatory cytokines | #333 |
| uptake brain | #333 |
| aaas | #333 |
| locomotor | #333 |
| experimental rat | #334 |
| increased binding | #335 |
| hydroxyindoleacetic | #335 |
| 13cglucose | #335 |
| neurotransmitter uptake | #335 |
| brain accumulation | #336 |
| 8 rats | #336 |
| nitrotyrosine | #337 |
| inhalation exposure | #338 |
| responsible | #339 |
| cortex brain | #339 |
| transport defect | #340 |
| positive synergistic | #340 |
| pdh activity | #341 |
| human hepatic | #341 |
| biological plausibility | #341 |
| mutant rats | #342 |
| cerebral cortical | #342 |
| reyes syndrome | #343 |
| altered mental status | #344 |
| brain 5 | #344 |
| benzodiazepine site | #344 |
| placebo improvement | #345 |
| dehydrogenase humans | #345 |
| dansyl | #346 |
| activation nmda | #346 |
| control values | #347 |
| vulnerable | #347 |
| acid gaba | #347 |
| intraventricularly | #347 |
| bdl rats | #349 |
| marked decreases | #349 |
| pigs groups | #350 |
| glutamate levels | #350 |
| increased immunoreactivity | #350 |
| patients dying | #351 |
| alanine amino | #351 |
| nonalcoholics | #351 |
| cortex cerebellum | #352 |
| consequent increase | #352 |
| manganese | #353 |
| proinflammatory cytokine release | #354 |
| western brain | #354 |
| series studies | #354 |
| consumption rats | #354 |
| apapinduced liver injury | #354 |
| expression increased | #355 |
| brain excitability | #356 |
| complex male | #356 |
| thiamine supplementation | #356 |
| duct ligated | #356 |
| deterioration | #357 |
| receptor sites | #357 |
| 5hiaa | #358 |
| wellestablished model | #358 |
| postmortem brain tissue | #358 |
| proposed role | #359 |
| convulsions | #359 |
| onset brain | #359 |
| increase extracellular | #361 |
| glutamate homeostasis | #361 |
| mammalian brain | #361 |
| autoradiography brain | #362 |
| metabolic events | #363 |
| neuroinflammatory | #363 |
| reduced plasma | #363 |
| histamine h1 | #363 |
| rats cns | #364 |
| expression pglycoprotein | #365 |
| 9998 | #365 |
| acids branched | #366 |
| white matter structures | #366 |
| neuroglia | #367 |
| posttranslational rats rats | #367 |
| folic acid antagonists | #368 |
| methoxytyramine | #369 |
| 56 mm | #370 |
| cerebral oedema | #370 |
| sulfate dheas | #370 |
| nacetylcysteine nac | #371 |
| sites binding | #371 |
| glutamate synthesis | #372 |
| perineuronal | #372 |
| metabolic impairment | #372 |
| chemical forms | #373 |
| affinities | #373 |
| encountered | #373 |
| induction cox2 | #373 |
| acid rats | #373 |
| 3hmk801 | #375 |
| accompanied | #375 |
| astrocytes microglia | #375 |
| anaplerotic | #376 |
| ca1 subfield | #376 |
| highaffinity | #376 |
| nh3 nh4 | #377 |
| antioxidant nacetylcysteine | #377 |
| cirrhosis alcoholic | #378 |
| acetyltransferase chat | #378 |
| ngnitro | #378 |
| novo synthesis | #379 |
| basal ganglia thalamus | #380 |
| cell swelling | #380 |
| positive allosteric | #380 |
| acute chronic | #382 |
| pons | #382 |
| epileptic patients | #382 |
| pregnenolone | #383 |
| overwhelming evidence | #383 |
| densities | #385 |
| transporter glut1 | #386 |
| exposure brain | #386 |
| dihydrolipoamide dehydrogenase | #386 |
| phenylalanine tyrosine | #388 |
| acetylcholine synthesis | #390 |
| pbz | #390 |
| focal cerebral ischemia | #390 |
| effects administration | #390 |
| hyperglycemic conditions | #390 |
| cerebral edema | #390 |
| pet assessment | #392 |
| mice enos | #393 |
| phthalaldehyde | #394 |
| thioacetamide induced | #394 |
| glycine transporter | #394 |
| phenylacetate | #395 |
| scatchard plot | #395 |
| model acute | #396 |
| failure induced | #396 |
| positive allosteric modulator | #397 |
| carnitine levels | #397 |
| omega 3 | #398 |
| methylhistamines | #399 |
| pathophysiological mechanism | #399 |
| bbb permeability | #399 |
| acetyl coa | #400 |
| patients platelets | #400 |
| korsakoff | #400 |
| vestibular nucleus | #400 |
| insulin metabolism | #401 |
| frontal | #401 |
| falls patients | #402 |
| inferior olive | #402 |
| radioligands | #403 |
| rats purpose | #405 |
| liver gut | #407 |
| concerted effort | #407 |
| marker enzymes | #408 |
| neuropathologic | #408 |
| methionine sulfoximine | #408 |
| releasable | #410 |
| adult activities | #412 |
| dopaminergic neurones | #414 |
| shunt surgery | #415 |
| patients ataxia | #416 |
| forebrain cholinergic | #416 |
| ketamine anesthesia | #417 |
| gabaa gammaaminobutyric acid | #418 |
| pk11195 | #419 |
| intellectual function | #419 |
| fibrillary | #421 |
| alcoholic liver | #421 |
| serotonin content | #422 |
| rats animal | #423 |
| asparagine | #423 |
| sham operation | #423 |
| housekeeping gene | #423 |
| regions brain | #423 |
| hypothermia | #424 |
| diazepam binding | #424 |
| tissues brain | #425 |
| salinetreated controls | #425 |
| binding parameters | #426 |
| aidsrelated complex | #426 |
| direct evidence | #426 |
| exsanguination | #427 |
| rats mutant | #428 |
| hepatocyte necrosis | #430 |
| glutamine levels | #431 |
| protein utilization | #431 |
| sacrificed | #432 |
| peripheral benzodiazepine | #434 |
| dawley tissue | #434 |
| hippocampus frontal cortex | #434 |
| onset severe | #434 |
| rats experimental | #435 |
| cytotoxic edema | #437 |
| patients pbc | #437 |
| 12 control subjects | #438 |
| benzoate | #438 |
| addition evidence | #439 |
| isoquinoline | #440 |
| ligand selectivity | #440 |
| attenuates | #441 |
| central process | #441 |
| acids brain | #442 |
| neurological syndrome | #442 |
| brain glucose | #443 |
| brain microglia | #443 |
| patients encephalopathy | #443 |
| 13c enrichment | #443 |
| arginine transport | #443 |
| glyt1 | #444 |
| cultured astrocytes | #444 |
| operated | #445 |
| cultured cerebellar | #445 |
| butterworth | #446 |
| compounds rats | #446 |
| brain water content | #447 |
| agematched controls | #450 |
| liver skeletal | #450 |
| topographic distribution | #450 |
| pyruvate dehydrogenase | #450 |
| brain tissue patients | #451 |
| effects liver | #451 |
| acute mice mice | #451 |
| t1weighted mri | #453 |
| severe liver | #454 |
| s100beta | #455 |
| aged amino | #455 |
| immunohistochemistry liver | #455 |
| central pontine myelinolysis | #455 |
| brain swelling | #456 |
| h1 receptor | #456 |
| parachlorophenylalanine | #456 |
| body evidence | #456 |
| aspartic | #457 |
| vitro binding assay | #457 |
| impaired liver function | #457 |
| brain monoamines | #458 |
| brain alterations | #460 |
| effects brain | #460 |
| neurobiology | #460 |
| increased release | #461 |
| neuropathology | #462 |
| substantial body | #463 |
| 5ht levels | #463 |
| equivocal | #463 |
| neurological | #465 |
| hepatic glutathione | #466 |
| dentate nuclei | #466 |
| neurobehavioural | #467 |
| studies reveal | #468 |
| central cholinergic | #469 |
| glutamic acid | #469 |
| reye | #470 |
| monoamine metabolism | #471 |
| amino acid levels | #471 |
| urea production | #472 |
| patients hippocampal | #473 |
| alcoholic liver disease | #473 |
| putamen patients | #474 |
| liver dysfunction | #475 |
| gaba glycine | #475 |
| glutamate transporters | #475 |
| ox42 | #475 |
| inherited defects | #476 |
| alcohol brain | #477 |
| thiamin | #477 |
| release proinflammatory cytokines | #479 |
| thiamine pyrophosphate | #479 |
| amino acid transporters | #480 |
| acid humans | #480 |
| parkinsons diseases | #481 |
| images brain | #482 |
| acute male | #482 |
| inferior colliculus | #482 |
| brain csf | #484 |
| chronic alcoholics | #484 |
| nitric oxide synthase | #487 |
| concentrations increased | #488 |
| manganese levels | #488 |
| triphosphate amino | #488 |
| acids rats | #490 |
| multinuclear nmr spectroscopy | #491 |
| urea ammonia | #491 |
| increased production | #492 |
| jadad | #492 |
| glial fibrillary | #492 |
| role brain | #492 |
| ischemic cortex | #493 |
| pet ligand | #494 |
| emitted radiation | #495 |
| ammonium ion | #495 |
| aspartate glutamate | #495 |
| outer mitochondrial membrane | #495 |
| pyruvates | #495 |
| schaffer collaterals | #496 |
| hexanones | #496 |
| rat hippocampal | #496 |
| ataxic | #499 |
| neurons nitric | #499 |
| brain diseases | #501 |
| beneficial | #502 |
| brain synaptosomes | #505 |
| 3hd | #505 |
| 5 hydroxytryptophan | #507 |
| ketoacid | #508 |
| acid metabolites | #509 |
| fatal complication | #510 |
| gene therapy treatment | #510 |
| discrete brain regions | #511 |
| medulla oblongata | #511 |
| histamine h1 receptors | #511 |
| increased icp | #511 |
| exposure rats | #515 |
| acids amino | #516 |
| abnormal metabolism | #517 |
| major feature | #517 |
| chain acyl | #518 |
| humans neurons | #518 |
| concentrations 5 | #521 |
| ltrp | #523 |
| neurochemistry | #523 |
| inflammation mediators | #525 |
| toxic agents | #526 |
| brain female | #530 |
| rat hippocampal slices | #530 |
| aom | #531 |
| agents dopamine | #533 |
| receptor complex | #533 |
| dawley receptors | #533 |
| ligation bdl | #534 |
| focal cerebral | #534 |
| 100 µg | #534 |
| neurotoxins | #534 |
| muscle loss | #534 |
| combined actions | #535 |
| cerebellum cerebral | #536 |
| bdz | #537 |
| divalent metals | #538 |
| selective | #539 |
| carroll | #539 |
| severe liver disease | #539 |
| alcoholic cirrhosis | #539 |
| tipss | #540 |
| tyrosine nitration | #541 |
| hydroxymethylbilane | #541 |
| moderate drinking | #542 |
| brain astrocytes | #542 |
| moderate increase | #543 |
| aspartate | #544 |
| portasystemic | #544 |
| pyruvate oxidation | #544 |
| organic osmolytes | #545 |
| liver enzyme | #545 |
| chronic liver | #545 |
| energy metabolism | #546 |
| model hepatic | #547 |
| unanesthetized rats | #548 |
| cumene | #548 |
| nitrosative stress | #548 |
| dissected | #548 |
| alpha1 alpha2 | #549 |
| unconjugated bilirubin | #549 |
| thalamic lesions | #550 |
| taurine levels | #551 |
| brain region | #551 |
| fatigue patients | #553 |
| genes brain | #553 |
| brain cytokines | #554 |
| glutamatergic neurotransmission | #554 |
| increased uptake | #555 |
| water ammonia | #555 |
| nmda receptor antagonist | #556 |
| disease liver | #557 |
| rats bile | #558 |
| failure liver | #558 |
| microdialysate | #563 |
| gabaergic gaba | #563 |
| levels hepatic | #563 |
| hydroxytryptophan | #564 |
| cortex female humans | #564 |
| microglial response | #566 |
| malnutrition patients | #567 |
| mhe patients | #567 |
| serum bilirubin levels | #567 |
| ischemia liver | #568 |
| established role | #568 |
| autoradiographic | #569 |
| lhistidine | #569 |
| transient increase | #569 |
| neurotransmitter glutamate | #571 |
| neurologic signs | #573 |
| pathway brain | #574 |
| gaba | #574 |
| decarboxylase gad | #576 |
| outcome liver | #577 |
| octopamine | #577 |
| apap induced | #578 |
| expression mrnas | #578 |
| il1beta expression | #578 |
| liver pathology | #580 |
| oxobutanoate | #580 |
| biogenic monoamines | #581 |
| increases blood | #582 |
| octanoic | #582 |
| pyridinium compounds | #582 |
| histological lesions | #583 |
| brain metabolism | #583 |
| 5hydroxytryptophan | #584 |
| neurobehavioral effects | #588 |
| edema formation | #589 |
| bloodbrain barrier | #589 |
| monoamine oxidases | #589 |
| human spinal | #590 |
| activity brain | #591 |
| 13c nuclear | #592 |
| accompanying | #593 |
| toxic levels | #593 |
| pathophysiological mechanisms | #594 |
| catalytic sites | #594 |
| endogenous opioid | #594 |
| t1weighted imaging | #597 |
| highenergy phosphates | #598 |
| aminobutyric acid gaba | #599 |
| extracellular fluid | #600 |
| leigh disease | #601 |
| neuroglial | #601 |
| neuronal nitric | #601 |
| include | #601 |
| taurine | #602 |
| 3hcholine | #602 |
| largest increases | #604 |
| methyltyrosines | #606 |
| male nitric | #606 |
| glutamine humans | #607 |
| extracellular compartment | #608 |
| vermis | #608 |
| acetyl | #609 |
| cirrhosis | #609 |
| molecular studies | #609 |
| cortical slices | #610 |
| male metabolism | #610 |
| ventricular enlargement | #612 |
| friedreich ataxia | #612 |
| ammonia concentration | #612 |
| animals autoradiography | #614 |
| spraguedawley receptors | #615 |
| neurovascular unit | #615 |
| microglial | #616 |
| axonopathy | #616 |
| selective accumulation | #616 |
| artery ligation | #618 |
| tricarboxylic | #618 |
| c57bl6 mice | #618 |
| normothermic | #619 |
| increased expression genes | #620 |
| mammillary | #620 |
| acidic protein | #621 |
| junction proteins | #624 |
| controls addition | #624 |
| oxidase mao | #625 |
| hippocampal slices | #625 |
| new approaches | #625 |
| semi quantitative | #626 |
| amino acid concentrations | #626 |
| edema brain | #627 |
| nimesulide | #628 |
| hepatic levels | #628 |
| experimental animal model | #628 |
| clf | #629 |
| dbi | #629 |
| free radical formation | #630 |
| blood borne | #631 |
| neurobehavior | #631 |
| dehydroepiandrosterone sulfate dheas | #633 |
| ataxia | #634 |
| dopamine striatum | #635 |
| allosteric interactions | #635 |
| urea synthesis | #635 |
| contributory role | #635 |
| encephalopathies | #636 |
| neurological damage | #637 |
| levels observed | #638 |
| neuroinflammation | #638 |
| harper | #638 |
| astrocyte cultures | #638 |
| cerebellum | #639 |
| conduction velocities | #640 |
| deleterious effects | #640 |
| rats glucose | #641 |
| acid hippocampus | #643 |
| receptor densities | #644 |
| excitatory inhibitory | #645 |
| neuronal excitability | #645 |
| early role | #646 |
| frontal temporal | #647 |
| nntetraacetic acid | #647 |
| chronic exposure | #647 |
| matsumoto | #652 |
| desoxycorticosterone | #652 |
| branched chain | #653 |
| excitatory amino | #653 |
| cytokines tnf | #654 |
| tricarbonyl | #655 |
| gabaa gaba | #656 |
| mental state | #657 |
| 1400w | #657 |
| enos gene | #659 |
| acid transporter | #659 |
| dawley sodium | #661 |
| potential toxic effects | #662 |
| cerebral cortex | #663 |
| uptake release | #664 |
| 3hspiperone | #665 |
| metabolic basis | #665 |
| fibrillary acidic | #666 |
| cycle enzymes | #668 |
| heterogeneous distribution | #669 |
| cogent | #670 |
| minocycline treatment | #673 |
| inhibitory properties | #673 |
| potassium concentration | #675 |
| metabolism rats | #675 |
| 7ni | #678 |
| 7nitroindazole | #679 |
| evoked release | #682 |
| reduction expression | #683 |
| neuropathological | #683 |
| excitatory | #684 |
| ammonia treatment | #684 |
| millimolar | #684 |
| ornithine | #684 |
| regional specificity | #684 |
| gammaaminobutyric acid | #685 |
| frontal cortex hippocampus | #686 |
| spraguedawley | #688 |
| microg m3 | #688 |
| cerebral atrophy | #688 |
| protein tspo | #691 |
| brain regions | #695 |
| hepatic damage | #695 |
| ca1 pyramidal cells | #695 |
| fulminant | #695 |
| acetylcysteine animals | #697 |
| daily administration | #697 |
| synthase nnos | #698 |
| extrapyramidal | #698 |
| enzyme complex | #699 |
| brain disorders | #700 |
| bcaas | #700 |
| immunolabeling | #701 |
| blood‐brain barrier | #701 |
| normoglycemic | #703 |
| ammonia production | #703 |
| autophagy markers | #704 |
| rats dawley receptors | #705 |
| quinolinic | #706 |
| ethanol ingestion | #706 |
| acetylcysteine nac | #709 |
| cornerstone | #711 |
| glut1 expression | #714 |
| cortex rats | #715 |
| reductions | #719 |
| bmax values | #723 |
| phenylbutyrate | #723 |
| 6 day | #724 |
| surgical samples | #724 |
| nutritional status patients | #725 |
| acute hepatic | #726 |
| ketoglutaric | #729 |
| contribute | #730 |
| serotoninergic | #730 |
| expression isoforms | #736 |
| intensive study | #737 |
| piribedil | #740 |
| fluorimetric detection | #741 |
| mm nacl | #742 |
| ligation liver | #744 |
| dopaminergic function | #745 |
| cerebellar granule | #746 |
| biochemical alterations | #746 |
| methylglucose | #747 |
| tight junction | #748 |
| glucose oxidation | #749 |
| male microdialysis | #749 |
| choline acetyltransferase chat | #752 |
| cytochrome oxidase activity | #753 |
| scatchard analysis | #754 |
| alterations | #754 |
| illness terminology | #756 |
| glutamate glu | #757 |
| portasystemic shunt | #757 |
| delta receptors opioid | #758 |
| alcoholism animals | #760 |
| ergic | #761 |
| varying degrees | #762 |
| substantial evidence | #763 |
| ammonium chloride | #763 |
| opioid delta receptors | #764 |
| tryptamines | #764 |
| neutron activation analysis | #765 |
| levels 5 | #768 |
| excitotoxic | #769 |
| gdh | #769 |
| normal liver function | #769 |
| barrier permeability | #770 |
| control genes | #773 |
| newborn astrocytes | #774 |
| peripheral organs | #775 |
| cellular energy metabolism | #776 |
| ethanol consumption | #777 |
| increased blood | #778 |
| brain gene | #780 |
| species reactive | #783 |
| hepatic dysfunction | #783 |
| receptor function | #784 |
| mnsod | #785 |
| cortex thalamus | #785 |
| methods principal findings | #785 |
| glut1 | #786 |
| messenger rats | #786 |
| globus pallidus | #787 |
| nakatpase | #787 |
| early alterations | #789 |
| brain function | #790 |
| probenecid | #791 |
| spraguedawley receptors messenger | #791 |
| major route | #791 |
| 2 fold | #792 |
| glyceraldehyde3 phosphate | #792 |
| hypothermia treatment | #793 |
| specific ligands | #793 |
| rat cerebral | #795 |
| selective effects | #796 |
| typical cases | #796 |
| ethanol solution | #797 |
| plasma clearance | #797 |
| neuronal integrity | #799 |
| severity liver | #799 |
| nitroarginine | #801 |
| pertinence | #805 |
| hiaa | #806 |
| ultimately | #807 |
| neurotoxic effects | #807 |
| nh4cl | #807 |
| pyruvate metabolism | #808 |
| mrna protein | #809 |
| chat | #811 |
| acute brain injury | #812 |
| predilection | #812 |
| role astrocytes | #812 |
| enos mice | #815 |
| coma | #816 |
| update | #816 |
| glycolytic activity | #819 |
| cerebellar granule cells | #820 |
| nmethyldaspartate | #822 |
| pbc patients | #823 |
| eaat1 | #823 |
| iii groups | #824 |
| complete disappearance | #825 |
| pathogenesis treatment | #825 |
| edema | #826 |
| age matched | #826 |
| alzheimer type | #828 |
| atomic absorption spectrometry | #828 |
| synthesis rates | #829 |
| nitrite nitrate | #829 |
| glial | #830 |
| neurons astrocytes | #831 |
| water homeostasis | #831 |
| alcoholics | #832 |
| diseases alcoholic | #832 |
| eaat2 | #833 |
| monoamine | #834 |
| decreases | #835 |
| manifested | #836 |
| operated rats | #837 |
| pathophysiological | #837 |
| amino3 | #838 |
| explain | #838 |
| oligonucleotide primers | #839 |
| animal cell | #839 |
| treatment improvement | #841 |
| metabolic disorder | #842 |
| expression ho1 | #843 |
| cell loss | #845 |
| isotopomer | #846 |
| hypothermia patients | #846 |
| cfos cjun | #848 |
| oblongata | #849 |
| pharmacokinetic analyses | #849 |
| chronic alcohol consumption | #851 |
| gaba receptors | #852 |
| nmda receptor | #853 |
| receptor mediated | #853 |
| matched age | #854 |
| daily injections | #854 |
| glutamatergic | #856 |
| consequence | #856 |
| compromised | #857 |
| bbb integrity | #858 |
| griess | #861 |
| aromatic amino acids | #861 |
| alcoholic | #862 |
| order role | #862 |
| hepatic disease | #862 |
| continues | #863 |
| antioxidant action | #863 |
| inflammatory mechanisms | #866 |
| thalamic nuclei | #866 |
| cerebellar ataxia | #867 |
| early induction | #867 |
| normalizes | #869 |
| manifest | #870 |
| chronic liver disease | #871 |
| oxide rats | #872 |
| fpc | #874 |
| succimer | #877 |
| low risk bias | #880 |
| nmda receptor antagonists | #881 |
| barrier bbb | #882 |
| greater susceptibility | #882 |
| cisterna magna | #882 |
| excitatory amino acid | #882 |
| stimulated release | #887 |
| western cells | #890 |
| dehydrogenase | #890 |
| comatose | #890 |
| multinuclear | #891 |
| shamoperated animals | #891 |
| cultured hippocampal | #892 |
| interfere | #893 |
| nutritional intervention | #893 |
| mutant mouse | #894 |
| lipoamide | #897 |
| neuropsychiatric symptoms | #898 |
| exp | #899 |
| acetaminophen apap | #900 |
| common death | #901 |
| dizocilpine maleate | #901 |
| sulfoximine | #901 |
| cirrhosis pbc | #902 |
| lowering | #904 |
| neurons rna | #904 |
| experimental animal | #905 |
| quinolinic acid | #905 |
| autopsy brain | #907 |
| pcs | #907 |
| brain activities | #908 |
| factor tumor | #912 |
| acid animals | #912 |
| colliculus | #913 |
| selective ligands | #913 |
| pathophysiology | #913 |
| placebo intervention | #919 |
| publication acidosis | #919 |
| cerebellar degeneration | #920 |
| microdialysis study | #920 |
| liver homogenates | #922 |
| rat cortical | #922 |
| delta receptors | #924 |
| survival mice | #926 |
| urea cycle | #929 |
| striatum hippocampus | #930 |
| pugh | #931 |
| nacetylcysteine | #931 |
| findings evidence | #932 |
| microglial activation | #932 |
| hydroxy2di | #933 |
| activities enzymes | #936 |
| reaction water | #942 |
| tartrates | #942 |
| developing rat brain | #942 |
| hepatic diseases | #942 |
| mammalian cns | #943 |
| study liver | #943 |
| injured liver | #943 |
| rats exposed | #943 |
| agents oxidative | #943 |
| marked | #945 |
| rapid removal | #945 |
| pca | #948 |
| maladies | #949 |
| cirrhosis magnetic | #950 |
| 25mm | #951 |
| concentrations observed | #954 |
| spontaneous release | #957 |
| altered | #962 |
| spraguedawley receptors rats | #963 |
| detailed review | #964 |
| putamen | #967 |
| assay rats | #967 |
| translocator protein | #969 |
| humans hypothermia | #969 |
| moderate hypothermia | #970 |
| chronic liver diseases | #971 |
| acid transport | #971 |
| intermediary metabolism | #971 |
| increased glycolysis | #971 |
| cerebral glucose | #971 |
| nm range | #973 |
| autoradiographic study | #974 |
| aspartic acid | #979 |
| kidney heart | #979 |
| post translational modifications | #980 |
| neurological disease | #983 |
| occludin | #984 |
| oxygenase1 ho1 | #988 |
| effective measures | #990 |
| pdh | #990 |
| 9 mice mice | #990 |
| aquaporin4 | #991 |
| cirrhosis experimental | #991 |
| rats ethanol | #992 |
| brain oedema | #992 |
| spared | #993 |
| increased plasma | #993 |
| propylaminotetralin | #998 |
| damage mechanisms | #999 |
| adaptive mechanisms | #1006 |
| role oxidative stress | #1006 |
| soluble guanylyl | #1008 |
| uptake kinetics | #1008 |
| flunitrazepam | #1008 |
| cerebro | #1009 |
| rifaximin | #1009 |
| metabolic consequences | #1010 |
| rat brain | #1012 |
| neurotoxic | #1013 |
| progressing | #1013 |
| modulatory | #1015 |
| presymptomatic | #1015 |
| fulminant hepatic | #1016 |
| electrified | #1016 |
| publication amino acids | #1017 |
| ligands receptors | #1019 |
| unsuspected | #1020 |
| abundant evidence | #1020 |
| animal models | #1020 |
| 1h | #1023 |
| acids bcaa | #1023 |
| pallidus humans | #1024 |
| antioxidant anti | #1029 |
| astrocyte | #1030 |
| metabolism inborn | #1031 |
| microsomes | #1032 |
| tele | #1032 |
| etanercept treatment | #1034 |
| 7 hours | #1036 |
| muscle expression | #1038 |
| catalepsy | #1039 |
| interleukin1beta | #1041 |
| nutritional assessment | #1043 |
| monoamine oxidase | #1045 |
| pharmacology | #1048 |
| gabaergic | #1050 |
| acid decarboxylase | #1050 |
| aqp4 | #1050 |
| major factor | #1053 |
| caudate nucleus | #1053 |
| endogenous | #1055 |
| aquaporin 4 | #1056 |
| hepatolenticular | #1057 |
| specific antagonist | #1057 |
| involved pathogenesis | #1058 |
| synthetase | #1058 |
| frontoparietal cortex | #1060 |
| adaptive mechanism | #1060 |
| oxygenase1 | #1064 |
| gabaa receptors | #1066 |
| 5ht neurons | #1067 |
| progression liver | #1067 |
| sodium acetate | #1072 |
| efficacy treatment | #1075 |
| rat hepatocytes | #1075 |
| reflex | #1077 |
| membrane preparations | #1077 |
| inflammation infection | #1078 |
| glucose blotting | #1080 |
| accompanies | #1081 |
| enzyme activities | #1083 |
| gilles | #1083 |
| 34dihydroxyphenylacetic acid | #1085 |
| nonneuronal | #1086 |
| content increased | #1090 |
| complex carbohydrates | #1092 |
| lactate concentrations | #1092 |
| major players | #1095 |
| muscle brain | #1097 |
| radioligand assay | #1098 |
| awaiting | #1099 |
| intense staining | #1099 |
| rat primary | #1101 |
| baptaam | #1102 |
| normal physiological conditions | #1106 |
| tpp | #1107 |
| cell culture studies | #1107 |
| junction protein | #1108 |
| medial septum | #1109 |
| hyperintensity | #1111 |
| 5 mm | #1111 |
| assay receptors | #1113 |
| human brain tissue | #1116 |
| patients alzheimers disease | #1117 |
| inflammation role | #1117 |
| cirrhotics | #1118 |
| atrophy brain | #1122 |
| severe malnutrition | #1122 |
| ischemic core | #1127 |
| sprague | #1128 |
| cirrhosis male | #1129 |
| findings role | #1129 |
| astrocytes | #1130 |
| transient elevation | #1131 |
| amino acids | #1134 |
| tetrabenazine | #1135 |
| weight brain | #1137 |
| age controls | #1138 |
| diagonal band | #1139 |
| haloperidol humans | #1142 |
| oxide synthase | #1143 |
| receptors histamine | #1145 |
| hepatobiliary | #1146 |
| pyruvate | #1148 |
| worsens | #1153 |
| lactic acidosis | #1153 |
| nonepileptic | #1153 |
| dehydroepiandrosterone sulfate | #1154 |
| control tissue | #1157 |
| altered brain | #1162 |
| biogenic amines | #1163 |
| cresyl | #1166 |
| portosystemic | #1167 |
| h1 | #1168 |
| benzilate | #1171 |
| combustion products | #1172 |
| emax | #1173 |
| enzymologic | #1174 |
| lactate | #1177 |
| etanercept | #1179 |
| rats subjected | #1180 |
| parkinsonian symptoms | #1181 |
| glutamate dehydrogenase | #1182 |
| peripheral tissues | #1182 |
| nerve conduction | #1183 |
| rats receptors | #1185 |
| nnos | #1185 |
| urine levels | #1186 |
| principally | #1189 |
| mechanisms involved | #1191 |
| synaptic cleft | #1192 |
| cardinal features | #1192 |
| hyperintensities | #1193 |
| delta opioid | #1196 |
| causal factor | #1197 |
| rapid onset | #1198 |
| gabaa receptor | #1199 |
| transcriptase polymerase | #1201 |
| venous blood | #1204 |
| dopamine uptake | #1205 |
| dawley | #1205 |
| death cells | #1207 |
| acetyl cysteine | #1207 |
| hepatolenticular degeneration | #1209 |
| development brain | #1211 |
| increasing body | #1214 |
| direct effects | #1216 |
| stereotypy | #1218 |
| radiometric | #1220 |
| binding inhibitor | #1220 |
| brains mice | #1220 |
| pig model | #1221 |
| 5htp | #1222 |
| nmethyld | #1223 |
| fold increase | #1224 |
| neuropsychological impairment | #1226 |
| skeletal rats rats | #1226 |
| mitochondrial swelling | #1228 |
| transjugular | #1229 |
| wilson disease | #1229 |
| deprenyl | #1229 |
| 100 iu | #1232 |
| cultured rat | #1234 |
| circadian rhythmicity | #1234 |
| severity assessment | #1234 |
| hippocampus vitro | #1236 |
| hyperexcitability | #1239 |
| nakatpase activity | #1239 |
| spraguedawley receptors opioid | #1239 |
| congenitally | #1241 |
| glyceraldehyde3 | #1242 |
| hypermetabolism | #1242 |
| brain axis | #1246 |
| partial recovery | #1251 |
| elucidation | #1252 |
| kinetics male | #1253 |
| receptors neurotransmitter | #1254 |
| sprague dawley | #1255 |
| convincing evidence | #1258 |
| methyl aspartate | #1259 |
| gabaa | #1260 |
| albumen | #1261 |
| 5hydroxyindoleacetic acid | #1261 |
| hippocampus striatum | #1262 |
| acetylcysteine | #1262 |
| clinical entities | #1262 |
| myoinositol | #1264 |
| overactivation | #1270 |
| 1h 13c | #1271 |
| astroglial | #1271 |
| olfactory bulbs | #1273 |
| rats expression | #1276 |
| maleate | #1276 |
| apoenzyme | #1281 |
| milligram | #1281 |
| vicious | #1281 |
| congenital | #1281 |
| variable degree | #1282 |
| glutamate decarboxylase | #1287 |
| patients tle | #1288 |
| loss expression | #1288 |
| induced inhibition | #1289 |
| brain inflammation | #1290 |
| acid male | #1291 |
| metabolite | #1291 |
| acid cycle | #1291 |
| cortex kidney | #1292 |
| quisqualate | #1294 |
| ischemia cerebral | #1295 |
| rifamycins | #1296 |
| radioreceptor | #1296 |
| deficient | #1297 |
| dawley animals | #1297 |
| protective | #1297 |
| zinc concentrations | #1300 |
| permeability blood | #1301 |
| synaptosomes | #1302 |
| potential therapeutic approach | #1305 |
| frontoparietal | #1306 |
| 7 males | #1308 |
| opioid delta | #1308 |
| neuronal dysfunction | #1310 |
| caveolin1 | #1310 |
| 5mm | #1314 |
| liver | #1314 |
| heme oxygenase1 | #1316 |
| greater magnitude | #1317 |
| adrenals | #1318 |
| 35°c | #1319 |
| threefold | #1320 |
| receptors methyl | #1321 |
| invariably | #1324 |
| neurotransmission | #1325 |
| dopamine serotonin | #1328 |
| nanomolar | #1328 |
| appearance | #1329 |
| guanylyl | #1329 |
| major complication | #1334 |
| animal electrophoresis | #1334 |
| signaling mechanisms | #1335 |
| acetyltransferase | #1337 |
| cerebellum hippocampus | #1344 |
| phosphate dehydrogenase | #1344 |
| astrocytes cells | #1346 |
| cgmp pathway | #1349 |
| heavy drinkers | #1350 |
| transporter proteins | #1352 |
| brain effects | #1358 |
| neuronal | #1361 |
| dopamine female | #1361 |
| female globus | #1364 |
| interleukin1 receptors | #1364 |
| shunt tips | #1368 |
| male rats rats | #1369 |
| hypoglycaemic | #1375 |
| small decrease | #1378 |
| fur | #1380 |
| electrolyte balance | #1381 |
| aromatic amino | #1383 |
| bile duct ligation | #1386 |
| chelation therapy | #1387 |
| synergism | #1387 |
| nitrated | #1388 |
| gaba agonists | #1389 |
| ca2independent | #1392 |
| preliminary studies | #1394 |
| neurological sequelae | #1395 |
| transamination | #1396 |
| occipital cortex | #1401 |
| intrauterine growth | #1402 |
| immediateearly genes | #1403 |
| guanylate | #1409 |
| pallidus | #1409 |
| larginine | #1412 |
| selectively | #1416 |
| cerebral | #1417 |
| patients findings | #1425 |
| paper details | #1426 |
| normo | #1427 |
| mutant strains | #1429 |
| acute brain | #1433 |
| motor nerve | #1441 |
| paralleled | #1444 |
| shamoperated | #1445 |
| childpugh score | #1450 |
| common approaches | #1450 |
| mitochondrial membranes | #1451 |
| risk falls | #1451 |
| peripheral | #1452 |
| longer wavelength | #1453 |
| hypoglycaemia | #1455 |
| intraventricular injections | #1456 |
| effective prevention | #1456 |
| benzodiazepinones | #1459 |
| clonazepam | #1460 |
| modulatory effects | #1462 |
| hydroxydopamines | #1465 |
| studies brain | #1471 |
| quinuclidinyl | #1472 |
| swelling | #1477 |
| brain tissues | #1479 |
| patients liver disease | #1481 |
| saturable | #1482 |
| 13c | #1485 |
| 23390 | #1485 |
| deficiency | #1486 |
| characteristic | #1488 |
| excitatory neurotransmission | #1488 |
| gfap | #1491 |
| dopamine agents | #1499 |
| messenger rats rats | #1504 |
| neuroprotective role | #1505 |
| histological studies | #1509 |
| primary concern | #1509 |
| bilirubin levels | #1509 |
| increases | #1512 |
| volume regulation | #1512 |
| cortex striatum | #1513 |
| primary biliary cirrhosis | #1514 |
| receptor subunits | #1515 |
| herniation | #1516 |
| liver disease | #1519 |
| rat cerebral cortex | #1519 |
| 1h magnetic | #1523 |
| glutamic acid decarboxylase | #1525 |
| integrity | #1525 |
| tyrosine residues | #1527 |
| branched | #1530 |
| tk | #1532 |
| temporal profile | #1539 |
| increased capacity | #1541 |
| transport animals | #1546 |
| brain homogenates | #1547 |
| acetylcarnitine | #1548 |
| apomorphine | #1548 |
| cholinergic | #1549 |
| vitamins minerals | #1550 |
| tricarboxylic acid | #1551 |
| wistar receptors rats | #1552 |
| lactulose | #1554 |
| regional differences | #1557 |
| pathological hallmark | #1557 |
| neurochemical | #1559 |
| lactate levels | #1561 |
| cirrhosis liver | #1564 |
| reflexes | #1566 |
| pathological mechanisms | #1567 |
| extracellular | #1568 |
| neurotransmitters | #1572 |
| poor diet | #1575 |
| major forms | #1579 |
| brain cerebral | #1580 |
| scad | #1584 |
| light energy | #1584 |
| biliary cirrhosis | #1584 |
| epilepsy tle | #1585 |
| tryptophan | #1585 |
| brain cell | #1586 |
| patients review | #1589 |
| ependymal cells | #1591 |
| ngnitrolarginine methyl ester | #1592 |
| new findings | #1594 |
| lesser extent | #1595 |
| pyruvate carboxylase | #1596 |
| aspartate nmda | #1598 |
| llysine | #1600 |
| pbc | #1601 |
| rat hippocampus | #1602 |
| mri signal | #1605 |
| specific therapies | #1606 |
| brain slices | #1606 |
| tdp | #1615 |
| ouabain | #1615 |
| travelled | #1618 |
| unanesthetized | #1623 |
| anastomosis | #1626 |
| acute mice | #1627 |
| neuroglia neurons | #1629 |
| deficient diet | #1631 |
| failure mechanisms | #1633 |
| receptor human | #1635 |
| prevents | #1637 |
| zinc copper | #1640 |
| cerebellar | #1641 |
| tritium | #1642 |
| dorsal raphe nucleus | #1646 |
| regulation animals | #1647 |
| male membrane glycoproteins | #1648 |
| died | #1650 |
| experimental treatment | #1651 |
| animals cerebral | #1651 |
| brain endothelial | #1652 |
| neuromodulatory | #1653 |
| synthase nitric | #1653 |
| amino acid transport | #1654 |
| distribution animals | #1657 |
| glutamate receptors | #1657 |
| fourfold | #1658 |
| extracellular space | #1660 |
| excitotoxicity | #1661 |
| rapid accumulation | #1664 |
| bbb disruption | #1664 |
| striking similarities | #1667 |
| gapdh | #1667 |
| supporting cells | #1669 |
| autoradiography | #1673 |
| previous findings | #1674 |
| synthetase activity | #1675 |
| messenger | #1677 |
| veratrum | #1688 |
| brain area | #1691 |
| dehydrogenase deficiency | #1694 |
| diseases metabolic | #1696 |
| glycogen metabolism | #1701 |
| brainstem | #1704 |
| midbrain | #1708 |
| postulated | #1708 |
| thp | #1710 |
| accumulate | #1716 |
| ibotenic | #1723 |
| fulminant hepatic failure | #1723 |
| inborn | #1724 |
| dizocilpine | #1724 |
| polyclonal antibody | #1725 |
| benzodiazepines | #1726 |
| phenomenon | #1726 |
| il1beta | #1733 |
| alternative mechanism | #1734 |
| carnitine | #1735 |
| animals arginine | #1735 |
| cumene hydroperoxide | #1737 |
| noninvasive techniques | #1737 |
| disorders nervous | #1739 |
| decarboxylase | #1750 |
| normalization | #1756 |
| alternative hypothesis | #1757 |
| liver disease patients | #1757 |
| magna | #1759 |
| consequent | #1760 |
| tricarboxylic acid cycle | #1761 |
| shunts | #1762 |
| c57bl6 | #1762 |
| spiperone | #1763 |
| metabolism glucose | #1769 |
| intrahepatic portosystemic | #1770 |
| allosteric | #1770 |
| critical appraisal | #1773 |
| betaamyloid | #1781 |
| granule neurons | #1785 |
| acetaminophen induced | #1788 |
| muscarinic | #1789 |
| cell damage | #1790 |
| brain damage | #1791 |
| rats spraguedawley receptors | #1791 |
| body temperature | #1794 |
| adult rat brain | #1794 |
| normothermia | #1794 |
| glucose utilization | #1797 |
| common complication | #1799 |
| nmr study | #1802 |
| ampa receptors | #1806 |
| superfusion | #1810 |
| preliminary investigation | #1812 |
| primary metabolism | #1813 |
| major organs | #1815 |
| coa dehydrogenase | #1815 |
| nutritional supplements | #1815 |
| endorphin | #1817 |
| pyruvic | #1822 |
| oxazepam | #1822 |
| rat | #1829 |
| hypertension intracranial | #1832 |
| dorsal raphe | #1833 |
| hippocampal ca1 | #1834 |
| hepatic failure | #1835 |
| vmax values | #1836 |
| major roles | #1837 |
| bdl | #1839 |
| mild | #1840 |
| reuptake | #1843 |
| neurological deterioration | #1844 |
| compared controls | #1845 |
| granule cells | #1846 |
| metalloproteinase9 | #1847 |
| γaminobutyric acid | #1849 |
| toxins | #1850 |
| regulatory processes | #1854 |
| capillary gas chromatography | #1856 |
| chronic alcohol | #1857 |
| ammonium compounds | #1857 |
| monoaminergic | #1862 |
| cirrhotic rats | #1863 |
| body water | #1865 |
| liver transplantation patients | #1865 |
| caudate | #1868 |
| cholinergic neurons | #1872 |
| stroke outcome | #1876 |
| lactate production | #1877 |
| immunoreactivities | #1877 |
| platelets patients | #1882 |
| disorder treatment | #1886 |
| neurotoxicity syndromes | #1886 |
| glutamate release | #1886 |
| beta endorphin | #1892 |
| acute | #1900 |
| locomotor activity | #1902 |
| hepatoprotective | #1903 |
| common feature | #1904 |
| induced liver | #1906 |
| atp adp | #1913 |
| induced rats | #1917 |
| cirrhosis biliary | #1919 |
| stereotyped | #1920 |
| penicillamine | #1920 |
| colorimetric assay | #1921 |
| patients cirrhosis | #1923 |
| rodent models | #1923 |
| grossly | #1925 |
| dipeptides | #1930 |
| behavioral abnormalities | #1932 |
| precipitated | #1934 |
| tspo | #1935 |
| nitration | #1937 |
| areas brain | #1941 |
| patients aids | #1944 |
| neurocognitive impairment | #1945 |
| major metabolite | #1952 |
| major site | #1957 |
| synthase | #1958 |
| dpat | #1961 |
| concomitant | #1962 |
| cerebral metabolism | #1965 |
| normal dogs | #1965 |
| acid transporters | #1966 |
| acid synthesis | #1966 |
| spectroscopy male | #1968 |
| manganese superoxide dismutase | #1970 |
| 5hydroxytryptamine | #1977 |
| globus | #1977 |
| nmethyldaspartate receptors | #1977 |
| druginduced liver injury | #1977 |
| 28 weeks | #1981 |
| mice compared | #1981 |
| degeneration humans | #1986 |
| potassium exchanging | #1987 |
| erk1 | #1990 |
| neurologic symptoms | #1991 |
| duct ligation | #1991 |
| cognitive dysfunction | #1991 |
| idazoxan | #1993 |
| ideal model | #1994 |
| oxotremorine | #1994 |
| 5 ht | #1996 |
| recirculating | #1997 |
| primary biliary | #2000 |
| radioligand | #2001 |
| 2fold increase | #2006 |
| mk801 | #2007 |
| ampa receptor | #2015 |
| heterogeneously | #2017 |
| cerebellar cortex | #2019 |
| overactivity | #2020 |
| injury mice | #2022 |
| arterio | #2023 |
| pet imaging | #2028 |
| glucose brain | #2034 |
| neurologic complications | #2036 |
| aminoacids | #2036 |
| sham rats | #2036 |
| microdialysis | #2036 |
| sham | #2040 |
| osmolytes | #2041 |
| peroneal nerve | #2041 |
| resonance nmr | #2043 |
| exchanging atpase | #2043 |
| cerebri | #2046 |
| cyclase | #2046 |
| pathogenetic mechanisms | #2047 |
| passive diffusion | #2050 |
| suggested | #2053 |
| groups iii | #2063 |
| tracings | #2064 |
| decreased activity | #2064 |
| 10 12 | #2068 |
| dawley rats | #2069 |
| convulsants | #2071 |
| stage liver | #2072 |
| vivo brain | #2074 |
| elucidated | #2077 |
| tumor necrosis factoralpha | #2079 |
| penumbra | #2080 |
| biochemical parameters | #2082 |
| deficit | #2084 |
| acetates | #2087 |
| transjugular intrahepatic | #2089 |
| trace amounts | #2090 |
| international society | #2094 |
| autopsy | #2098 |
| ensuing | #2103 |
| zo1 | #2106 |
| solely | #2108 |
| atrophies | #2109 |
| p0018 | #2111 |
| nitric oxide synthesis | #2117 |
| portal pressure | #2117 |
| parallel | #2121 |
| chp | #2121 |
| synthase type | #2125 |
| neurological manifestations | #2141 |
| ligase | #2142 |
| exception | #2143 |
| synergistically | #2143 |
| brain barrier | #2148 |
| subsequent degradation | #2149 |
| indicative | #2150 |
| rats spraguedawley | #2158 |
| time onset | #2158 |
| bmax | #2158 |
| intracranial pressure | #2167 |
| amnestic | #2169 |
| male rat | #2170 |
| muscimol | #2173 |
| acute effects | #2178 |
| human patients | #2179 |
| gaa | #2180 |
| neural inhibition | #2180 |
| reactive nitrogen | #2187 |
| subchronic | #2189 |
| apap | #2194 |
| blood csf | #2194 |
| increasing recognition | #2200 |
| cox2 | #2203 |
| overt | #2205 |
| parkinsonism | #2209 |
| methysergide | #2212 |
| homovanillic acid | #2217 |
| pressure icp | #2217 |
| vitamin supplements | #2220 |
| nitroarginine methyl | #2223 |
| hypothermic | #2223 |
| brain cells | #2225 |
| function brain | #2230 |
| antiparkinson | #2232 |
| liver enzymes | #2238 |
| minocycline | #2242 |
| pss | #2244 |
| chelators | #2245 |
| neurological disorders | #2248 |
| humans liver | #2249 |
| diminution | #2262 |
| liver circulation | #2265 |
| blood brain | #2265 |
| symporters | #2265 |
| doubt | #2267 |
| nutritional deficiencies | #2268 |
| messenger systems | #2271 |
| gliosis | #2279 |
| behavior rats | #2280 |
| additional factors | #2297 |
| synaptic vesicles | #2297 |
| rats liver | #2299 |
| phosphate | #2300 |
| eeg activity | #2302 |
| acrylamides | #2303 |
| patients minimal | #2304 |
| isoxazolepropionic | #2307 |
| immunoreactive neurons | #2308 |
| superoxide dismutase | #2314 |
| tle | #2315 |
| memantine | #2320 |
| multiorgan failure | #2322 |
| cortex hippocampus | #2325 |
| brain expression | #2326 |
| cultured cerebral | #2327 |
| systemic inflammatory response | #2328 |
| primary cultures | #2328 |
| male nerve | #2330 |
| blindly | #2333 |
| hrqol patients | #2334 |
| housekeeping | #2336 |
| relative increase | #2338 |
| acidosis | #2338 |
| convincing | #2340 |
| scatchard | #2349 |
| lactates | #2359 |
| binding assays | #2360 |
| ligands | #2360 |
| olivary | #2362 |
| benzoic | #2364 |
| inbred strains | #2366 |
| patients increased | #2373 |
| endstage liver disease | #2376 |
| voluntary | #2377 |
| synaptic dysfunction | #2377 |
| competitive inhibitor | #2380 |
| clinical condition | #2391 |
| mental fatigue | #2392 |
| deficiencies | #2392 |
| potential adverse effects | #2393 |
| exchanging | #2401 |
| brains patients | #2401 |
| neurotoxin | #2406 |
| homovanillic | #2416 |
| lnmma | #2430 |
| induced brain | #2432 |
| protein mrna | #2433 |
| transporter 2 | #2443 |
| calcium binding | #2449 |
| cerebral metabolic | #2467 |
| extracellular levels | #2471 |
| 01 mm | #2473 |
| histamine receptor | #2483 |
| fluorescence detection | #2489 |
| peripheral inflammation | #2490 |
| adult male rats | #2491 |
| bbb | #2498 |
| receptors ampa | #2502 |
| synaptic function | #2508 |
| pathogenic role | #2509 |
| count cell | #2510 |
| effects alcohol | #2511 |
| pyridinium | #2513 |
| animal model | #2513 |
| activation microglia | #2514 |
| noxious stimuli | #2518 |
| hypotonia | #2524 |
| vmax | #2529 |
| 5ht | #2530 |
| physical conditioning | #2532 |
| dopac | #2534 |
| nuclear magnetic | #2534 |
| metabolic acidosis | #2541 |
| expression endothelial | #2563 |
| alcohol induced | #2566 |
| male matrix | #2571 |
| fmol | #2572 |
| humans ligands | #2573 |
| understanding pathophysiology | #2573 |
| ataxias | #2577 |
| receptor density | #2577 |
| alpha1 | #2577 |
| vessel walls | #2581 |
| postmortem brain | #2588 |
| microglia neurons | #2591 |
| mao | #2594 |
| multiple mechanisms | #2597 |
| acetylcholinesterase | #2598 |
| cerebrospinal | #2601 |
| groups subjects | #2608 |
| il1β il6 | #2619 |
| possibility | #2621 |
| 10 microm | #2621 |
| cognitive motor | #2623 |
| 15–30 | #2625 |
| greater extent | #2626 |
| methylaspartate | #2630 |
| normalisation | #2632 |
| nitrosation | #2635 |
| biochemical evidence | #2639 |
| deteriorating | #2640 |
| circulating concentrations | #2640 |
| day treatment | #2647 |
| activity rats | #2661 |
| transcriptase | #2663 |
| thalamic | #2663 |
| chc | #2665 |
| nitric | #2665 |
| katpase | #2665 |
| binding competitive | #2668 |
| glutathione levels | #2669 |
| olfactory bulb | #2669 |
| osmolar | #2683 |
| patients alcoholic | #2684 |
| guanylyl cyclase | #2685 |
| glial cell | #2686 |
| serotonin 5 | #2689 |
| effects ethanol | #2695 |
| indwelling | #2704 |
| nerve terminals | #2705 |
| rats control | #2705 |
| laboratory findings | #2710 |
| groups animals | #2715 |
| lactic | #2723 |
| situ nickend | #2733 |
| publication animals behavior | #2737 |
| frontal lobe | #2742 |
| hemodiafiltration | #2755 |
| suggests | #2760 |
| glutaminase | #2764 |
| functional integrity | #2767 |
| regions | #2769 |
| 6hydroxydopamine | #2771 |
| neurons animals | #2774 |
| kindred | #2775 |
| leucine | #2779 |
| turnover rate | #2779 |
| 24h | #2786 |
| glutamate receptor | #2789 |
| systemic circulation | #2789 |
| animal rats | #2790 |
| rhythmicity | #2798 |
| amino acid | #2798 |
| severity patients | #2806 |
| osmolar concentration | #2813 |
| inbred strains mice | #2814 |
| pontine | #2817 |
| exposed | #2821 |
| mechanisms | #2824 |
| hydroxy5 | #2826 |
| microglial cells | #2827 |
| p38mapk | #2831 |
| gastrointestinal agents | #2833 |
| neurological deficit | #2834 |
| regulation enzymologic | #2834 |
| minneapolis | #2835 |
| blood brain barrier | #2841 |
| brain calcium | #2847 |
| marked decrease | #2867 |
| bilirubin | #2876 |
| twofold increase | #2877 |
| alcoholic fatty | #2882 |
| amino | #2882 |
| nerve cells | #2883 |
| alanine | #2885 |
| synaptic | #2888 |
| diabetic animals | #2890 |
| ca2dependent | #2893 |
| pet study | #2897 |
| mmt | #2898 |
| trafficking | #2901 |
| kainate | #2903 |
| rigidity | #2905 |
| slices | #2905 |
| standpoint | #2906 |
| ameliorating | #2910 |
| confirming | #2918 |
| clinical syndrome | #2931 |
| cell volume | #2936 |
| dying | #2938 |
| normal control | #2938 |
| normal animals | #2939 |
| translocator | #2943 |
| subfield | #2943 |
| 12 weeks treatment | #2944 |
| receptors opioid | #2962 |
| impaired | #2964 |
| 11c | #2965 |
| assist devices | #2970 |
| astrocytes cell | #2971 |
| brain uptake | #2974 |
| unaffected | #2982 |
| inflammation liver | #2982 |
| pyruvic acid | #3000 |
| excitatory synapses | #3000 |
| intermediary | #3008 |
| normal values | #3015 |
| aquaporin | #3036 |
| uptake | #3039 |
| kainic | #3043 |
| barrier brain | #3047 |
| incubation medium | #3051 |
| cox2 expression | #3051 |
| ca1 pyramidal | #3053 |
| biliary obstruction | #3054 |
| weighted magnetic | #3069 |
| concert | #3073 |
| tmp | #3076 |
| portosystemic shunt | #3078 |
| metabolite concentrations | #3078 |
| harmful effects | #3082 |
| attenuation | #3083 |
| selegiline | #3086 |
| activated microglia | #3088 |
| reserpine | #3093 |
| liver injury | #3095 |
| cd1 | #3099 |
| catecholaminergic | #3109 |
| atp levels | #3111 |
| adult rats | #3113 |
| renal vein | #3115 |
| valine | #3133 |
| short halflife | #3136 |
| toxic effects | #3137 |
| relative roles | #3149 |
| decreased | #3156 |
| myo inositol | #3161 |
| higher doses | #3168 |
| animals binding | #3169 |
| dhea | #3171 |
| nmda | #3172 |
| loss | #3180 |
| carboxamide | #3189 |
| endorphins | #3192 |
| failure | #3192 |
| relation | #3194 |
| abruptly | #3195 |
| radical scavengers | #3198 |
| inhalation | #3199 |
| bcaa | #3199 |
| mental retardation | #3201 |
| enzymologic genes | #3209 |
| clinical presentations | #3210 |
| liver function | #3214 |
| ketanserin | #3214 |
| heavy drinking | #3218 |
| coenzymes | #3220 |
| noradrenaline | #3224 |
| imidodiphosphate | #3226 |
| active transport | #3232 |
| portal | #3235 |
| gad | #3238 |
| shortchain fatty acids | #3238 |
| acidic | #3243 |
| synaptic membranes | #3244 |
| pyrophosphate | #3248 |
| induced hepatic | #3252 |
| treated rats | #3256 |
| nitrogen species | #3267 |
| systemic | #3276 |
| oxidative metabolism | #3281 |
| respects | #3285 |
| induced seizures | #3287 |
| synaptosomal | #3291 |
| drug repositioning | #3296 |
| behavioral symptoms | #3300 |
| water electrolyte | #3306 |
| kcl | #3307 |
| cell death | #3311 |
| metabolic alterations | #3324 |
| anterolateral | #3326 |
| reverse | #3327 |
| metabolized | #3331 |
| nanomolar concentrations | #3335 |
| sedatives | #3342 |
| general circulation | #3344 |
| nac | #3347 |
| dab | #3352 |
| regionally | #3359 |
| rats received | #3359 |
| benzoates | #3360 |
| membrane transport | #3361 |
| dosedependent fashion | #3364 |
| aspartate receptors | #3366 |
| rats inbred | #3368 |
| subsequent studies | #3371 |
| phenylalanine | #3384 |
| cerebral ischemia | #3388 |
| opioid | #3388 |
| inbred strains receptors | #3389 |
| cortex | #3391 |
| robust evidence | #3394 |
| hydroxytryptamine | #3402 |
| tyrphostins | #3403 |
| galactosamine | #3404 |
| brain disease | #3407 |
| brain lesions | #3412 |
| falls | #3421 |
| disturbances | #3421 |
| progressive increase | #3423 |
| histamine | #3423 |
| ldopa | #3426 |
| quaternary ammonium | #3427 |
| morphologic | #3428 |
| transaminases | #3432 |
| gln | #3436 |
| decreased levels | #3437 |
| modulation | #3439 |
| levels liver | #3443 |
| indole3 | #3446 |
| superior colliculus | #3451 |
| epilepsy temporal | #3453 |
| toxic | #3455 |
| strains mice | #3456 |
| biogenic | #3458 |
| accumulates | #3462 |
| timecourse | #3467 |
| phosphocreatine | #3473 |
| rats rats | #3474 |
| indomethacin | #3480 |
| striatum | #3482 |
| developing rat | #3485 |
| upregulation | #3491 |
| glycine | #3492 |
| brain stem | #3495 |
| subcortical structures | #3497 |
| liver male | #3497 |
| new evidence | #3499 |
| electrochemical detection | #3499 |
| basal ganglia | #3500 |
| rat models | #3503 |
| lobe epilepsy | #3503 |
| previous observations | #3507 |
| aids patients | #3511 |
| huntington | #3515 |
| dehydroepiandrosterone | #3537 |
| aging brain | #3542 |
| rats treatment | #3545 |
| neurons oxidative | #3545 |
| kidney liver | #3555 |
| tyramine | #3558 |
| fold | #3563 |
| cytokines disease | #3576 |
| nerve degeneration | #3584 |
| portal vein | #3600 |
| inferior vena cava | #3600 |
| tissue distribution | #3600 |
| brain structure | #3613 |
| antioxidant properties | #3627 |
| truncated 250 | #3627 |
| pathology | #3635 |
| cofactor | #3636 |
| prolonged exposure | #3636 |
| hypertonic saline | #3638 |
| disease states | #3648 |
| implication | #3650 |
| increased activity | #3655 |
| hydroxydopamine | #3657 |
| ache | #3664 |
| precipitating | #3664 |
| fatty liver | #3666 |
| investigator | #3675 |
| circadian rhythms | #3680 |
| scavengers | #3682 |
| lobe | #3694 |
| splanchnic | #3699 |
| regional variation | #3700 |
| arginine | #3718 |
| proinflammatory cytokine | #3722 |
| new model | #3723 |
| medial | #3735 |
| thioacetamide | #3741 |
| cassette transporters | #3742 |
| treated animals | #3746 |
| induced neurotoxicity | #3751 |
| stress rats | #3755 |
| normal mice | #3758 |
| consensus statement | #3765 |
| dopamine d1 | #3773 |
| 4 wk | #3786 |
| 1968 | #3791 |
| parietal lobe | #3793 |
| acetylcholinesterase ache | #3799 |
| dietary protein | #3801 |
| mitochondrion | #3807 |
| finding | #3814 |
| major | #3815 |
| diazepam | #3825 |
| neural cell | #3825 |
| control animals | #3825 |
| resemble | #3833 |
| western blot analyses | #3838 |
| systemically | #3846 |
| inborn errors | #3846 |
| prefrontal | #3857 |
| effects chronic | #3872 |
| nmr spectroscopy | #3879 |
| malabsorption | #3896 |
| type nitric | #3897 |
| dopamine d1 receptors | #3899 |
| dopa | #3907 |
| enhanced production | #3909 |
| metabolic pathway | #3911 |
| elucidate | #3914 |
| levels measured | #3915 |
| new therapeutic approaches | #3919 |
| nitric oxide production | #3919 |
| tone | #3924 |
| pindolol | #3929 |
| peripheral neuropathy | #3937 |
| ascorbate | #3942 |
| reabsorption | #3949 |
| medulla | #3949 |
| csf | #3949 |
| wet weight | #3951 |
| tourette | #3975 |
| neuropsychiatric disorders | #3978 |
| purkinje cells | #3983 |
| antiinflammatory | #3987 |
| complication | #3992 |
| fatigue | #3992 |
| tca cycle | #4003 |
| pseudotumor | #4006 |
| brain activation | #4009 |
| day 5 | #4011 |
| treatment prevention | #4021 |
| transporter | #4026 |
| elevated blood | #4053 |
| nmda receptors | #4053 |
| bz | #4054 |
| strains receptors | #4069 |
| neurotoxicity | #4070 |
| fischer | #4082 |
| cultured neurons | #4097 |
| remove | #4101 |
| gastrointestinal bleeding | #4103 |
| involve | #4104 |
| nonalcoholic | #4111 |
| intracranial | #4134 |
| coa | #4138 |
| visible spectrum | #4140 |
| induced mitochondrial | #4149 |
| exacerbate | #4165 |
| lower affinity | #4172 |
| motor activity | #4178 |
| future clinical trials | #4178 |
| reverse transcriptase | #4185 |
| nitroso | #4190 |
| nuclear magnetic resonance | #4193 |
| oxide production | #4198 |
| ampa | #4204 |
| endothelial nitric | #4205 |
| liver cirrhosis | #4232 |
| steadystate levels | #4244 |
| knockout receptors | #4249 |
| enkephalins | #4276 |
| tips | #4318 |
| isoenzymes | #4321 |
| contention | #4326 |
| pathogenetic | #4326 |
| 3h | #4342 |
| oxidase inhibitors | #4346 |
| female frontal | #4355 |
| alcohol abuse | #4357 |
| matched | #4358 |
| chelator | #4359 |
| vitro model | #4364 |
| groups rats | #4365 |
| chorea | #4373 |
| acids | #4373 |
| geniculate | #4374 |
| prevention | #4375 |
| ratelimiting enzyme | #4382 |
| neocortical | #4398 |
| rtpcr | #4402 |
| mrna expression | #4418 |
| enos | #4425 |
| hepatic artery | #4425 |
| immunohistochemical analysis | #4428 |
| peripherally | #4430 |
| postnatally | #4433 |
| 10 micrograms | #4438 |
| carbon isotopes | #4449 |
| specific activities | #4449 |
| acid amino | #4455 |
| inos | #4460 |
| tetrahydrobiopterin | #4480 |
| diencephalon | #4481 |
| citric | #4487 |
| agents steroidal | #4499 |
| isoleucine | #4507 |
| chemical drug | #4509 |
| incompletely | #4517 |
| hippocampal neurons | #4518 |
| endogenously | #4521 |
| potent inhibitor | #4528 |
| pglycoprotein | #4535 |
| tissue concentrations | #4552 |
| model chronic | #4561 |
| animal studies | #4562 |
| gssg | #4562 |
| mitochondrial dysfunction | #4575 |
| substantia nigra | #4577 |
| neurological function | #4585 |
| explanation | #4600 |
| acetaminophen | #4606 |
| transaminase | #4608 |
| 250 | #4627 |
| small increase | #4629 |
| liver diseases | #4637 |
| mrna | #4639 |
| narcotic | #4643 |
| models neurological | #4666 |
| enzymes | #4671 |
| myo | #4677 |
| dopamine | #4679 |
| choline | #4683 |
| nitrites | #4684 |
| worsening | #4685 |
| tremor | #4694 |
| relate | #4701 |
| ho1 | #4704 |
| diphosphate | #4705 |
| neuronal survival | #4712 |
| develops | #4714 |
| realtime quantitative pcr | #4719 |
| techniques male | #4729 |
| key enzymes | #4730 |
| debilitating | #4732 |
| skeletal muscle | #4736 |
| amines | #4737 |
| receptors tumor | #4740 |
| motor coordination | #4745 |
| neurovascular | #4749 |
| patients liver cirrhosis | #4749 |
| triphosphate | #4752 |
| receptors | #4761 |
| apoptotic cell death | #4774 |
| patients liver | #4775 |
| neuroprotective agents | #4778 |
| mn2 | #4792 |
| male rats | #4793 |
| ulnar | #4795 |
| opioid peptides | #4821 |
| ganglia | #4828 |
| failing | #4835 |
| membrane cells | #4837 |
| liver regeneration | #4853 |
| constellation | #4875 |
| regional cerebral | #4875 |
| nonselective | #4891 |
| opioid receptors | #4901 |
| modulator | #4905 |
| tyrosine | #4906 |
| transporters | #4906 |
| 001 | #4915 |
| animals antioxidants | #4919 |
| injections intraperitoneal | #4921 |
| neurons rats | #4927 |
| glucose humans | #4936 |
| epilepsy humans | #4940 |
| degree | #4943 |
| kainic acid | #4963 |
| evident | #4988 |
| rapid progression | #4996 |
| viral hepatitis | #4998 |
| indazoles | #5000 |
| methyl2 | #5002 |
| clinical conditions | #5004 |
| 25 mm | #5009 |
| ammonium | #5017 |
| acid metabolism | #5018 |
| neurological diseases | #5024 |
| raphe | #5043 |
| consequences | #5048 |
| immunostaining | #5051 |
| weighted mri | #5053 |
| offspring | #5054 |
| tight | #5055 |
| alcoholism | #5063 |
| cyclooxygenase2 | #5066 |
| malnutrition | #5080 |
| metabolism | #5084 |
| suggesting | #5106 |
| endoperoxide | #5129 |
| clinical criteria | #5130 |
| acid | #5133 |
| nitric oxide | #5140 |
| disorder | #5143 |
| sarcopenia | #5163 |
| anticonvulsant | #5164 |
| glial cells | #5213 |
| temporal lobe | #5226 |
| leads | #5232 |
| animals | #5236 |
| portal hypertension | #5238 |
| child pugh | #5266 |
| severe | #5277 |
| sustained | #5277 |
| normal rats | #5278 |
| cerebrum | #5280 |
| organ dysfunction | #5288 |
| cerebrospinal fluid | #5299 |
| animal brain | #5308 |
| restores | #5312 |
| reversal | #5325 |
| methylarginine | #5330 |
| intoxication | #5344 |
| major impact | #5349 |
| 4 groups | #5350 |
| animal humans | #5364 |
| biomarkers brain | #5401 |
| gastroenterology | #5403 |
| experimental model | #5414 |
| superoxide production | #5416 |
| publication animals | #5417 |
| presynaptic | #5426 |
| induced acute | #5434 |
| regional brain | #5435 |
| gastrointestinal diseases | #5444 |
| intracellular levels | #5450 |
| postsynaptic | #5452 |
| concentrations | #5459 |
| food deprivation | #5463 |
| blotting western | #5466 |
| focal | #5466 |
| thioredoxins | #5505 |
| halflife | #5506 |
| aquaporins | #5515 |
| involving | #5517 |
| cns | #5517 |
| effects exposure | #5523 |
| nash | #5525 |
| controls | #5541 |
| catecholamines | #5549 |
| isolated rat | #5552 |
| affinity | #5553 |
| tca | #5564 |
| glucose metabolism | #5569 |
| lack | #5572 |
| higher density | #5575 |
| sleep disturbances | #5580 |
| hyperbilirubinemia | #5586 |
| glucose transport | #5607 |
| n11 | #5608 |
| summarizes | #5611 |
| platelets | #5615 |
| endotoxemia | #5639 |
| major complications | #5645 |
| free radicals | #5647 |
| postnatal development | #5651 |
| magnetic resonance images | #5652 |
| cachexia | #5666 |
| acute ischemic | #5672 |
| drinkers | #5693 |
| antimetabolites | #5699 |
| tnf | #5709 |
| 73 patients | #5711 |
| transport systems | #5712 |
| receptor binding | #5730 |
| 24 hours | #5741 |
| icp | #5768 |
| evidence base | #5790 |
| precipitate | #5790 |
| nonalcoholic steatohepatitis | #5796 |
| dehydrogenases | #5796 |
| p005 | #5800 |
| brain animals | #5810 |
| depolarization | #5812 |
| aspartate receptor | #5824 |
| serotonin | #5840 |
| substances | #5848 |
| prefrontal cortex | #5859 |
| extravasation | #5862 |
| steroidal | #5865 |
| neuroprotective | #5883 |
| levels elevated | #5885 |
| ketone | #5892 |
| western blot analysis | #5897 |
| appropriately | #5900 |
| mounting evidence | #5926 |
| enkephalin | #5928 |
| potentiate | #5945 |
| detoxification | #5949 |
| acrylamide | #5950 |
| disaccharides | #5950 |
| acid antagonists | #5952 |
| background objectives | #5954 |
| 100 microm | #5954 |
| bulb | #5976 |
| muscle mass | #5993 |
| metabolites | #5993 |
| coenzyme | #5994 |
| etiologies | #5997 |
| anterior cingulate cortex | #6016 |
| antagonist | #6019 |
| butyric | #6023 |
| reversible | #6029 |
| aged rats | #6030 |
| sodium potassium | #6068 |
| additional evidence | #6080 |
| transporter 1 | #6103 |
| methyl4 | #6109 |
| zona | #6114 |
| chemistry | #6120 |
| occurs | #6122 |
| barrier | #6138 |
| trh | #6148 |
| cirrhosis patients | #6152 |
| postmortem | #6152 |
| cortical regions | #6162 |
| hippocampus | #6166 |
| hydroperoxide | #6169 |
| deoxyglucose | #6171 |
| risk bias | #6188 |
| inbred | #6199 |
| esters | #6202 |
| proteins rats | #6221 |
| reduction oxidative | #6231 |
| nervous cns | #6235 |
| disruptions | #6250 |
| vascular endothelium | #6265 |
| anti inflammatory | #6284 |
| mitochondrial function | #6287 |
| hematoxylin | #6290 |
| lactate dehydrogenase | #6298 |
| chain | #6315 |
| carboxylase | #6322 |
| alpha2 | #6323 |
| protein expression | #6343 |
| induced increases | #6360 |
| 20 cases | #6371 |
| rna messenger | #6388 |
| dha | #6392 |
| cbf | #6404 |
| gamma | #6412 |
| remained | #6413 |
| chelating agents | #6422 |
| olfactory | #6441 |
| prosencephalon | #6456 |
| snap | #6464 |
| rats animals | #6469 |
| roi | #6470 |
| antagonists | #6475 |
| peripheral nerve | #6478 |
| histidine | #6482 |
| acyltransferases | #6490 |
| patients chronic | #6498 |
| mesencephalon | #6508 |
| notion | #6511 |
| disease brain | #6514 |
| bromocriptine | #6531 |
| ingestion | #6548 |
| ligation | #6552 |
| dopaminergic | #6553 |
| humans kinetics | #6566 |
| control mice | #6572 |
| longterm treatment | #6575 |
| nomenclature | #6576 |
| disease aged | #6579 |
| physiological function | #6586 |
| humans mitochondria | #6594 |
| microg | #6596 |
| oxidase | #6596 |
| led | #6597 |
| accumulation | #6599 |
| fluid csf | #6600 |
| mmol | #6609 |
| animal dose | #6610 |
| glycolytic | #6625 |
| publication analysis | #6642 |
| inducible nitric | #6643 |
| resonance spectroscopy | #6660 |
| lowers | #6665 |
| glu | #6665 |
| animals bile | #6671 |
| slowing | #6682 |
| p001 | #6684 |
| patients placebo | #6688 |
| proceedings | #6700 |
| interferongamma | #6742 |
| differential effects | #6755 |
| poisoning | #6767 |
| granule | #6768 |
| dystonia | #6769 |
| psychometric | #6774 |
| lad | #6783 |
| rats wistar receptors | #6791 |
| biological transport | #6801 |
| specific regions | #6806 |
| transport proteins | #6806 |
| cortices | #6825 |
| nitrates | #6833 |
| n5 | #6849 |
| inflammatory processes | #6849 |
| protects | #6857 |
| receptors dopamine | #6859 |
| tomography emission | #6887 |
| acetaldehyde | #6894 |
| enter | #6908 |
| patients brain | #6909 |
| sleep disorders | #6915 |
| mitochondrial membrane | #6916 |
| nutritional | #6921 |
| hypothalamus | #6930 |
| humans intracranial | #6937 |
| nutrition | #6972 |
| rendered | #6975 |
| cerebral blood flow | #6981 |
| low affinity | #6986 |
| acid levels | #7005 |
| eosin | #7011 |
| vitamins | #7012 |
| ascites | #7020 |
| adenosine triphosphate | #7030 |
| patients alzheimer | #7040 |
| compensatory | #7089 |
| free radical | #7092 |
| rois | #7098 |
| common form | #7109 |
| general agreement | #7117 |
| expression | #7125 |
| prothrombin | #7133 |
| mice treated | #7139 |
| synthases | #7140 |
| 13c nmr | #7146 |
| methyl | #7151 |
| hippocampus male | #7165 |
| methyl ester | #7177 |
| tartrate | #7178 |
| levels blood | #7198 |
| central nervous cns | #7202 |
| protective agents | #7214 |
| catecholamine | #7216 |
| undertaken | #7226 |
| probiotics | #7244 |
| humans inflammation | #7253 |
| systemic inflammation | #7280 |
| antiinflammatory agents | #7284 |
| neurodegeneration | #7290 |
| male sprague | #7307 |
| bile duct | #7311 |
| additional studies | #7322 |
| animal doseresponse relationship | #7334 |
| nh4 | #7336 |
| glucose transporter | #7337 |
| cyclooxygenase 2 | #7344 |
| life hrqol | #7350 |
| administration | #7353 |
| preliminary evidence | #7358 |
| symptomatic | #7371 |
| neuroprotection | #7374 |
| histamine release | #7378 |
| regional | #7382 |
| urea | #7386 |
| hippocampal | #7389 |
| insult | #7392 |
| pyridines | #7404 |
| intravenous infusion | #7420 |
| competitive | #7424 |
| animal | #7433 |
| excitability | #7442 |
| molecular mechanisms | #7448 |
| restored | #7464 |
| spectrophotometric | #7474 |
| osmotic | #7475 |
| biochemical studies | #7481 |
| ht | #7485 |
| excreted | #7507 |
| urease | #7536 |
| organ specificity | #7540 |
| lipid peroxidation | #7550 |
| dismutase | #7553 |
| pathological conditions | #7553 |
| brain ischemia | #7557 |
| implicating | #7564 |
| onset | #7570 |
| cytoprotection | #7580 |
| neuropathic pain | #7583 |
| imaging magnetic | #7585 |
| chromatography mass | #7603 |
| microglia | #7605 |
| matrix metalloproteinase | #7621 |
| mental status | #7630 |
| blood platelets | #7640 |
| characterized | #7659 |
| neuroprotective effects | #7659 |
| deleterious | #7665 |
| neurologic examination | #7672 |
| cortical neurons | #7687 |
| diminished | #7696 |
| specific binding | #7700 |
| guanidines | #7737 |
| perturbations | #7769 |
| alpha tnf | #7777 |
| oxide | #7779 |
| immunoreactivity | #7801 |
| oedema | #7810 |
| il6 levels | #7833 |
| tissue proteins | #7854 |
| tnf α | #7864 |
| animals blotting | #7882 |
| albumins | #7888 |
| m3 | #7897 |
| ca1 | #7899 |
| parietal cortex | #7915 |
| brain development | #7915 |
| cells brain | #7932 |
| freely | #7932 |
| lname | #7950 |
| aspartate aminotransferases | #7961 |
| assayed | #7986 |
| metabolic | #7989 |
| aetiology | #8016 |
| mouse brain | #8023 |
| alzheimer | #8025 |
| liver transplantation | #8033 |
| ka | #8038 |
| constitutes | #8040 |
| computerized | #8040 |
| organometallic compounds | #8052 |
| established | #8056 |
| brain humans | #8073 |
| cerebrovascular circulation | #8079 |
| chelation | #8081 |
| inferior | #8097 |
| reproduces | #8103 |
| modulate | #8143 |
| confirm | #8153 |
| produces | #8156 |
| large variety | #8164 |
| intraperitoneally | #8167 |
| immunohistochemistry male | #8184 |
| maintained | #8185 |
| benzazepines | #8192 |
| organs | #8193 |
| fluorescence intensity | #8201 |
| reduced | #8207 |
| neurologic | #8214 |
| dopamine receptor | #8253 |
| abnormally | #8260 |
| norepinephrine | #8288 |
| inflammatory agents | #8301 |
| neuronal damage | #8302 |
| antioxidant | #8310 |
| condition | #8326 |
| dependent | #8332 |
| therapeutic implications | #8336 |
| epileptic | #8359 |
| chromatography pressure | #8383 |
| turn | #8404 |
| gray matter | #8407 |
| reflect | #8410 |
| and or | #8413 |
| wistar receptors | #8433 |
| receptor expression | #8442 |
| chain reaction | #8446 |
| hyponatremia | #8454 |
| plasma levels | #8470 |
| hyperglycemia | #8472 |
| citalopram | #8472 |
| stereotaxic | #8495 |
| systemic inflammatory | #8499 |
| polymerase chain | #8501 |
| purkinje | #8517 |
| immunocytochemical | #8519 |
| brain imaging | #8538 |
| chloride | #8546 |
| copper | #8549 |
| intracellular ca2 | #8583 |
| restoration | #8595 |
| hepatotoxicity | #8598 |
| ischemia | #8616 |
| activates | #8631 |
| hippocampus humans | #8641 |
| oxide nitric | #8664 |
| levodopa | #8665 |
| n10 | #8672 |
| inflammatory cytokines | #8690 |
| male middle aged | #8715 |
| organometallic | #8716 |
| pyramidal cells | #8724 |
| retardation | #8736 |
| oxidative | #8742 |
| gsh | #8742 |
| 37°c | #8758 |
| emission computed | #8767 |
| parietal | #8790 |
| potassium chloride | #8814 |
| hplc | #8824 |
| nmr | #8871 |
| superoxide | #8875 |
| tonic | #8879 |
| sulfates | #8892 |
| devoid | #8898 |
| egf receptor | #8905 |
| lactic acid | #8906 |
| minimal | #8910 |
| caveolin | #8912 |
| oxo | #8932 |
| biochemical | #8935 |
| consciousness | #8985 |
| reflected | #9011 |
| intravenous injection | #9019 |
| alanine transaminase | #9038 |
| encephalitis | #9077 |
| emission tomography | #9083 |
| methylmercury | #9099 |
| aminotransferases | #9108 |
| acetate | #9111 |
| syndromes | #9112 |
| brain cognition | #9130 |
| aimed | #9163 |
| awake | #9175 |
| 62 patients | #9176 |
| likewise | #9181 |
| treated mice | #9194 |
| normal | #9207 |
| dysfunction | #9218 |
| corpus striatum | #9247 |
| key factors | #9254 |
| elevated | #9263 |
| deprived | #9285 |
| neuropathy | #9344 |
| cerebrospinal fluid csf | #9364 |
| cerebral blood | #9391 |
| pressure liquid | #9396 |
| deoxy | #9420 |
| immunoblotting | #9445 |
| complications patients | #9489 |
| citric acid | #9505 |
| intrahepatic | #9572 |
| oxidative stress | #9585 |
| irreversible | #9607 |
| naloxone | #9609 |
| absence | #9615 |
| synthase inos | #9615 |
| occipital | #9621 |
| neurons | #9627 |
| seizures | #9631 |
| terminals | #9647 |
| nerve tissue | #9655 |
| postoperative day | #9682 |
| compensate | #9687 |
| micromol | #9692 |
| imaging studies | #9718 |
| ameliorated | #9722 |
| bw | #9727 |
| protective effects | #9749 |
| 2 mm | #9756 |
| 064 | #9783 |
| neuro | #9788 |
| tumor necrosis | #9791 |
| middle cerebral | #9809 |
| chelating | #9823 |
| dependently | #9825 |
| patch clamp | #9830 |
| succinate | #9834 |
| diseases liver | #9842 |
| prevented | #9863 |
| severely | #9864 |
| contributes | #9880 |
| receptor agonist | #9912 |
| microm | #9930 |
| necrosis factor | #9933 |
| quantitative | #9943 |
| tight junctions | #9963 |
| liver cells | #9987 |
| neurobiological | #10000 |
| binding cassette | #10002 |
| central nervous | #10003 |
| conflicting | #10023 |
| kinetic parameters | #10033 |
| cycle | #10052 |
| mediated | #10072 |
| cortical | #10128 |
| cava | #10136 |
| dopamine receptors | #10169 |
| liver damage | #10178 |
| negative impact | #10202 |
| minerals | #10211 |
| stores | #10215 |
| ros production | #10235 |
| attenuated | #10240 |
| expression activity | #10242 |
| cgmp | #10262 |
| glutathione gsh | #10266 |
| transport complex | #10286 |
| plasma concentrations | #10292 |
| plasma patients | #10296 |
| urinary excretion | #10301 |
| adversely | #10328 |
| vitamin deficiency | #10328 |
| forebrain | #10337 |
| cassette | #10370 |
| permeable | #10373 |
| specific activity | #10384 |
| electroencephalogram | #10395 |
| steatohepatitis | #10395 |
| areas | #10419 |
| subacute | #10435 |
| biliary | #10436 |
| protein levels | #10453 |
| hrqol | #10455 |
| liver transplant | #10455 |
| nigra | #10479 |
| cerebral artery | #10481 |
| positron emission tomography | #10525 |
| biosynthesis | #10531 |
| substantia | #10550 |
| nervous | #10616 |
| transmitter | #10626 |
| twofold | #10627 |
| management patients | #10657 |
| lipopolysaccharide | #10674 |
| alzheimers disease | #10694 |
| dose dependent | #10699 |
| normal range | #10730 |
| protein level | #10752 |
| nutritional status | #10752 |
| quaternary | #10765 |
| glutathione | #10772 |
| glucose | #10806 |
| water content | #10826 |
| monophosphate | #10827 |
| liver mice | #10852 |
| vena | #10853 |
| nervous diseases | #10861 |
| microgram | #10880 |
| performance liquid | #10883 |
| entity | #10889 |
| eventually | #10941 |
| intraventricular | #10958 |
| occur | #10968 |
| saline | #10968 |
| dietary proteins | #10978 |
| breakdown | #10983 |
| earlier studies | #10997 |
| etiology | #10998 |
| doses | #11003 |
| accumbens | #11004 |
| impair | #11006 |
| rats inbred strains | #11023 |
| behavior animal | #11026 |
| radioimmunoassay | #11026 |
| atrophy | #11041 |
| tnfalpha | #11044 |
| atp binding | #11055 |
| tests male | #11061 |
| western | #11061 |
| peroxidation | #11077 |
| riboflavin | #11140 |
| positron emission | #11153 |
| potentiated | #11172 |
| preparations | #11184 |
| precursor | #11188 |
| adult male | #11195 |
| broad spectrum | #11196 |
| superoxides | #11202 |
| nick | #11227 |
| steroids | #11232 |
| animals anti | #11234 |
| acyl | #11314 |
| enzyme activity | #11342 |
| drug induced | #11347 |
| early identification | #11376 |
| neuropathic | #11380 |
| necrotic | #11392 |
| neurodegenerative disease | #11395 |
| centrally | #11415 |
| depletion | #11434 |
| major component | #11447 |
| clinical signs | #11463 |
| 3 weeks | #11495 |
| receptor antagonist | #11502 |
| animals disease | #11503 |
| complications | #11504 |
| alteration | #11581 |
| il1β | #11649 |
| trp | #11651 |
| prostaglandins | #11656 |
| survival cells | #11657 |
| kd | #11671 |
| dogs | #11676 |
| gut | #11676 |
| alcohol | #11740 |
| wilson | #11741 |
| dentate | #11769 |
| disappearance | #11773 |
| receptor antagonists | #11774 |
| ibuprofen | #11820 |
| neuron | #11824 |
| radiopharmaceuticals | #11825 |
| appears | #11872 |
| pigs | #11917 |
| inherited | #11924 |
| organ size | #11944 |
| mild cognitive impairment | #11954 |
| pyramidal | #12051 |
| corpus callosum | #12054 |
| gasoline | #12095 |
| aged alzheimer | #12101 |
| circulating levels | #12111 |
| carrier proteins | #12112 |
| reactive | #12134 |
| severity | #12227 |
| receptor activation | #12230 |
| blotting | #12274 |
| huntington disease | #12346 |
| infusions | #12347 |
| electrophysiological | #12375 |
| elevation | #12412 |
| aphasia | #12425 |
| emerging evidence | #12434 |
| atpase | #12447 |
| subclinical | #12476 |
| nh3 | #12499 |
| aminotransferase | #12509 |
| peripheral nervous | #12515 |
| absorbed | #12546 |
| cyclooxygenase | #12569 |
| exerts | #12573 |
| scavenger | #12589 |
| bile ducts | #12634 |
| c57bl 6 | #12683 |
| publisher | #12687 |
| chlorides | #12701 |
| reversed | #12782 |
| subcellular fractions | #12790 |
| inositol | #12832 |
| neuronal death | #12840 |
| measured | #12864 |
| intraperitoneal | #12878 |
| disorders | #12899 |
| cultured cells | #12900 |
| tnf alpha | #12912 |
| mediate | #12984 |
| mars | #13100 |
| slowly | #13118 |
| vesicular | #13121 |
| lesser | #13134 |
| cerebral infarction | #13141 |
| pretreatment | #13141 |
| therapeutic strategies | #13143 |
| basal | #13155 |
| 005 | #13194 |
| positron | #13197 |
| tomography pet | #13207 |
| circadian | #13222 |
| md | #13224 |
| caused | #13226 |
| hypotheses | #13238 |
| infused | #13242 |
| ischemic | #13289 |
| subjected | #13291 |
| methionine | #13299 |
| disrupted | #13336 |
| animals biomarkers | #13337 |
| normal controls | #13360 |
| anticonvulsants | #13440 |
| downregulation | #13444 |
| neurodegenerative | #13467 |
| reduction | #13499 |
| 23 patients | #13506 |
| chronic | #13511 |
| histocytochemistry | #13552 |
| psychomotor | #13555 |
| tissue | #13620 |
| sodium | #13631 |
| interleukin1 | #13734 |
| alpha | #13754 |
| cerebrovascular | #13767 |
| agonist | #13768 |
| partially | #13885 |
| oxidant | #13907 |
| postural | #13923 |
| mainstay | #13926 |
| sulfate | #13971 |
| nerve | #14045 |
| necrosis | #14050 |
| improvement | #14081 |
| gray | #14104 |
| hypothesize | #14117 |
| μmol | #14145 |
| skeletal | #14152 |
| exposure | #14214 |
| alcohol drinking | #14214 |
| electroencephalography | #14223 |
| sulfhydryl | #14242 |
| glia | #14250 |
| deficient mice | #14274 |
| blot analysis | #14352 |
| cytokine production | #14379 |
| multifactorial | #14398 |
| p002 | #14416 |
| damage | #14417 |
| enzyme inhibitors | #14422 |
| normalized | #14430 |
| dinoprostone | #14442 |
| permanent | #14471 |
| limbic | #14474 |
| cingulate | #14502 |
| healthrelated quality | #14573 |
| release | #14673 |
| 11 patients | #14695 |
| pge2 | #14705 |
| male | #14712 |
| ethanol | #14751 |
| chronic disease | #14773 |
| alzheimer disease | #14778 |
| cell count | #14785 |
| learning memory | #14831 |
| triphosphate animals | #14839 |
| vivo studies | #14851 |
| understood | #14879 |
| uric | #14905 |
| nmol | #14931 |
| agonists | #14948 |
| subcortical | #14957 |
| imbalance | #14958 |
| weighted | #15064 |
| manifestations | #15066 |
| lactation | #15115 |
| psychiatric | #15192 |
| creatine | #15221 |
| fluid | #15257 |
| cytokines | #15272 |
| triphosphatases | #15273 |
| intake | #15351 |
| protein tyrosine | #15367 |
| tissues | #15409 |
| localized | #15466 |
| ester | #15533 |
| synapses | #15538 |
| intellectual | #15568 |
| 042 | #15583 |
| evoked potentials | #15595 |
| prophylaxis | #15602 |
| clamp | #15646 |
| drinking | #15676 |
| sclerosis | #15727 |
| cholestasis | #15758 |
| nafld | #15783 |
| signs | #15804 |
| adenosine | #15804 |
| hypothesis | #15809 |
| trace | #15853 |
| chromatography | #15875 |
| exert | #15905 |
| appeared | #15927 |
| degeneration | #15939 |
| subcutaneously | #15941 |
| vivo vitro | #16006 |
| magnetic resonance | #16007 |
| reflects | #16036 |
| killed | #16092 |
| released | #16133 |
| parkinsons disease | #16161 |
| plays | #16220 |
| randomized controlled | #16247 |
| therapeutic | #16276 |
| 0001 | #16290 |
| hepatectomy | #16303 |
| muscle skeletal | #16331 |
| 1 week | #16336 |
| dorsal | #16343 |
| symptoms | #16440 |
| cytosolic | #16446 |
| aspect | #16495 |
| hepatitis chronic | #16549 |
| 5 | #16588 |
| transport | #16615 |
| abnormalities | #16625 |
| nucleus accumbens | #16636 |
| induction | #16656 |
| inadequate | #16667 |
| involves | #16686 |
| hepatocyte | #16740 |
| psychometrics | #16793 |
| decreasing | #16803 |
| cd40 | #16918 |
| random allocation | #16959 |
| pet | #17001 |
| mechanism | #17020 |
| spontaneous | #17046 |
| folic | #17100 |
| 10 patients | #17114 |
| organ | #17129 |
| 05 | #17137 |
| administered | #17168 |
| impairment | #17220 |
| transported | #17290 |
| reduces | #17300 |
| prominent | #17312 |
| publication aged aged | #17315 |
| tnfα | #17356 |
| diagnose | #17452 |
| humans | #17580 |
| parkinson | #17599 |
| mitochondrial | #17645 |
| incubation | #17654 |
| evoked | #17725 |
| modulates | #17799 |
| stimulatory | #17860 |
| commonly | #17870 |
| spectroscopy | #18016 |
| alter | #18029 |
| removed | #18045 |
| pharmacological | #18082 |
| 21 patients | #18092 |
| enzyme | #18126 |
| cognition disorders | #18188 |
| adult brain | #18254 |
| hepatocytes | #18338 |
| prevent | #18353 |
| blood samples | #18374 |
| moderately | #18395 |
| putative | #18427 |
| partly | #18450 |
| suffer | #18502 |
| stimulate | #18563 |
| animals biological | #18741 |
| neurodegenerative diseases | #18774 |
| depressed | #18788 |
| metalloproteinase | #18921 |
| vein | #19240 |
| ascorbic | #19380 |
| plasma | #19440 |
| 7 | #19485 |
| blot | #19526 |
| correlated | #19582 |
| membrane potentials | #19625 |
| serves | #19635 |
| depleted | #19648 |
| neuropsychological tests | #19672 |
| traumatic brain injury | #19727 |
| mm | #19825 |
| animals calcium | #19827 |
| soluble | #20005 |
| acetic | #20054 |
| frequently | #20106 |
| tumor necrosis factor | #20133 |
| serine | #20180 |
| dosedependent manner | #20198 |
| vitro techniques | #20371 |
| controversial | #20390 |
| motor | #20407 |
| radical | #20464 |
| ventral | #20527 |
| micrograms | #20674 |
| circulation | #20783 |
| raised | #20843 |
| inducible | #20861 |
| hypothalamic | #20873 |
| oxidation reduction | #20882 |
| counts | #20909 |
| brain mapping | #21000 |
| reactive oxygen | #21049 |
| 16 patients | #21061 |
| underlying mechanisms | #21109 |
| weeks | #21219 |
| labeled | #21292 |
| rodent | #21335 |
| method female | #21700 |
| maximal | #21940 |
| species ros | #22112 |
| vivo | #22128 |
| blood | #22216 |
| response relationship | #22303 |
| inflammation | #22526 |
| 073 | #22553 |
| induced cell | #22589 |
| 13 patients | #22656 |
| activation | #23016 |
| sufficient | #23212 |
| male membrane | #23275 |
| imaging mri | #23302 |
| gastrointestinal | #23302 |
| inflammatory | #23317 |
| intravenously | #23392 |
| infusions intravenous | #23567 |
| releasing | #23665 |
| magnetic resonance imaging | #23801 |
| intracellular | #24009 |
| cellular | #24252 |
| reducing | #24301 |
| c57bl | #24413 |
| correlate | #24434 |
| displayed | #24599 |
| unable | #24707 |
| 096 | #24715 |
| assess | #24780 |
| 12 patients | #24814 |
| activity | #25360 |
| body | #25376 |
| acquired | #25673 |
| modify | #25866 |
| limiting | #25928 |
| inbred c57bl | #26079 |
| inhibit | #26079 |
| modulated | #26122 |
| remain | #26178 |
| immunohistochemical | #26211 |
| cognitive | #26948 |
| represents | #26971 |
| management | #27196 |
| reflecting | #27352 |
| mental | #27490 |
| improves | #27652 |
| preventing | #27673 |
| behavioral | #27813 |
| hydrogen ion | #28292 |
| concluded | #28335 |
| proven | #28570 |
| aims | #28575 |
| evaluate | #28931 |
| proteins mice | #28975 |
| ion concentration | #29194 |
| magnetic | #29339 |
| mechanisms underlying | #29900 |
| subcellular | #29913 |
| mice inbred | #30075 |
| stained | #30210 |
| quantitatively | #30454 |
| arterial | #30516 |
| abnormal | #30579 |
| corrected | #30667 |
| humans hydrogen | #30710 |
| demonstrated | #30993 |
| sensitive | #31344 |
| resonance | #31346 |
| induces | #31608 |
| cultured | #31958 |
| enzyme activation | #32060 |
| markedly | #32813 |
| animals apoptosis | #33677 |
| remains | #34554 |
| unclear | #34875 |
| subsequent | #35401 |
| hypothesized | #36243 |
| treated | #36316 |
| inhibited | #36986 |
| linked | #37013 |
| inbred c57bl mice | #39261 |
| induce | #39552 |
| aged | #56385 |
Kjør rapport | |
Prominent publications by Roger F Butterworth∗
Region selective alterations of soluble guanylate cyclase content and modulation in brain of cirrhotic patients
[ PUBLICATION ]
Modulation of soluble guanylate cyclase (sGC) by nitric oxide (NO) is altered in brain from experimental animals with hyperammonemia with or without liver failure. The aim of this work was to assess the content and modulation of sGC in brain in chronic liver failure in humans. Expression of the alpha-1, alpha-2, and beta-1 subunits of sGC was measured by immunoblotting in autopsied frontal cortex and cerebellum from cirrhotic patients and controls. The contents of alpha-1 and alpha-2 ...
| Kjent for Guanylate Cyclase | Cirrhotic Patients | Modulation Sgc | Nitric Oxide Brain | Cerebellum Activation |
Hypothermia attenuates oxidative/nitrosative stress, encephalopathy and brain edema in acute (ischemic) liver failure
[ PUBLICATION ]
Encephalopathy and brain edema are serious complications of acute liver failure (ALF). The precise pathophysiologic mechanisms responsible have not been fully elucidated but it has been suggested that oxidative/nitrosative stress is involved. In the present study we evaluated the role of oxidative/nitrosative stress in the pathogenesis of hepatic encephalopathy and brain edema in rats with ALF resulting from hepatic devascularization. We also studied the effect of hypothermia, a ...
| Kjent for Brain Edema | Alf Rats | Nitrosative Stress | Liver Failure | Coma Stages |
KOL-Index: 13463
Acute liver failure (ALF) results in alterations of energy metabolites and of glucose-derived amino acid neurotransmitters in brain. However, the dynamics of changes in glucose metabolism remain unclear. The present study was undertaken using (1)H and (13)C nuclear magnetic resonance (NMR) spectroscopy to determine the rates of incorporation of glucose into amino acids and lactate via cell-specific pathways in relation to the severity of encephalopathy and brain edema in rats with ALF ...
| Kjent for Brain Lactate | Acute Liver | Magnetic Resonance | Coma Stages | Amino Acids |
Effects of hypothermia on brain glucose metabolism in acute liver failure: a 1H/13C-nuclear magnetic resonance study
[ PUBLICATION ]
BACKGROUND & AIMS: Mild hypothermia has a protective effect on brain edema and encephalopathy in both experimental and human acute liver failure. The goals of the present study were to examine the effects of mild hypothermia (35 degrees C) on brain metabolic pathways using combined (1)H and (13)C-Nuclear Magnetic Resonance (NMR) spectroscopy, a technique which allows the study not only of metabolite concentrations but also their de novo synthesis via cell-specific pathways in the ...
| Kjent for Acute Liver | Mild Hypothermia | Brain Glucose Metabolism | Magnetic Resonance | Frontal Cortex |
Neuroactive amino acids and glutamate (NMDA) receptors in frontal cortex of rats with experimental acute liver failure
[ PUBLICATION ]
It has been proposed that alterations of excitatory and inhibitory amino acids play a role in the pathogenesis of hepatic encephalopathy in acute liver failure. To evaluate this possibility, in vivo cerebral microdialysis was used to sample extracellular concentrations of amino acids in the frontal cortex of unanesthetized rats at various times during the progression of encephalopathy resulting from acute liver failure. Liver failure was induced by portacaval anastomosis followed 24 ...
| Kjent for Amino Acids | Frontal Cortex | Acute Liver Failure | Extracellular Concentrations | Hepatic Encephalopathy |
KOL-Index: 12801
Mild hypothermia is effective in the prevention of brain edema associated with cerebral ischemia and traumatic brain injury. Brain edema is also a serious complication of acute liver failure (ALF). To assess the effectiveness of hypothermia in ALF, groups of rats were subjected to hepatic devascularization (portacaval anastomosis, followed 48 hours later by hepatic artery ligation), and body temperatures were maintained at either 35 degrees C (hypothermic) or 37 degrees C (normothermic). ...
| Kjent for Mild Hypothermia | Brain Edema | Acute Liver | Rats Alf | Hepatic Encephalopathy |
Ammonia‐induced brain edema and intracranial hypertension in rats after portacaval anastomosis
[ PUBLICATION ]
Brain edema, leading to intracranial hypertension and brain herniation, is a major cause of death in fulminant liver failure. Astrocyte swelling is a prominent neuropathological feature in experimental fulminant liver failure. It has been postulated that the osmotic effects of glutamine, generated in astrocytes from ammonia and glutamate in a reaction catalyzed by glutamine synthetase, could mediate brain swelling. Normal rats and rats that received a portacaval anastomosis were infused ...
| Kjent for Intracranial Hypertension | Brain Edema | Portacaval Anastomosis | Ammonium Acetate | Osmotic Effects |
Effect of Portacaval Anastomosis on Glutamine Synthetase Protein and Gene Expression in Brain, Liver and Skeletal Muscle
[ PUBLICATION ]
The effects of chronic liver insufficiency resulting from end-to-side portacaval anastomosis (PCA) on glutamine synthetase (GS) activities, protein and gene expression were studied in brain, liver and skeletal muscle of male adult rats. Four weeks following PCA, activities of GS in cerebral cortex and cerebellum were reduced by 32% and 37% (p<0.05) respectively whereas GS activities in muscle were increased by 52% (p<0.05). GS activities in liver were decreased by up to 90% (p<0.01), a ...
| Kjent for Skeletal Muscle | Portacaval Anastomosis | Gene Expression | Surgical Rna | Pca Rats |
Cerebral inflammation contributes to encephalopathy and brain edema in acute liver failure: protective effect of minocycline
[ PUBLICATION ]
Encephalopathy and brain edema are serious complications of acute liver failure (ALF). The precise pathophysiologic mechanisms responsible have not been fully elucidated but it has been recently proposed that microglia-derived proinflammatory cytokines are involved. In the present study we evaluated the role of microglial activation and the protective effect of the anti-inflammatory drug minocycline in the pathogenesis of hepatic encephalopathy and brain edema in rats with ALF resulting ...
| Kjent for Brain Edema | Liver Failure | Rats Alf | Microglial Activation | Pathogenesis Hepatic Encephalopathy |
KOL-Index: 11822
There is evidence to suggest that, in acute liver failure (ALF), brain ammonia and proinflammatory cytokines may act synergistically to cause brain edema and its complications (intracranial hypertension, brain herniation). However, the molecular mechanisms involved remain to be established. In order to address this issue, semi-quantitative RT-PCR was used to measure the expression of genes coding for astrocytic proteins with an established role in cell volume regulation in cerebral ...
| Kjent for Brain Edema | Liver Failure | Proinflammatory Cytokines | Astrocytic Proteins | Cultured Astrocytes |
KOL-Index: 11726
Although earlier studies on thiamine deficiency have reported increases in extracellular glutamate concentration in the thalamus, a vulnerable region of the brain in this disorder, the mechanism by which this occurs has remained unresolved. Treatment with pyrithiamine, a central thiamine antagonist, resulted in a 71 and 55% decrease in protein levels of the astrocyte glutamate transporters GLT-1 and GLAST, respectively, by immunoblotting in the medial thalamus of day 14 symptomatic rats ...
| Kjent for Medial Thalamus | Glutamate Transporter | Glt1 Glast | Spraguedawley Statistics | Protein Levels |
KOL-Index: 11620
N-acetylcysteine (NAC) is an effective antidote to treat acetaminophen (APAP)-induced acute liver failure (ALF). NAC is hepatoprotective and prevents the neurological complications of ALF, namely hepatic encephalopathy and brain edema. The protective effect of NAC and its mechanisms of action in ALF due to other toxins, however, are still controversial. In the present study, we investigated the effects of NAC in relation to liver pathology, hepatic and cerebral glutathione, plasma ...
| Kjent for Liver Failure | Nac Alf | Induced Acute | Aom Mice | Brain Edema |
Ammonia and related amino acids in the pathogenesis of brain edema in acute ischemic liver failure in rats
[ PUBLICATION ]
The pathogenesis of brain edema in acute liver failure is poorly understood. We have previously shown that rats with ischemic acute liver failure (portacaval anastomosis followed by hepatic artery ligation) exhibit brain edema and intracranial hypertension, with swelling of cortical astrocytes as the most prominent neuropathological abnormality. Because ammonia has been shown to induce swelling of astrocytes in vivo and in vitro, we examined the relationship between brain ammonia, amino ...
| Kjent for Amino Acids | Brain Edema | Portacaval Anastomosis | Liver Failure | Glutamine Alanine |
Ammonia induces MK‐801‐sensitive nitration and phosphorylation of protein tyrosine residues in rat astrocytes
[ PUBLICATION ]
Astrocytes play a key role in the pathogenesis of ammonia-induced neurotoxicity and hepatic encephalopathy. As shown here, ammonia induces protein tyrosine nitration in cultured rat astrocytes, which is sensitive to the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801. A similar pattern of nitrated proteins is produced by NMDA. Ammonia-induced tyrosine nitration depends on a rise in [Ca2+]i, IkB degradation, and NO synthase (iNOS) induction, which are prevented by MK-801 and the ...
| Kjent for Rat Astrocytes | Glutamine Synthetase | Protein Tyrosine | Ammonia Induces | Oxide Nitric |
Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure: Role of glutamine redefined
[ PUBLICATION ]
Acute liver failure (ALF) is characterized neuropathologically by cytotoxic brain edema and biochemically by increased brain ammonia and its detoxification product, glutamine. The osmotic actions of increased glutamine synthesis in astrocytes are considered to be causally related to brain edema and its complications (intracranial hypertension, brain herniation) in ALF. However studies using multinuclear (1)H- and (13)C-NMR spectroscopy demonstrate that neither brain glutamine ...
| Kjent for Brain Edema | Acute Liver Failure | Hepatic Encephalopathy | Intracranial Hypertension | Glutamine Synthesis |
Nøkkelpersoner for Hepatic Encephalopathy
Toppkols i verden
Roger F Butterworth∗:Ekspertvirkning
Konsepter somRoger F Butterworth∗har direkte innflytelse:Hepatic encephalopathy, Acute liver failure, Liver failure, Thiamine deficiency, Cirrhotic patients, Brain edema, Portacaval anastomosis, Mild hypothermia.
Roger F Butterworth∗:Kol Impact
Konsepter relatert til arbeidet til andre forfattere somfor which Roger F Butterworth∗ har innflytelse:Hepatic encephalopathy, Acute liver failure, Thiamine deficiency, Liver cirrhosis, Oxidative stress, Brain edema, Cirrhotic patients.
Tools
Er dette profilen din? Krev profilen din Kopier url Legg inn lenke til profilen din |